Q-fficiency   Version 5.0 
Protocol# BWI_2017_07  February 3, 2021 
 Biosense Webster,  Inc  
 CONFIDENTIAL    
 
Evaluation of QDOT MICRO ™ catheter 
for pulmonary vein isolation (PVI) in 
subjects with P aroxysmal Atrial 
Fibrillation  (PAF)  
(Q-fficiency ) IDE # G180176 
 
Clinical Study  Protocol 
 
Protocol# BWI_2017_07 
 
 
Version  5.0 
February 3, 2021  
 
   
Sponsor:  BIOSENSE  WEBSTER,  INC.  
33 Technology Dr Irvine , CA  92618  
USA

Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 2 of 135 Table of Contents  
1.0 List of Acronyms and Abbreviations ........................................................................ 8  
2.0 Key Roles and Responsible Parties ........................................................................... 9  
3.0 Statement of Compliance  ........................................................................................ 10  
4.0 Protocol Summary .................................................................................................. 11  
5.0 Schematic of Study Design ..................................................................................... 21  
6.0 Background Information and Scientific Rationale ................................................. 23  
6.1 Background .................................................................................................................... 23  
6.2 Previous Exper ience with the QDOT MICRO™ Catheter and nMARQ RF Generator  24 
6.2.1  QMODE Animal Testing  ........................................................................................ 24  
6.2.2  QMODE+ Mode with the QDOT MICRO™ Catheter Animal Testing  ................. 26  
6.2.3  QDOT MICRO GLP Study  .................................................................................... 29  
6.2.4  QDOT FIM Studies ................................................................................................. 30  
6.3 Rationale ......................................................................................................................... 31  
6.3.1  Ablation Parameters for the QDOT MICRO™ Catheter  ....................................... 32  
6.4 Potential Risk and Benefit .............................................................................................. 36  
6.4.1  Description and Analysis of Risks .......................................................................... 36  
6.4.2  Minimization of Risks ............................................................................................. 39  
6.4.3  Precautions  .............................................................................................................. 40  
6.5 Known Potent ial Benefits ............................................................................................... 40  
7.0 Study Objectives and Purpose ................................................................................ 41  
7.1 Purpose ........................................................................................................................... 41  
7.2 Objectives  ....................................................................................................................... 41  
8.0 Study Design and Endpoints ................................................................................... 42  
8.1 Description of the Study Design .................................................................................... 42  
8.1.1  Cardiac CT/MRA Subset  ........................................................................................ 43  
8.2 Study Endpoints ............................................................................................................. 43  
8.2.1  Primary Safety Endpoint ......................................................................................... 43  
8.2.2  Primary Effectiveness Endpoint ............................................................................. 44  
8.2.3  Secondary Endpoints(s) .......................................................................................... 45  
9.0 Study Population ..................................................................................................... 47  
9.1 Subject Selection  ............................................................................................................ 47  
9.1.1  Inclusion Criteria  .................................................................................................... 47  
9.1.2  Exclusion Criteria  ................................................................................................... 47  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 3 of 135 9.2 Strategies for Recruitment and Retention  ...................................................................... 48  
9.3 Subject Withdrawal/Early Termination  ......................................................................... 49  
9.4 Subjects Lost to Follow up ............................................................................................. 50  
9.5 Subject Disposition  ........................................................................................................ 50  
10.0  Responsibilities  ....................................................................................................... 51  
10.1  Study Timelines  .......................................................................................................... 51  
10.2  Investigator Responsibilities ....................................................................................... 51  
10.3  Sponsor Responsibilities............................................................................................. 52  
10.4  Training ...................................................................................................................... 53  
10.4.1  Research Team  .................................................................................................... 53  
10.4.2  Investigator Training ........................................................................................... 53  
11.0  Study Device Description ....................................................................................... 53  
11.1  Device Acquisition  ..................................................................................................... 53  
11.2  Device Storage and Stability  ...................................................................................... 54  
11.3  Instructions for Use (IFU) .......................................................................................... 54  
11.4  Device Description  ..................................................................................................... 54  
11.4.1  QDOT MICRO™ Catheter  ................................................................................. 54  
11.4.2  nMARQ® Multi- channel RF Generator (D -1341- 07-I) ..................................... 57  
11.4.3  TX eco EXT Interface Cable (D -1357-03- SI) ..................................................... 58  
11.4.4  TX eco Cable Dongle (EM -5050-055F) ............................................................. 59  
11.4.5  CARTO® 3 v6.0.60 QDOT MICRO™ Software Module ................................. 60  
11.5  Required Study Devices and Equipment .................................................................... 63  
11.6  System Components and Set- Up ................................................................................ 64  
12.0  Study medications ................................................................................................... 65  
12.1  Antiarrhythmic Drugs ................................................................................................. 65  
12.1.1  Definitions  ........................................................................................................... 65  
12.2  Study specific anticoagulation requirements .............................................................. 66  
13.0  Study Schedule, Procedures, and Assessments....................................................... 67  
13.1  Screening and Informed Consent  ............................................................................... 67  
13.1.1  Patient Screening  ................................................................................................. 67  
13.1.2  Informed Consent ................................................................................................ 67  
13.2  Pre-Procedure/Baseline Assessments, Evaluations and Procedures  ........................... 68  
13.3  Study Ablation Procedure ........................................................................................... 69  
13.3.1  QMODE+ Recommended Ablation Parameters  ................................................. 71  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 4 of 135 13.3.2  General AF Procedure Guidelines for QMODE+  ............................................... 72  
13.3.3  Esophageal Monitoring ....................................................................................... 74  
13.3.4  Ablation Outside the PV Ostia  ............................................................................ 74  
13.3.5  QMODE Ablation Parameters and Workflow .................................................... 75  
13.4  Post Ablation  .............................................................................................................. 76  
13.5  Data collection During the Study Procedure .............................................................. 77  
13.5.1  Collection of Ablation Procedure data for post-analysis .................................... 78  
13.6  Repeat Procedures  ...................................................................................................... 78  
13.7  Post Procedure Follow- up Assessments ..................................................................... 78  
13.8  Standard Tests and Procedures ................................................................................... 81  
13.9  Unscheduled visit ....................................................................................................... 84  
13.10  Hear t Rhythm Monitoring .......................................................................................... 84  
13.11  Repeat AF Ablation Procedures ................................................................................. 84  
13.12  Core Laboratory .......................................................................................................... 85  
14.0  Assessment of Safety  .............................................................................................. 85  
14.1  Adverse Event Recording  ........................................................................................... 85  
14.2  Classification  .............................................................................................................. 86  
14.2.1  Primary Adverse Event ....................................................................................... 86  
14.3  Serious AEs ................................................................................................................ 90  
14.4  Non-Serious AEs  ........................................................................................................ 90  
14.5  Anticipated AEs  .......................................................................................................... 90  
14.6  Unanticipated Serious Adverse Device Effect  ........................................................... 94  
14.7  Clinical Investigation Device Failure/Malfunction/Deficiency  ................................. 94  
14.8  Reporting Requirements ............................................................................................. 94  
14.9  Intensity or Severity .................................................................................................... 95  
14.10  Outcome...................................................................................................................... 96  
14.11  Causality  ..................................................................................................................... 96  
14.12  Documentation............................................................................................................ 97  
14.13  Safety Oversight ......................................................................................................... 97  
14.14  Clinical Events Committee (CEC)  ............................................................................. 97  
15.0  Deviations from Protocol and Good Clinical Practice ............................................ 97  
16.0  Device Accountability  ............................................................................................ 98  
16.1  Device Accountability  ................................................................................................ 98  
16.2  Device Returns  ........................................................................................................... 98  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 5 of 135 17.0  Monitoring the Study .............................................................................................. 99  
17.1  Early Termination Monitoring Visit ......................................................................... 100  
18.0  Statistical Analysis Methods  ................................................................................. 100  
18.1  Study Design............................................................................................................. 100  
18.2  Treatment  Assignment .............................................................................................. 100  
18.3  Interval Windows ..................................................................................................... 100  
18.4  Primary and Secondary Endpoint(s), and Associated Hypotheses ........................... 100  
18.4.1  Study Success .................................................................................................... 100  
18.4.2  Prima ry Endpoint(s) and Associated Hypotheses ............................................. 101  
18.4.3  Secondary Endpoints and Associated Hypotheses ............................................ 101  
18.4.4  Other Endpoints................................................................................................. 102  
18.5  Levels of Significance .............................................................................................. 102  
18.6  Analysis Set  .............................................................................................................. 102  
18.7  Sample Size Justification  .......................................................................................... 102  
18.8  Data Monitoring Committee  ..................................................................................... 103  
18.9  Analyses to be Conducted ........................................................................................ 104  
18.9.1  General Conventions ......................................................................................... 104  
18.9.2  Disposition of Study Subjects ........................................................................... 104  
18.9.3  Demographic and Baseline Characteristics  ....................................................... 104  
18.9.4  Analysis of Primary Endpoint Analyses ........................................................... 104  
18.9.5  Analyses of Secondary and Additional Endpoints ............................................ 105  
18.9.6  Plans for Interim Analysis ................................................................................. 106  
18.9.7  Handling of Missing Data ................................................................................. 106  
18.9.8  Sensitivity Analyses  .......................................................................................... 107  
18.9.9  Subgroup Analyses ............................................................................................ 107  
18.9.10  Assessment of Site Homogeneity  ...................................................................... 107  
19.0  Ethics and Protection of Human Subjects ............................................................. 108  
19.1  Ethics Review  ........................................................................................................... 108  
19.2  Patient Informed Consent ......................................................................................... 108  
19.3  Confidentiality  .......................................................................................................... 108  
19.4  Subject Confidentiality/Record ................................................................................ 108  
20.0  Data Management  ................................................................................................. 109  
20.1  Electronic Case Report Forms (CRFs)  ..................................................................... 109  
20.2  Data Reporting  .......................................................................................................... 109  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 6 of 135 20.3  Data Review  ............................................................................................................. 110  
20.4  Procedural Data  ........................................................................................................ 110  
20.5  Source Documentation ............................................................................................. 110  
21.0  Quality Assurance and Quality Control ................................................................ 110  
22.0  Administrative Responsibilities  ............................................................................ 111  
22.1  Records and Reports ................................................................................................. 111  
22.1.1  Records  .............................................................................................................. 111  
22.1.2  Record Retention ............................................................................................... 111  
22.1.3  Investigator’s Final Report ................................................................................ 112  
23.0  Termination of the Study ...................................................................................... 112  
24.0  Data and Publication Policy .................................................................................. 112  
25.0  Document Filing  ................................................................................................... 112  
26.0  References:  ............................................................................................................ 113  
27.0  Appendix A: Study Definitions ............................................................................ 116  
28.0  Appendix B: QMODE .......................................................................................... 120  
28.1  Use of the QDOT MICRO™ QMODE algorithm  ................................................... 120  
28.2  Recommended ablation parameters  .......................................................................... 121  
29.0  Appendix C:  Justification of Safety Performance Goal ....................................... 124  
30.0  Appendix D Adaptive Design Main Study ........................................................... 127  
30.1  Introduction .............................................................................................................. 127  
30.1.1  Endpoints ........................................................................................................... 127  
30.2  Adaptive Design ....................................................................................................... 127  
30.2.1  Primary Analysis  ............................................................................................... 127  
30.2.2  Interim Analyses for Early Success  .................................................................. 128  
30.2.3  Longitudinal Modeling for Effectiveness ......................................................... 129  
30.3  Simulation Scenarios  ................................................................................................ 129  
30.3.1  Effectiveness Profiles  ........................................................................................ 129  
30.3.2  Adverse Event Rate Profiles  ............................................................................. 130  
30.3.3  Enrollment Rates  ............................................................................................... 131  
30.3.4  Attrition Rate Profile  ......................................................................................... 131  
30.4  Operating Characteristics  ......................................................................................... 131  
30.4.1  Type I Error Control .......................................................................................... 131  
30.4.2  Probability of Success ....................................................................................... 132  
30.4.3  Sensitivity to Enrollment Rate  .......................................................................... 134  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 7 of 135 31.0  APPENDIX E ADAPTIVE DESIGN SECOND (VARIABL FLOW) STUDY
 Error! Bookmark not defined.  
31.1  Introduction ................................................................. Error! Bookmark not defined.  
31.1.1  Endpoints .............................................................. Error! Bookmark not defined.  
31.2  Adaptive Design .......................................................... Error! Bookmark not defined.  
31.2.1  Safety and Effectiveness Analysis for the Second (Variable Flow) Study .. Error! 
Bookmark not defined.  
31.2.2  Interim Analyses for Early Success  ..................... Error! Bookmark not defined.  
31.2.3  Modeling for Effectiveness .................................. Error! Bookmark not defined.  
31.3  Simulation Scenarios  ................................................... Error! Bookmark not defined.  
31.3.1  The Effectiveness Endpoint ................................. Error! Bookmark not defined.  
31.3.2  The Safety Endpoint ............................................. Error! Bookmark not defined.  
31.3.3  Enrollment Rates  .................................................. Error! Bookmark not defined.  
31.3.4  Attrition Rate Profile  ............................................ Error! Bookmark not defined.  
31.4  Operating Characteristics for the Second (Variable Flow) Study .... Error! Bookmark 
not defined.  
31.4.1  Type I Error Control ............................................. Error! Bookmark not defined.  
31.4.2  Power  .................................................................... Error! Bookmark not defi ned.  
 
 
                     
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 8 of 135 1.0 LIST OF A CRONYMS  AND ABBREVIATIONS  
AAD  Antiarrhythmic drug  ICF Informed consent form  
ACC  American College of Cardiology    
ACT  Activated clotting time  IEC Independent Ethics Committee  
AE Adverse event  IFU Instructions for use  
AF Atrial fibrillation  IRB Institutional Review Board  
  ITT Intent -to-treat 
HIPAA  Health Insurance Portability and 
Accountability Act  
AFL  Atrial flutter  
AHA  American Heart Association  LA Left atrium  
ANOVA  Analysis of variance  MI Myocardial infarction  
AT Atrial tachycardia  MRI  Magnetic resonance imaging  
AV Atrioventricular  MV Mitral valve  
BP Blood pressure    
CEC  Clinical Events Committee  PAF Paroxysmal atrial fibrillation  
CHF  Congestive heart failure  PCI Pecutaneous coronary intervention  
CF Contact force  PIU Patient Interface Unit  
PP Per protocol  
CFAE  Complex fractionated atrial electrogram  PV Pulmonary vein  
CHADS  Congestive heart failure, High blood 
pressure, Age 75+, Diabetes, previous Stroke 
or transient ischemic attack  PVI Pulmonary vein isolation  
 
QOL   
Quality of life  
CPVI  Complete pulmonary vein isolation  
CRF  Case Report Form  RA Right atrium  
CS Coronary sinus  REB  Review Ethics Board  
CT Computed tomography  RF Radiofrequency  
CTI Cavotricuspid isthmus  SADE  Serious adverse device effect  
CVA  Cerebrovascular accident  SAE  Serious adverse event  
ECAS  European Cardiac Arrhythmia Society    
EPU  External processing unit  SAP Statistical analysis plan  
ESC European Society of Cardiology  SF Surround Flow  
FDA  Food Drug Administration  SVC  Superior vena cava  
GCP  Good Clinical Practice  TIA Transient ischemic attack  
ECG  Electrocardiogram  TEE Transesophageal echocardiogram  
EHRA  European Heart Rhythm Association  TTE Transthoracic echocardiogram  
HRS  Heart Rhythm Society  TTM  Transtelephonic monitoring  
ICD Implantable cardioverter defibrillator  UADE  Unanticipated adverse device effect  
ICE Intracardiac echocardiography  USADE  Unanticipated serious adverse device effect  
  VT Ventricular tachycardia  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 9 of 135 2.0 KEY ROLES AND RESPONSIBLE PARTIES  
SPONSOR:  
Biosense Webster, Inc.  
part of the Johnson & Johnson family of companies  
33 Technology Drive,  Irvine, CA 92618  USA  
 
 CONTACTS:  
Clinical Research Manager   
  
33 Technology Drive,  Irvine, CA 92618  USA  
  
  
 Franch
ise Medical Manager  
  
33 Technology Drive,  Irvine, CA 92618  USA  
   
  
  CRO(S) AND CORE LAB(S):  
The sponsor maintains a list of CRO(s) and Core Lab(s) and their contact information.   INVESTIGATORS:  
The sponsor maintains a list of study Investigators and their contact information.      
  

Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 10 of 135 3.0 STATEMENT OF COMPLIANCE  
Study Title:  Evaluation of the QDOT MICRO™  Catheter for pulmonary vein isolation (PVI) 
in subjects with Paroxysmal Atrial Fibrillation (PAF) (Q-fficiency ) 
Study #: BWI_2017_07 
Protocol Type Revision Rationale Effective Date  
Original #1 Original submission July 17, 2018 
Amendment  #2 Changes made in response to the FDA deficiency letter September 29, 2018 
Amendment  #3 Changes made in response to the conditional approval 
from FDA  November 19, 2018 
Amendment  #4 Inclusion of the second study  in the clinical study  September 10, 2019 
Amendment  #5 Administrative  and COVID-19 study assessment 
updates  February 3, 2021  
 
I have read this protocol and agree to conduct this clinical investigation in accordance with the design and specific provisions outlined herein. I understand the protocol, and I understand I am solely responsible to ensure the investigation is conducted in accordance with Good Clinical Practices (GCP), applicable country regulations the Declaration of Helsinki, the signed clinical study contract with Sponsor and with the protocol outlined herein. I will conduct this study as outlined therein and will make reasonable effort to complete the study within the time period designated by the Sponsor.    
I will provide copies of the protocol and all pertinent information to all individuals responsible to 
me who will assist in the conduct of this study. I will discuss this material with them to ensure they are fully informed regarding the device and the conduct of the study.  
I will fulfill the requirements of my Institutional Review Board (IRB)/Ethics Committee (EC), or 
other oversight committee, to ensure complete and continual oversight of this clinical investigation. I will use an Informed Consent Document approved by the Sponsor and my reviewing IRB/EC (where required).  
I agree to report all information or data in accordance with the protocol and, in particular,  I agree 
to report any serious adverse events, device related adverse events, or procedure related adverse 
events as defined in this protocol to the Sponsor, and comply with all adverse event reporting requirements of my reviewing IRB/EC.  I agree to permit the Sponsor, its authorized representatives, my reviewing IRB/EC, and any regulatory authority/body access to all records relating to the clinical investigation.  
The below signature confirms I have read and understood this protocol and its associated amendments or attachments and  will accept respective revisions or amendments provided by the 
Sponsor.  
____________________________   _____________________________  _______________  Principal Investigator      Signature      Date  
 Name (PRINT)  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 11 of 135 4.0 PROTOCOL  SUMMARY 
Evaluation of QDOT MICRO™  Catheter for pulmonary vein isolation (PVI) in subjects 
with PAF (QDOT IDE# G180176 ) 
  
Full Title & Protocol Number  Evaluation of QDOT MICRO™  Catheter for pulmonary vein isolation 
(PVI) in subjects with PAF  
Protocol #: BWI_2017_07  
Short Title  Q-fficiency  
IDE/IND number    G180176  
Sponsor  CSS/BWI  
Indication  Atrial Fibrillation  
Study Article Description  • QDOT MICRO™  Catheter (D -1394- XX-SI and D -1395- XX-SI) 
o Interface Cable (D -1357- 03-SI) 
o Dongle (EM-5050- 055F)  
• nMARQ Multi- Channel RF Generator v3.0.1 (D -1341- 07I) 
o v3.0.1 – Main Study  
o v3.0.6 – Second (Variable Flow) Study  
• CARTO ® 3 v6.0.60 QDOT MICRO™  Software Module  
Study Design  Prospective, non- randomized, pre -market clinical evaluation of the QDOT 
MICRO™  Catheter to demonstrate the safety and effectiveness when 
compared to an historical control performance goal .  
The tri al will have 2 studies:  
• The Main  study include s subjects treated with nMARQ RF generator 
with constant flow rate (8mL/min)  for QMODE+ RF applications .  
• The Second (variable flow ) study will include  subjects treated with 
the nMARQ RF generator with variable flow rate for QMODE+ RF 
application s.   
QMODE RF applications will use the same flow rates for both studies. 
To assess PV stenosis, embedded within the Study will be a Cardiac 
Computed Tomography (CT) or Magnetic Resonance Angiogram (MRA) 
image (CT/MRA) subset with consecutive enr ollment (n=40) .  
The Main  study  will enroll 1 85 subjects  who are candidates for catheter 
ablation . Bayesian adaptive design will be used to assess early success at 
one interim analysis . The study will be considered successful if primary 
endpoints are met for Main  study.  
A second (variable flow) study  of subjects will enroll 92 subjects who are 
candidates for catheter ablation . Enrollment  for the second study will begin 
after enrollment for the Main  study is complete. The second study will use 
the same eligibility criteria and the same sites as the  Main study. The 
success of the second (variable flow) study  will be based on same endpo ints 
and hypotheses formulated for the main study . 
 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 12 of 135 Sample Size  N = 277 subjects  at up to 30  US sites  with 185 subjects in the Main study  
of the study and 92 in the second study.  
Study Population Subjects undergoing electrophysiology mapping and RF ablation for 
treatment of Antiarrhythmic Drug (AAD) Refractory symptomatic 
paroxysmal AF with the QDOT MICRO™  catheter.  
Geographic areas to be included  Geographic involvement will include the US  
Study Duration ~18-20 months (including 6-8 months enrollment and 12 months follow up 
from LPI)  for the Main  study 
~ 18 months (including 6 months enrollment and 12 months follow up from 
LPI for Second  (variable flow ) study .  
Start Date:  4Q18 End Date: 4Q21  
Procedure(s) Description  In this study protocol, QMODE+ (90W 4 sec) is the primary temperature 
control mode for pulmonary vein isolation. If the investigator deems 
QMODE+ unable to achieve PVI , the study catheter in QMODE 
temperature control mode (25-50W) should be used to complete the PVI 
procedure.  
In addition, QMODE+ and QMODE (25 -50W) are to be used to treat non-
PV triggers, Linear ablation lines and the right atrial CTI line when atrial 
tachycardias are documented during the procedure or by medical history.  
 QDOT MICRO™  Catheter Parameter Tables:   
 For the Main  study:  
 
Table A : RF and Flow Settings during RF applications  
Power Target Temp*  Cut-off Temp  Nominal 
Irrigation 
Flow rate  Range  Maximum 
allowed  Range  Maximum 
allowed  
25-35 W  40-50ºC  50ºC  50-55ºC  55ºC  4mL**  
36-
50W*** 40-50ºC  50ºC  50-55ºC  55ºC  15mL**  
90W†  40-60ºC  60ºC  60-70ºC  70ºC  8mL**  
* Temperatures displayed on the RF generator do not represent tissue temperature 
or electrode tissue interface temperature.  
**A minimum flow rate of 2mL during mapping is recommended.  
*** RF applications at 36- 50W should not exceed 60 sec.  
† The study recommends using this power setting for PVI as a primary ablation 
Strategy.  RF applications at this power setting are limited up to 4 sec.  It is 
recommended to use lower target temp s etting for the posterior wall RF 
applications.  
 
For the Second (variable flow) study:  
 
Table B: RF and Flow Settings during RF applications  
Power Target Temp*  Cut-off Temp  Nominal 
Irrigation 
Flow rate  Range  Maximum 
allowed  Range  Maximum 
allowed  
25-35 W  40-50ºC  50ºC  50-55ºC  55ºC  4mL**  
36-
50W*** 40-50ºC  50ºC  50-55ºC  55ºC  15mL**  
90W†  40-60ºC  60ºC  60-70ºC  70ºC  4- 15 ml 
** 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 13 of 135 * Temperatures displayed on the RF generator do not represent tissue temperature 
or electrode tissue interface temperature.  
**A minimum flow rate of 2mL during mapping is recommended.  
*** RF applications at 36- 50W should not exceed 60 sec.  
† The study recommends using this power setting for PVI as a primary ablation 
Strategy.  RF applications at this power setting are limited up to 4 sec. It is 
recommended to use lower targ et temp setting for the posterior wall RF 
applications.  
 
QDOT MICRO™  Ablation:  
The QDOT MICRO™  Catheter utilizes a temperature- controlled  ablation 
(QMODE) designed to maximize RF lesion efficiency by using temperature 
feedback measured at the tip to adjust power and irrigation flow.  The QMODE temperature control mode monitors the temperature rate of change 
in relationship to the set target temperature during RF application.  To 
maintain desired power levels at a safe temperature, the QMODE 
temperature control mode  utilizes changes in the irrigation flow rate as a 
first-order approach to maintain temperature. If the change in irrigation 
flow 
rate is not sufficient, the RF energy is also titrated to maintain 
temperature.  
Irrigation Titration  for the main  study: 
• For power settings, 35W or lower: The flow rate starts at low flow (4ml, lowest setting).  If the temperature approaches or exceeds  the set 
target temperature (50°C), the generator changes the pump flow rate from low (4mL) to high flow (15 mL) to maintain the set maximum 
power at its setting.  Once the temperature decreases the pump 
irrigation flow rate is returned to low (4mL).  
• For p ower settings, greater than 35W: The flow rate starts at high flow 
(15ml). If the target temperature is not reached , the generator changes 
the pump from high (15 mL) to low (4mL) flow. Once the temperature increases the pump irrigation flow rate is returned to high (15mL).  
• For power settings up to 90W: The flow rate starts at moderate flow (8mL) and is maintained throughout the ablation.  The duration of the ablation is limited to 4 seconds at this power setting.  
• At any set power (1 -90W), as the tip tempe rature approaches the 
selected target temperature (i.e. 50°C) the power level will also titrate 
down to not exceed the target temperature.  If the cut -off temperature 
is reached, the generator will stop the ablation.  
 
Irrigation Titration  for the second (variable flow) study: 
• For power settings, 35W or lower: The flow rate starts at low flow (4ml, lowest setting).  If the temperature approaches or exceeds the set 
target temperature (50°C), the generator changes the pump flow rate 
from low (4mL) to high flow (15 mL) to maintain the set maximum 
power at its setting.  Once the temperature decreases the pump 
irrigation flow rate is returned to low (4mL).  
• For power settings, greater than 35W: The flow rate starts at high flow (15ml). If the targ et temperature is not reached, the generator changes 
the pump from high (15 mL) to low (4mL) flow. Once the temperature increases the pump irrigation flow rate is returned to high (15mL).  
• For power settings up to 90W: The flow rate starts at moderate flow  
(4mL) and is maintained throughout the ablation.  The duration of the 
ablation is limited to 4 seconds at this power setting.  
• At any set power (1 -90W), as the tip temperature approaches the 
selected target temperature (i.e. 50°C) the power level will als o titrate 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 14 of 135 down to not exceed the target temperature.  If the cut -off temperature 
is reached, the generator will stop the ablation  
Recommendation for CoolFlow® Irrigation Pump Setting and RF Power-
delivery  
• The CoolFlow® Irrigation Pump will deliver a contin uous infusion of 
2 ml/min of room temperature heparinized saline (1 u heparin/1 ml 
saline) during mapping.  
• The nominal irrigation setting will start up to 2 seconds before the onset of RF energy delivery  
 QDOT MICRO™  Contact Force (CF) Settings:   
When us ing the study catheter in  both QMODE and QMODE+ , operators 
should Target:  
• Target CF:  10g 
• CF Range:   5-30g  
 
Post procedure:  
20 minutes waiting period is required followed by adenosine/isoproterenol challenge  
 
Primary Objective  The primary objective of this clinical investigation is to demonstrate the 
safety and 12- month effectiveness of the QDOT MICRO ™ catheter for 
pulmonary vein isolation (PVI) in the treatment of subjects with paroxysmal 
atrial fibrillation.  
Specifically: 
• To demonstrate the safety based on the proportion of subjects with early -onset (within 7 days of ablation procedure) primary adverse 
events  
• To demonstrate the 12- month effectiveness based on the proportion of 
subject with freedom from docume nted left atrial arrhythmia (atrial 
fibrillation (AF), atrial tachycardia (AT) or atrial flutter (AFL)) 
episodes during the effectiveness evaluation period (Day 91- 365)  
Secondary Objectives  The major secondary objectives of this study are:  
Safety:  
• to evaluate the incidence of serious adverse events during and after procedure up to 3 months following procedure.  
Acute Effectiveness:  
• Acute Procedural Success as defined by:  
o The % of subjects with electrical isolation of PVs
 (entrance 
block) at  the end of the procedure, and  
 The % of subjects with electrical isolation of PVs  (entrance 
block) using QMODE+ as only ablation strategy  
 The % of subjects with electrical isolation of PVs  (entrance 
block) at all power settings combined  
o The % of subjects with electrical isolation of PVs  (entrance 
block) after waiting period and adenosine challenge   
 
Exploratory Objectives  N/A 
Primary Endpoints & Follow -up 
Intervals  Acute Safety:  
• Incidence of early onset primary adverse events (PAE) related to the 
device or procedure. Occurrence of Primary AEs within 7 days of an 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 15 of 135 ablation procedure. (refer to Appendix A for a comprehensive 
definition list of primary adverse events)  
12-Month Chronic  Effectiveness:  
• Freedom from documented (Symptomatic and asymptomatic) atrial 
arrhythmia (atrial fibrillation (AF), atrial tachycardia (AT) or atrial flutter (AFL)) episodes during the effectiveness evaluation period (Day 91- 365) 
 
Effectiveness Monitoring:   
Effectiveness monitoring will include event Monitoring (TTM). Each 
subject will be provided an event monitor (Transtelephonic monitor, TTM) 
no later than at the 3-month visit, episodes ≥ 30 secs on TTM or 
continuously recorded on the standard 12 -leads EC G will be considered 
recurrence. Subjects will be expected to transmit asymptomatic recordings  
once every week starting no later than the month 3 visit until the month 6 
visit.  Starting from month 6, subjects will record and transmit once every 
month until the end of the 12 -month follow -up period.   All symptomatic 
cardiac episodes should be recorded and transmitted soon after the event occurs during the Evaluation Period (Day 91- 365).  
Secondary Endpoints & Follow -
up Intervals  Secondary Safety Endpoints:  
• Incidence of Unanticipated Adverse Device Effects (UADEs)  
• Incidence of Serious Adverse Events (SAEs) within 7 days (early onset), >7 to 30 days (peri -procedural) and >30 days (late onset) of 
initial ablation  
• Incidence of bleeding complication: a) Major , b) clinically relevant 
non-major and c) minor bleeding as defined in the 2017 
HRS/EHRA/ECAS/APHRS /SOLAECE Consensus Statement  
Secondary Effectiveness Endpoints:  
• Acute Procedural success:  
o % of subjects with electrical isolation of all PVs (entrance block) at 
the end of the procedure  
 The % of subjects with electrical isolation of PVs (entrance 
block) using QMODE+ as only ablation strategy  
o % of subjects with electrical isolation of all PVs (entrance block) 
after first encirclement (evaluated prior to the 20-minute waiting 
period and adenosine challenge)  
o % of subjects with electrical isolation of all PVs (entrance block) 
after first encirclement without acute reconnection, after waiting period and adenosine challenge   
o % of  subjects and % of PVs with touch -up (ablation of acute 
reconnection) among all targ eted veins and touch -up location  
o Anatomical location of acute PV reconnection after first 
encirclement  
• Repeat Ablation Procedures:  
o Incidence (%) of repeat ablation procedures during 12- months 
period post -procedure   
o % PVs re -isolated among all of the tar geted PVs at repeat procedure  
o % repeat ablation procedures requiring new linear lesions and/or 
identifying new foci outside of initially isolated area among the 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 16 of 135 repeat ablation procedures  
• 12-Month Single Procedure Success  
o The 12 -month single procedure success is defined as freedom from 
documented AF/AFL/AT recurrence (episodes > 30 secs) during 
the Evaluation Period after a single ablation procedure and off 
AADs. Any repeat ablation procedure or AAD therapy will be deemed effectiveness failure for this analysis  
Additional Endpoints:  
• Procedural data 
o total procedure time, PVI time, RF application time, mapping time , 
and RF application time per lesion  
o fluoroscopy time/dose  
o location of RF applications, number of RF applications  
o RF ablation parameters per application  
o Total fluid/irrigation delivered  
o Esophageal monitoring  
o VISITAG™ parameters will be collected in the CARTO® 3 system 
during the ablation procedures for generation of LA ablation maps  
o VISITAG SURPOINT™ values (Tag Index) per RF application  
• Quality of Life (QOL) status (AFEQT  scores)  
• Cardiac CT/ MRA  Subset for PV Stenosis Assessment  
• HEMA  
o Incidence of hospitalizations post -index ablation procedure  
Inclusion Criteria  Subjects must meet all of  the following inclusion criteria to be eligible for 
participation in this study:  
1. Symptomatic paroxysmal AF with one electrocardiographically 
documented AF episode within 6 months prior to enrollment ,a 
physician’s note indicating recurrent self -terminating AF  within 7 
days. Documentation may include electrocardiogram (ECG); 
Transtelephonic monitoring (TTM), Holter monitor or telemetry 
strip.  
2. Failed at least one (1) antiarrhythmic drug (AAD) (class I or III) as 
evidenced by recurrent symptomatic AF, contraindicated or 
intolerable to the AAD.  
3. Age 18 years or older.  
4. Signed Patient Informed Consent Form (ICF).  
5. Able and willing to comply with all pre -, post -, and follow -up testing 
and requirements.  
Exclusion Criteria  Subjects who meet any of the following exclusion criteria are not eligible 
for enrollment.  
1. Previous surgical or catheter ablation for atrial fibrillation.  
2. AF secondary to electro lyte imbalance, thyroid disease, or reversible 
or non- cardiac cause.  
3. Patient on amiodarone at any time during the past 3 months prior to enrollment.  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 17 of 135 4. Previously diagnosed with persistent or long -standing persistent AF 
and/or Continuous AF lasting > 7 days  
5. CABG surgery within the past 6 months (180 days).  
6. Valvular cardiac surgical/percutaneous procedure (i.e., 
ventriculotomy, atriotomy, and valve repair or replacement and 
presence of a prosthetic valve).  
7. Any carotid stenting or endarterectomy within the last 6 months.  
8. Documented LA thrombus on imaging (within 48 hr prior of a study 
ablation procedure).  
9. Documented LA size > 50 mm (parasternal long axis vie w). 
10. Documented LVEF < 40%.  
11. Contraindication to anticoagulation (e.g. heparin)  
12. History of blood clotting or bleeding abnormalities  
13. MI/PCI within the past 2 months (60 days)  
14. Documented thromboembolic event (including TIA) within the past 12 months (365 days)  
15. Rheumatic Heart Disease  
16. Uncontrolled heart failure or NYHA function class III or IV  
17. Severe mitral regurgitation (Regurgitant volume ≥ 60 mL/beat, Regurgitant fraction ≥ 50%, and/or Effective regurgitant orifice area ≥ 0.40cm
2) 
18. Awaiting cardiac transplantation or other major cardiac surgery 
within the next 12 months (365 days)  
19. Unstable angina  
20. active systemic infection or sepsis  
21. Diagnosed atrial myxoma or presence of an interatrial baffle or patch.  
22. Presence of implanted ICD/CRT -D. 
23. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other 
disease or malfunction of the lungs or respiratory system that 
produces chronic symptoms.  
24. Severe Gastroesophageal Reflux Disease (GERD; active requiring 
significant intervention not including OTC medication)  
25. Significant congenital anomaly or medical problem that in the 
opinion of the investigator would preclude enrollment in this study.  
26. Women who are pregnant (as evidenced by pregnancy test if pre -
menopausal), lactating, or who are of child bearing age and plan on becoming pregnant during the course of the study  
27. Enrollment in an investigational study evaluating another device, biologic, or drug.  
28. Presence of intramural thro mbus, tumor or other abnormality that 
precludes vascular access, or manipulation of the catheter.  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 18 of 135 29. Presence of an inferior vena cava filter.  
30. Presenting contra -indication for the devices (e.g. TTE, CT, etc.) used 
in the study, as indicated in the respective instructions for use.  
31. Life expectancy less than 12 months  
Statistical Analysis  For the Main  study : 
Primary Safety Endpoint  
Sample Size and Power Calculations  
• Based on a performance goal of 14%, an anticipated rate of 7% for 
the primary safety endpoint, approximately 185 evaluable subjects 
will provide at least 80% power to declare success for the primary 
safety endpoint in the main  study controlling one -sided alpha of 
2.5% , assuming a 5% attrition rate.   
Primary Effectiveness Endpoint  
Sample Size and Power Calculations  
• Based on a performance goal of 50%, and anti cipated freedom 
from AF/AT/AFL recurrence rate of 65%, approximately 185 
evaluable subjects will b e required to obtain at least 80% power 
to declare success for primary effectiveness endpoint  in the main  
study controlling one-sided alpha of 2.5% , assuming a 12% 
attrition rate . 
The Final analyses for primary safety and effectiveness endpoints will apply 
Bayesian methods and use a beta -binomial model  (assuming early success 
is not achieved for the primary effectiveness endpoint) .  
 
For the Variable  flow study : 
Primary Safety Endpoint  
Sample Size and Power Calculations  
• Based on a performance goal of 14%, an anticipated rate of 7% for 
the primary safety endpoint, with borrowing up to 91 subjects from  
the main study,  the sample size of  92 subjects, will provide close to 
80% power for testing the primary safety endpoint controlling one -
sided alpha of 2.5%, assuming a 5% attrition rate in the variable flow study.  
Primary Effectiveness Endpoint  
Sample Size and Power Calculations  
• Based on a performance goal of 50%, and anticipated freedom from AF/AT/AFL recurrence rate of 65%, with borrowing  up to 
91 subjects  from  the main study , the sample size of  92 subjects 
will be requ ired to obtain at least 80% power to achieve success 
for primary effectiveness endpoint controlling one -sided alpha of 
2.5%, assuming a 12% attrition rate in the variable flow study . 
The analyses for primary safety and effectiveness endpoints will apply 
Bayesian methods and use a beta -binomial with data borrowing from the 
Main study using a propensity score -integrated power prior approach.  
Interim Analysis  One early success claim interim analysis will be executed for main  study  
Determination if DMC/CEC required  CEC will be convened to adjudicate the primary safety endpoint.  Data 
Monitoring Committee (DMC) will be responsible for reviewing the study results. The same committees will be responsible for both studies. 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 19 of 135 Time and Events Schedule  Subjects will be evaluated prior to the procedure, prior to discharge, and 
post procedure at 7 days (7-10 days), 1 month (23- 37 days), 3 months (76 -
104 days), 6 months (150 -210 days), and 12 months (335 -395 days) unless 
otherwise specified in the protocol.  
• Baseline  
o Demographics  
o Medical History  
 AAD Medication Histor y 
 Arrhythmia History  
o Quality of Life Assessment  
 Quality of Life – Atrial Fibrillation Effect on Qualit y of life 
(AFEQT) 
o Device Interrogation (if applicable)  
o TTE or TEE evaluation  
• Ablation Procedure  
o Ablation procedure strategy  outside of the pulmonary vein ostia  
will utilize QMODE +/ QMODE and Investigator’s Standard of 
Care  
 
Data Collection:  
o Catheter Information (Serial #, Lot #)  
o Dongle (Serial #)  
o RF Generator Information (Serial #)  
o Target sites for RF lesion application  
 Targ et Sites  
 Number of RF Applications per target  
 total RF duration per application (sec)  
 Fluoroscopy time/ dose 
 Esophageal temperature monitoring  
 ICE usage, if used  
 Procedure Times  
- Total procedure time  
- Total mapping time  
- Total RF time  
- Time to PVI  
 Fluid delivered  
- From the Study Catheter  
- From IV (if applicable)  
o CARTO and modified RF Generator download for offline 
analysis   
 Segmentation of LA ablation maps based on chosen CARTO 
tags 
 Full Case backup [including complete VISITAG export] and 
CARTO Case record ing 
 RF Ablation parameters per application: Power, Impedance, 
Flow Rate, Temperature, and Time 
 Contact force measurements and RF ablation parameters  
 VISITAG SURPOINT™ value per application , if used  
 Localized ECG Electrodes measurements for offline analysi s 
o Acute Success (entrance and exit block PVI)  
o Adverse Events  
o Cardiac medications  
• Discharge o Recurrence of arrhythmia prior to discharge  
o Device Interrogation (if applicable)  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 20 of 135 o HEMA Billing information  
o Adverse Events  
• Follow -up Assessments Post Ablation*  
o 7 Day phone Call  
o 1-month  
o 3-month  
o 6-month  
o 12-month  
Data to be collected during the study visits will include:  
• Adverse Events (since last visit)  
• Physical Exam  
• Medication update/changes  
• Quality of Life Assessment (at 3 -, 6-, and 12 -month visit)  
o Quality of Life – Atrial Fibrillation Effect on QualiTy of life 
(AFEQT)  
• Billing Information for all hospitalizations, ER visits and outpatient 
visits for economic analyses  
• ECG  
• Recurrence of Study Arrhythmia (each patient will be provided a TTM 
event monitor)  
• Repeat ablation procedures/subject during the follow -up period, repeat 
ablation procedure will be at the discretion of the investigator     
• Throughout the 12- month effectiveness follow -up period, arrhythmia 
status will be assessed by symptom- initiated event monitoring.   
 Device Interrogation (if applicable)  
 All symptomatic cardiac episodes will be documented   
*based on the initial ablation procedure  
QUALIFICATION AND 
ACTIVATION OF OPERATORS  • Experience with Focal Catheters and AF ablation  ≥100 cases  
• Operators – Investigator training is required for the Protocol  and 
Investigational QDOT MICRO™  Catheter  
 
Q-fficiency   Protocol# BWI_2017_07   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 21 of 135 5.0 SCHEMATIC OF STUDY DESIGN 
 
 
Study Enrollment (N=185 ) 
12-month  post -ablation follow -up  
For all treated subjects  
 
Pre-Ablation: Obtain informed consent and then perform baseline 
assessments as described in the Section 14 of the Protocol.  
Procedure : Perform procedure as described in Section 14 of the Protocol.  
Pre-discharge : Perform Pre -discharge assessments as described in Section 14 
of the Protocol.  
7 Day Follow -up: Call subject 7 days (7 -10 days) post procedure to assess 
adverse events as described in the Section 14 of the Protocol.  
1 Month Follow -up: Perform 1 -month (23 -37 days) post procedure 
assessments as described in Section 14 of the Protocol.  
3 Month Follow -up: Perform 3 -month (76 -104 days) post procedure  
assessments as described in Section 14 of the Protocol.  
6 Month Follow -up: Perform 6 -month (150 -210 days) post procedure 
assessments as described in Section 14 of the Protocol.  
12 Month Follow -up: Perform 12 -month (335 -395 days) post procedure 
assessments as described in Section 14 of the Protocol.  
  
NAE Subset  
  
  
(n 
  
=40 
) 
  
Cardiac CT/MRA Subset  
(n =40)  
Study Enrollment (N= 92) 
12-month post -ablation follow -up for all treated subjects  
 
Pre-Ablation : Obtain informed consent and then perform baseline 
assessments as described in the Section 14 of the Protocol.  
Procedure : Perform procedure as described in Section 14 of the 
 
Pre-discharge : Perform Pre -discharge assessments as described in 
Section 14 of the Protocol.  
7 Day Follow -up: Call subject 7 days (7 -10 days) post procedure to 
assess adverse events as described in the Section 14 of the Protocol.  
1 Month Follow -up: Perform 1 -month (23 -37 days) post procedure 
assessments as described in Section 14 of the Protocol.  
3 Month Follow -up: Perform 3 -month (76 -104 da ys) post procedure 
assessments as described in Section 14 of the Protocol.  
6 Month Follow -up: Perform 6 -month (150 -210 days) post procedure 
assessments as described in Section 14 of the Protocol.  
12 Month Follow -up: Perform 12 -month (335 -395 days) post  
procedure assessments as described in Section 14 of the Protocol.  Second Study  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 22 of 135  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 23 of 135 Evaluation of QDOT MICRO™  catheter for pulmonary vein isolation 
(PVI) in subjects with Paroxysmal Atrial Fibrillation (PAF)  
6.0 BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE  
6.1 Background 
Atrial fibrillation (AF) is the most common sustained arrhythmia in humans. It affects 
anywhere from 0.4% to 1% of the general population, and increases in prevalence with age, from < 1% in young adults to 8% in patients over 80 years of age.[1 -4] 
Radiofrequency (RF) catheter ablation has provided excellent results for treating many types of supraventricular arrhythmias.[1, 5]  Its utility in treating paroxysmal AF has 
already been established; studies have s hown high rates of elimination of the 
arrhythmia.[6, 7]   In a non- randomized clinical trial evaluating the imp act of contact 
force on successful outcomes, RF ablation with the THERMOCOOL SMARTTOUCH® SF catheter was associated with elimination of symptomatic atrial arrhythmias in 72.5% of patients at 1 year. [8]  
The 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Consensus Statement states that 
electrical isolation of the pulmonary veins (PVs) from the left atrium is “the cornerstone for most AF ablation procedures.”
[4] Creation of transmural, continuous, and durable 
RF lesions is the objective of PVI. Conventional parameters of radiofrequency (RF) ablation with irrigated catheters involves the delivery of moderate power (2 0-40W) for 
a relatively long duration (20- 40sec) at a contact force range of 10 -20g.  Still, the 
incidence of acute PV reconnection remains frequent, occurring after PVI at a frequency 15-22%.[9, 10]  While the mechanisms underlying PV reconnection are not entirely 
understood, catheter instability, tissue edema, and reversible non- transmural injury have 
been suggested as major contributor.[11, 12] 
RF lesion formation results from two thermal heating phases; resistive and conductive 
heating.  Resistive heating is highly dependent on RF power immediately creating a hot 
spot ~2mm from the tip.  This resistive heating phase creates a heat source that extends passively to deeper tissue layers during the conductive phase.  Conductive heating is time dependent, with heat conducted from the hot spot into the deeper layers of the myocardium.[13]  
Modification of the relationship between the resistive and conductive heating phases, 
by increasing the resistive heating phase to deliver immediate heating to the full thickness of the LA tissue circumferential to the PVs, may achieve uniform, transmural lesions. By reducing the conductive heating phase collateral tissue damage could be limited. [14, 15] This can be achieved by delivering a large current for a short duration.  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 24 of 135 6.2 Previous Experience with the QDOT MICRO™  Catheter and nMARQ RF 
Generator  
6.2.1 QMODE Animal Testing  
6.2.1.1 QMODE wit h the QDOT MICRO™  Catheter  Thigh Prep  
Animal testing was performed using the catheter and complete system per study 
protocol P -0022114 and test report TR-0022114, Verification of QDOT Micro-
Electrode Catheter with Q -mode Ablation Mode – Canine Thigh Preparation Test.  
Purpose:  
The purpose of this study was to evaluate the safety and performance of the QDOT 
MICRO™  electrode catheter using Q MODE  ablation mode (Test Catheter) when 
compared with STSF and ST catheters using power control mode (Control catheters)  
using a well-established canine thigh muscle model. 
Scope:  
The QDOT MICRO™ catheter is intended to be used clinically thus the primarily focus 
of this test was to assess the safety and performance of QDOT MICRO™  electrode 
catheter using Q MODE  ablation mode.  The following objectives were tested: 
• Char/coagulum and steam pop rate  of QDOT MICRO™  catheter using Q MODE  
ablation mode compared with STSF and ST catheters using power control mode.  
• Lesion dimensions (max depth, max diameter and surface diameter) comparison 
between test and control catheters.  
• Ablation parameters were collected for analysis for characterizat ion purposes to 
understand the similarities and differences in their behavior when compared to control catheters: average power, maximum electrode temperature, Temperature Rise, Initial Impedance, Impedance Drop.  
Summary: 
The overall incidence of coagulum observed with the QDOT MICRO™  catheter in 
QMODE  ablation mode was similar to STSF (Control Catheter) and significantly less 
compared to the ST (Control catheter). The overall incidence of Steam pops observed 
with the QDOT MICRO™  catheter in Q MODE  ablation mode was similar compared to 
the STSF and ST (Control catheters). The lesion characteristics were similar between the QDOT MICRO™  catheter and the control catheters. The overall performance of the 
QDOT MICRO™  catheter, in the Q MODE  ablation mode was simila r or better 
compared to the control catheters (ST and STSF) in power control ablation mode. 
Conclusions:  
Based on the results of the canine thigh prep study, the overall safety and performance 
(Coagulum, Steam pops) of the QDOT MICRO™  catheter, when used i n the QMODE 
ablation mode, is similar compared to the control catheters (STSF, ST) being used in power control mode. The maximum ablation parameters identified for the QDOT 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 25 of 135 MICRO™  catheter, in the QMODE ablation mode have been tested and assessed to be 
safe and effective based on the results of this canine thigh prep study. 
6.2.1.2 QMODE with the QDOT MICRO™  Catheter  In Vivo Animal Testing  
Animal testing was performed using the catheter and complete system per study 
protocol P -0023068 and test report TR -0023068, Evaluation of QDOT MICRO-
Electrode Catheter with Q -mode Ablation Mode - Beating Heart Animal Study. 
Purpose:  
The purpose of this acute study was to evaluate the safety and overall functional performance of the QDOT MICRO™  electrode catheter, in the QMODE ablation mode 
(nMARQ multichannel RF generator), when simulating a clinical pulmonary vein isolation (PVI) procedure. The overall safety and functional performance of the QDOT MICRO™  electrode catheter and QMODE ablation mode was compared to the control 
catheter (Smart Touch SF) being used in power control mode (Smart Ablate generator).  
Discussion:  
The QMODE Beati ng Heart study was conducted according to the study protocol design 
and its requirements.  
No char/coagulum observed on the test catheter ( QDOT MICRO™ ). The overall 
incidence of steam pop observed with QDOT MICRO™  (0 in RA, 5/9 in the LV and 0 
in all other  locations) was lower compared to the control STSF catheter (0 in RA, 3/36 
during PVI, 5/12 in LA wall, 5/6 in LV and 1/7 in RV). Of note, there were zero 
incidence of steam pop occurrence in both left and right atrial ablations using QDOT 
MICRO™  catheter with QMODE at the study settings.  
The QDOT MICRO™  ablation catheter used in conjunction with the QMODE ablation 
mode was able to:  
• Deliver RF energy at a target site  
• Demonstrate acute isolation of the pulmonary vein. 
• Demonstrate clinically acceptable sign al quality which was comparable to control. 
• Pace from ring electrodes and microelectrodes during idle -state and during 
ablation. 
• Provide significantly better temperature feedback during ablation than control 
catheter.  
• Function effectively when used in conjunction with ancillary equipment like 
nMARQ multichannel RF generator, QDOT Dongle, CoolFlow pump and CARTO 3 mapping system. 
The QDOT MICRO™  ablation catheter, when used with QMODE ablation mode, was 
able to produce effective electrogram signal attenuatio n and equivalent to (or better) 
lesions as compared to that with the STSF catheter in all four cardiac chambers.  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 26 of 135 The nMARQ generator was able to successfully modify the irrigation flow rate based 
on QDOT MICRO™  catheter electrode temperature response and p ower settings to 
maintain temperature limit when used in the QMODE ablation mode.  
Conclusions:  
The QDOT MICRO™  ablation catheter with QMODE ablation mode using the 
temperature target and flow rate settings as set forth by the protocol, meets all acceptance criteria as listed in protocol P -0023068.  
The overall functionality and the safety of the QDOT MICRO™  ablation catheter with 
QMODE ablation mode is equivalent to or better than that of the control STSF catheter.  
6.2.2 QMODE+ Mode with the QDOT MICRO™  Catheter Animal Testing  
6.2.2.1 QMODE+ Mode with the QDOT MICRO™  Catheter Thigh Prep  
Animal testing was performed using the catheter and complete system per study protocol P -0022211 and test report TR -0022211, Verification of QDOT Micro -
Electrode Catheter with QMODE+ Ablation Mode – Canine Thigh Preparation Tests. 
Purpose:  
The purpose of this study was to evaluate the safety and performance of the QDOT 
MICRO™  Catheter in QMODE+  (high power, short duration) ablation mode (90W/4s) 
using the nMARQ Multi -channel RF generator. The overall safety and performance of 
the QDOT MICRO™  catheter in the QMODE+  ablation mode was compared to the 
safety and performance of STSF catheter (Control catheter) in power control mode at two different settings (50W/10s or 30W/30s) using the Smart Ablate RF generator, 
using a well-established canine thigh muscle model. 
Scope:   
The QDOT MICRO™  catheter is intended to be used clinically thus the primarily focus 
of this test was to assess the safety and performance of QDOT MICRO™  electrode 
catheter using QMODE+  ablation mode.  The following objectives were tested: 
• Safety of QDOT MICRO™  catheter using QMODE+  ablation mode 
(char/coagulum and steam pop) compared with STSF catheter using power control 
mode.  
• Lesion dimensions (max depth, max diame ter and surface diameter) comparison 
between test and control catheters.  
• The following ablation parameters were collected for analysis for characterization purposes only (no acceptance criteria) in order to understand the similarities and differences in their behavior when compared to control catheter: average power, maximum electrode temperature, Temperature Rise, Initial Impedance, Impedance Drop. 
Summary: 
There was no significant difference in the overall incidence of coagulum observed w ith 
the QDOT MICRO™  catheter in QMODE+  ablation mode compared to the STSF 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 27 of 135 (Control Catheter) in power control mode, when tested in both perpendicular and 
parallel orientations. A small Grade 1 (Grade 1: ≤1mm3) was observed with the Qdot catheter at 90W/4s with perpendicular orientation at 30g. Whereas one Grade 1(Grade 
1: ≤1mm3) observed with STSF catheter at 50W/10s with parallel orientation at 10g and one Grade 2 (Grade 2:>1mm3) was observed at 30W/30s with parallel orientation at 30g.  
No Steam pop was observed with the QDOT MICRO™  catheter in QMODE+  ablation 
mode in Perpendicular as well as Parallel orientation at 10g and 30g. One steam pop 
was observed with STSF catheter (Control Catheter) at 50W/10s with perpendicular orientation at 30g and two steam pops were observed at 30W/30s with parallel orientation at 30g.  
The lesion depth was significantly smaller with the QDOT MICRO™  in QMODE+  
ablation mode than the STSF catheter in Power control mode for both perpendicular and 
parallel with 10g and 30g. The l esion diameter was greatest with the STSF catheter in 
power control mode for 30W/30s for both perpendicular and parallel orientation at 10g and 30g. However, lesion diameter of QDOT MICRO™  catheter in QMODE+  ablation 
mode (90W/4s) and STSF (50W/10s) in pow er control mode was similar. The overall 
safety of the QDOT MICRO™  catheter, in the QMODE+  ablation mode was similar or 
better compared to the control catheter (STSF) in power control ablation mode. 
Conclusion:  
Based on the results of the canine thigh prep study, the maximum ablation parameters 
identified for the QDOT MICRO™  catheter, in the QMODE+  ablation mode have been 
tested and assessed to be safe and effective.  
6.2.2.2 QMODE+ Mode with the QDOT MICRO™  Catheter In Vivo Animal 
Testing  
Animal testing was performed using the catheter and complete system per study 
protocol P -0022212 and test report TR -0022212, Acute Canine Beating Heart Study for 
Validation of QMODE+ with QDOT MICRO™  Catheter.  
Purpose:  
The purpose of this study was to verify safety and effectiveness of the QDOT MICRO™  
catheter using the QMODE+  mode (test group) as compared to the STSF catheter using 
the power control mode (control group) in a simulated clinical environment using the canine b eating heart model.  
Scope:  
The test focused on the safety and effectiveness of the QDOT MICRO™  catheter with 
QMODE+  mode as compared with the STSF catheter using power control mode.  
• QMODE+  primary safety endpoints 
o Char, Coagulum and Steam pop 
o Primary adve rse event: cardiac perforation, tamponade and death  
o Collateral damage in the heart and adjacent organ/tissues  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 28 of 135 • QMODE+ secondary effectiveness endpoints 
o Endocardial and epicardial surface diameters  
o Lesion depth and transmurality and PVI rate 
o Signal quality ( M1-4 compared to control, μ1- 3 qualitive measurements)  
 
Discussion:  
 The QMODE+  Beating Heart study was conducted according to the study protocol 
design and its requirements.   No char/coagulum observed on the test catheter ( QDOT MICRO™ ). The overall 
incidence of steam pop observed with QDOT MICRO™  (0 in all locations) was lower 
comp ared to the control STSF catheter (1 in LA PVI). Of note, there were zero incidence 
of steam pop occurrence in the right atrial location and both the left and right ventricular locations using QDOT MICRO™  catheter with QMODE+  at the study settings. 
 The QDOT MICRO™  ablation catheter used in conjunction with the QMODE+  mode 
was able to:  
• Deliver RF energy at a target site  
• Demonstrate acute isolation of the pulmonary vein. 
• Demonstrate clinically acceptable signal quality which was comparable to control.  
• Pace from ring electrodes and microelectrodes during idle -state and during 
ablation. 
• Provide significantly better temperature feedback during ablation than control catheter.  
• Function effectively when used in conjunction with ancillary equipment like nMARQ multichannel RF generator, QDOT MICRO Dongle, CoolFlow pump, and 
CARTO 3 mapping system. 
 The QDOT MICRO™  ablation catheter, when used with QMODE+  mode, was able to 
produce effective electrogram signal attenuation with equivalent (or better) lesions as compared  to those with the STSF catheter in all four cardiac chambers.  
 Conclusions:  
 The QDOT MICRO™  ablation catheter with QMODE+  ablation mode using the 
temperature target and flow rate settings as set forth by the protocol, meets all acceptance criteria as li sted in protocol P-0022212.  
 The overall functionality and the safety of the QDOT MICRO™  ablation catheter with 
QMODE+  mode is equivalent to or better than that of the control STSF catheter. 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 29 of 135 6.2.3 QDOT MICRO  GLP Study  
 
Purpose:  
 This study was designed to evaluate overall safety of a new modified therapeutic micro -
electrode ablation catheter ( QDOT MICRO™) and demonstrated that added catheter 
features do not introduce any new safety risks when compared to its predicate device Biosense Webster THERMOCOOL SMARTTOUCH® SF catheter.  
 Results:  
 Overall, The GLP study findings met all endpoints concerning the safety of the Test catheter:  
• Occurrence of thrombus and/or charring on the catheter tip: 
There was no evidence of thrombus and/or charring on any of the catheters used and examined , following delivery of RF energy. 
• Occurrence of mural thrombus in the treated heart chambers: 
There was no evidence of mural thrombus detected during the ablation or follow-up procedures using intracardiac echo or at the treatment si tes that could be detected 
macroscopically or microscopically.   
• Pulmonary vein stenosis: 
There was no evidence of pulmonary vein stenosis in any of the animals regardless of treatment or group assignment. 
• Occurrence of collateral damage:  
Collateral damage to the adjacent tissues was rare, was occasionally observed at the hilus in the right lung lobes and in the pulmonary artery and aorta. These lesions were self -limited, did not disrupt the integrity of tissues involved and showed optimal 
healing through fibrosis.  
• Occurrence of device related mechanical injury:  
There was no pathologically meaningful procedural trauma in any of the treated sites with rare exceptions of minor endocardial tears that were fully healed at 30 days with no evidence of prior thrombosis.  
• Occurrence of peripheral thrombo- emboli: 
No thrombo- emboli or ischemic lesions were observed in downstream tissues: brain, 
myocardium, kidneys, liver, spleen and lungs based on screening through systematic bread -loafing with gross evaluation and systemic sampling for microscopic 
evaluation. 
 Overall, The GLP study findings met all endpoints concerning efficacy of the Test catheter:  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 30 of 135 • Effectiveness of ablation in the left atrium  
Elimination of PV electrical potential could be confirmed immediately following 
ablations in all animals regardless of group assignment or treatment received. In addition, this study demonstrated long term effectiveness of pulmonary vein isolation using the Test or Control catheters as delayed conduction (only in Animal 1244, 
Group 2) or no electrical potential could be detected in the treated pulmonary veins at 35 -36 days post isolation. 
• Effectiveness of ablation in the right atrium  
All ablations delivered to the right atrium regardless of ablation settings or a blation 
catheter use were found effective as a greater than 50% reduction in the electrogram amplitude.   
 Conclusions:  
 Biosense Webster QDOT MICRO™  ablation catheter met the safety and efficacy 
criteria set forth in the study protocol when used with nMAR Q™ RF generator, Carto 
3 EP navigation system, CoolFlow irrigation pump, catheter interface cable, and standard pacing system for ablation in the beating heart of a chronic canine model without any significant device related clinical adverse events.  
 In conclusion, this study demonstrated that added catheter features do not introduce any 
new safety risks when compared to its predicate device Biosense Webster THERMOCOOL SMARTTOUCH® SF catheter.  
6.2.4 QDOT FIM Studies  
Two feasibility  studies a re underway to assess  the performance  of the QDOT Micro™  
Catheter.  
6.2.4.1 QDOT MICRO™  Workflow 
The purpose of QDOT MICRO™  Workflow study is to evaluate the workflow and acute 
performance, during standard electrophysiology mapping and RF ablation procedures, of the QDOT MICRO™  cathet er. This study is a prospective, multi -center, non-
randomized, interventional clinical study.  The target population are paroxysmal AF 
subjects who are scheduled to undergo a clinically- indicated ablation procedure for 
managemen t of their paroxysmal AF . Subjects will be followed up at 7 days and 3-
month post-procedure.  
The main objectives of the study are acute device performance and acute safety. The 
study will enroll 50 subjects at 5 centers in Europe.  
 
6.2.4.2 QDOT MICRO™  QMODE+ FIM  
The purpose of this feasi bility study is to evaluate safety and acute performance of the 
QDOT Micro™  catheter used in combination with the nMARQ™ Multi-Channel RF 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 31 of 135 Generator with QMODE+ mode in the treatment of Paroxysmal Atrial Fibrillation (PAF) 
during standard electrophysiology mapping and RF ablation procedures. This a 
prospective, multi-center, non-randomized, interventional clinical study. 50 paroxysmal AF subjects who are scheduled to undergo a clinically-indicated ablation procedure for management of their paroxysmal AF will be enrolled at up to 10 centers in Europe. The subjects will be followed till 3 -months post-procedure. 
6.3 Rationale 
The Biosense Webster QDOT MICRO™  Catheter is a steerable multi -electrode luminal 
catheter with a deflectable tip designed to facilitate electrophysiological mapping of the 
heart and to transmit radiofrequency (RF) current to the catheter tip electrode for ablation purposes.  In addition to force -sensing technology, the catheter incorporates six 
thermocouple temperature sensors and three micro electrodes embedded in the 3.5 mm tip electrode.  
The measured temperature can be used by the operator to assess the efficiency of ablation in real time. The localized temperature measurement will provide a highly sensitive measure of catheter location stability and/or movement during RF application and may reduce the need for additional RF applications.   
The micro electrodes will provide high quality localized electrograms that will allow 
finer endocardial electrical mapping and a better assessment of possible conduction gaps 
in the ablation lesion sets used to isolate the pulmonary veins and determining bidirectional block of linear lesion sets.   
Finally, the catheter tip has incorporated a new angled design of the irrigation ports.  
This new design allows for reduced incidence/risk of charring and coagulum on the 
catheter increasing safety during the ablation procedure. 
A series of In vivo and in vitro experiments, including thigh muscle preparation model 
and in vivo beating heart experiments, were conducted to determine an appropriate QMODE+  setting that could be demonstrated to be safe and deliver uniform transmural 
lesion near the PV circumference. The main objective was to identify and evaluate an optimal ablation setting that allows maximal power output at the shortest duration possible, without char or steam -pop formation.   A range of power (i.e. 50 -100W) and 
durations (3- 15 seconds) were studied and analyzed.  The data from these evaluations 
suggests that using higher power to promote resistive heating while shortening the duration to limit the impact of conductive heating through adjacent tissue provides the optimal balance for efficiency, eff ectiveness and safety.  The conclusion from these 
studies has been implemented as the QMODE+ algorithm using ablation parameters of 
90W for a duration of 4s (irrigation setting at 8ml/min). These parameters were used for validation of animal studies as summarized in this study protocol (refer to Sections 6.2.2 and 6.2.3).  
Delivery of high RF power for short duration (90W, 4 seconds) achieves uniform 
transmural lesions, main ly relying on resistive heating [16-19] QMODE+ at up to 90W, 
4 seconds may significantly shorten RF ablation time while maintaining the effectiveness and safety profile.  A temperature limit has been defined to maintain the ablation safety profile.  Ablation effectiveness may be improved since the physician is 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 32 of 135 required to maintain catheter stability for a short duration. By reducing the conductive 
heating phase, QMODE+ may minimize the risk of collateral damage to adjacent 
structures.   
6.3.1 Ablation Parameters for the QDOT MICRO™  Catheter  
The ablation algorithm is d esigned to maximize RF lesion efficiency by using temperature 
feedback from the tip to adjust power and irrigation flow. The QMODE Temp erature mode  
monitors the temperature rate of change in relationship to the set target temperature during RF application.  To maintain desired power levels at a safe temperature, the QMODE  
adjusts the irrigation flow rate as a first order of control.  A secondary control of power titration is also used if the temperature cannot be maintained with the increased irrigation flow rate alone.  Typical temperature control algorithms for mainstream commercial 
irrigation RF catheters rely purely on power titration to maintain the desired temperature.  
By utilizing the irrigation flow rate first, the Q -dot catheter is able to deliver consistent 
power for efficient ablations without compromise of safety.  
RF Energy Modulation:  
The RF energy application is separated into two distinct zones: 1-50W and 90W.   For power settings from 1- 50W, the approach is to modulate irrigation and then t itrate 
power as needed to maintain the target temperature. As an example (see Figure 7.3.1a ), the 
power delivery (e.g. 35W) would start with the irrigation setting at 4 ml/min until it reaches a target temperature (e.g. 50°C).  When the catheter reaches the target temperature, irrigation is then changed to 15 ml/min automatically by the generator algorithm.  This increase in irrigation flow rate cools the tip and allows the generator to maintain the delivered power.  If the temperature decreases, the pump irrigation flow rate is returned to the lower setting (i.e. 4mL). Under circumstances when increased irrigation flow does not sufficiently reduce the tip temperature, power delivery is automatically reduced.  
 In a second example (see Figure 7.3.1b), the power delivery (e.g. 50W) starts with the 
irrigation setting at 15 ml/min until it reaches a target temperature (e.g. 50°C).  If the catheter is below the desired temperature initially, the irrigation is automatically reduced to 4ml/min by the generator algor ithm to maximize the sensitivity to temperature.  Once 
the temperature sensed at the tip starts to rise, the generator automatically increases the irrigation flow back to 15 ml/min.  This cycle continues between low and high irrigation settings in order to maintain the target temperature.  Again, under circumstances where the 
tip temperature is above 50°C, the power delivery is automatically reduced.   Main  Study  
For power settings at 90W (Figures 6.3.1C and 6.3.1D ), the maximum duration is set to 4 
seconds. Therefore, the approach is to only titrate power.  At this setting, power delivery is delivered at a constant irrigation flow of 8 ml/min with no modulation given the short duration.   
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 33 of 135  
Figure 6.3.1A-D : Graphs of the Generator Power over Time 
A. RF P ower Delivery at 35W  
 
 B. RF Power Delivery at 50W  
 
 C. RF Power Delivery at 90W  

Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 34 of 135  
 
D. RF Power Delivery at 90W, power titration evident  
 
Second (Variable Flow) Study  
 RF energy modulation for V ariable Flow rate:  
 The QDOT MICRO catheter is designed to work in a temperature control/power and irrigation modulation mode.  This is how the system works for QMODE (refer to Figures  
6.3.1A and Figure 6.3.1B above).  However, when making 90W RF applications with a constant irrigation flow (8 mL/min) the system only worked in power control mode.    The purpose of the variable flow irrigation option is to improve the catheter tip temperature response during high power, short duration (Qmode+) ablations. This is 

Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 35 of 135 achieved by optimizing the flow rate (4- 15 mL/min), which minimizes the impact of 
constant irrigation (8 mL/min) on the lack of catheter tip temperature response during 
short duration (4s) 90W RF applications (refer to Figure 6.3.2A and Figure 6.3.2B).   For power settings at 90W (Figures 6.3.2A and 6.3.2B), the maximum duration is set to 4 seconds. Therefore, the approach is to only titrate power.  At this setting, power delivery is delivered with a variable flow rate. Irrigation at 4 mL/min starts with the initiation of 
90W energy application.  The flow r ate remains at 4 mL/min if the catheter tip 
temperature remains below the target energy cutoff temperature (refer to Figure 6.3.2A ). 
If the catheter tip reaches the target temperature, irrigation is then changed to 15 ml/min 
automatically by the generator algorithm.  This increase in irrigation flow rate cools the 
tip and allows the generator to maintain the delivered power (refer to  Figure 6.3.2B ). 
 Figure 6.3.2A-B : Graphs of the Generator Power over Time 
A. Example 1 at 90W: Temperature does not approach Target Temperature 
(flow rate 4mL/min)  
 
 
B. Example 2 at 90W: Temperature approaches Target Temperature (flow rate 
changes to 15 mL/min)  
 

Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 36 of 135 6.4 Potential Risk and Benefit  
After over two decades of intracardiac radiofrequency (RF) catheter ablation, the 
procedural risks and complications associated with routine RF ablation are well documented and understood.  Procedural risks posed by the QDOT MICRO™  catheter 
are expected to  be comparable to these known anticipated risks.[3, 4, 20].  Few, if any, 
additional risks that might occur during and following RF ablation of symptomatic PAF are anticipated for subjects enrolled in this study. 
A summary  of risks  associated  with catheter  ablation, including analysis  of and plans to 
minimize  these risks  is provided below: 
6.4.1 Description  and Analysis of Risks   
Risks  associated with  catheter ablation 
Studies have reported low rates of major complications (0.8%)[21, 22]  with major centers 
worldwide reporting rates lower that <5%[23, 24] associated with catheter ablation.  
The most common complications associated with catheter ablation of AF include:  
 Cardiac tamponade  is reported at approximately 0.2 to 5% in catheter ablation of atrial 
fibrillation (AF) [4], comprising mainly pulmonary vein isolation (PVI ) procedures. Data 
presented by recent meta- analysis of 34,943 ablation procedures by Michowitz et al 
reported incidence of 0.8% [25]. Rates as low as 0.18% have also been reported in a recent 
study that reviewed complications among 2,750 procedures[22].   The general incidence of pericardial effusion during AF ablation is around 1.2% to 1.3%[21, 23]. Cardiac perforation may result from catheter manipulation or application of radiofrequency current.  Published risks of cardiac perforation range from <1% to 
2.4%[23] . However the ris k of perforation is decreased with advances in catheter 
technology[26]. This potentially life -threatening injury may result in cardiac tamponade 
and may require percutaneous pericardial drainage or surgical repair.  Significant hemodynamic compromise can result in neurologic injury or death.  An increased risk of 
cardiac perforation may be associated with the use of a saline -irrigated electrode catheter 
due to its ability to create a larger, deeper RF lesion.  This risk is greatest in a thin walled chamber (i.e., RA, LA, appendage, or RV).   Pulmonary vein stenosis : Pulmonary vein stenosis (PVS) is a well -known complication 
of radiofrequency catheter ablation of atrial fibrillation. Incidence of severe PVS (>70% diameter reduction) w as found to be <1% in a recent study with 976 subjects [27]. Incidence 
of only 0.5% was reported in a large systematic review on complications of radiofrequen cy 
catheter ablation.  
 Esophageal injury: Since the left atrium has close anatomical proximity to the esophagus, catheter ablation on the LA posterior wall may thermally damage the esophagus and eventually generate an esophageal ulcer with a prevalence of  5% [28] that rarely may 
progresses to an atrial esophageal fistula (AEF) with catastrophic consequences [29]. 
Esophageal injury by endoscopy has a prevalence between 2.2 to 21% [28]. Esophageal 
perforation is a dreaded complication of atrial fibrillation ablation that occurs in 0.02 to 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 37 of 135 11% [28, 30]  of atrial fibrillation ablation procedures. Delayed diagnosis is associated with 
the development of atrial -esophageal fistula (AEF) and increased mortality. Complication 
rates for esophageal injury are quite varied, depending upon lesion location and type  of 
lesion found (erythema, necrotic ulceration, perforation, or fistula formation). The 
incidence of AEF post -ablation of AF is supposed to be around 0.1% of the procedures [31]. 
Studies using luminal temperature monitoring to identify potentially dangerous heating of the esophagus during ablation have not been able to  demonstrate reduction in incidence[32].   Phrenic nerve paralysis : Currently, this complication has been reported in less than 0.5%, 
with permanent paralysis between 0% to 0.4% when the isolation of right PV is not 
obtained during PV antra isolation and RF ablation is performed inside at carina the right PVs [4, 32, 33]. A 2018 published study reported very low rates of PNP of 0.04% among 
2,750 procedures [22]. Prior to ablation in the region of the RSPV, investigators are 
encouraged to perform precautionary measures such as evaluation of proximity to the phrenic nerve and pacing maneuvers.   Death  is an uncommon complication associated with CA techniques. Overall incidence of 
death has been reported to be <0.1% to 0.4% [4]. A 2010-published global survey provided 
an overall mortality rate of 0.1%.
  Another report from an international survey of AF 
ablation of 162 centers provided details on 32 deaths that occurred during or after AF ablation procedures in 32,569 patients (0.1%) [34, 35] . Among the most frequent causes of 
death were cardiac tamponade (25% of deaths), stroke (16%), atrio- esophageal fistula 
(16%) and massive pneumonia (6%)[35]. 
 
Radiofrequency current may cause occlusion of a coronary artery, either by direct thermal damage, spasm, or thrombus formation.  Acute coronary artery occlusion is a very rare but potentially life -threatening complication of RFCA [36]. Experience at numerous centers 
suggests that the risk of coronary occlusion is less than 0.5% [37].  Coronary arterial 
occlusion could produce myocardial infarction (MI), angina or death.  Occlusion of a coronary artery can be treated by restoring coronary blood flow through pharmacological, catheter and/or surgical intervention as medically indicated.  The application of radiofrequency current close to the AV node or His bundle could damage or destroy the normal AV conduction system, producing complete heart block and requiring implantation of a permanent pacemaker.   Thromboembolic events: Thrombus generation during the procedure may pose a serious 
and even life -threatening risk to the patient.  Thrombus may form on the ablation electrode 
during the application of radiofrequency current with or without any change in impedance.  The thrombus might become dislodged and embolize to produce an ischemic stroke, MI, or other occlusive injury. Although some observational studi es have shown a relatively 
lower stroke rate after catheter ablation, whether catheter ablation can reduce the thromboembolic risk remains unclear.   The mean incidence of thromboembolism associated with AF ablation was reported by Cappato et al in 2010 to be between 1% and 2% [23]. More recently, Fuji et al have reported 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 38 of 135 incidence of th romboembolism up to 5% of patients undergoing AF ablation despite 
perioperative anticoagulation[38]. Ischemic stroke events typically occur within 24 hours 
of the AF ablation procedure with the higher risk period covering for the first two weeks 
following ablation[39].  Pulmonary hemorrhage is a rare but severe complication of PVI. Late hemoptysis and pulmonary hypertension can occur  secondary to pulmonary vein stenosis (PVS) after 
ablation. Acute pulmonary hemorrhage also has been reported[40]. Mechanical trauma from catheter manipulation is a possible mechanism for pulmonary hemorrhage[41]. Injury to a cardiac valve may result from catheter manipulation or the application of radiofrequency current (risk <1%)[42] . This may produce valvular insufficiency and 
possibly require valve replacement surgery.   Vascular access / bleeding complication : Arterial or venous injury, including arterial 
dissection, thrombosis, occlusion or hemorrhage at the catheter insertion sites or at other 
sites along the vessels (risk 0.2% to 1.5%).[4, 43, 44]  These types of injuries may cause 
hemorrhage, hematoma or ischemic injury to an extremity or major organ.   Hemorrhage could occur as a result of anticoagulation (risk < 0.5%), which may require transfusion.[43, 44]  Radiation exposure : Radiation exposure during the fluoroscopic imaging of the catheters 
may result in an increase in the lifetime risk of developing a fatal malignancy (0.1%) or a 
genetic defect in offspring (0.002%).[45 -47] 
 Allergic Reaction : A patient could develop an allergic reaction to the local anesthetic, 
sedatives, x -ray dye, heparin, protamine, or other agents administered during the procedure 
(risk < 1%).[48 -52] 
 Infection : The percutaneous procedure carries risk of infection, either at the catheter 
insertion site or systemically, including endocarditis and septic emboli (risk < 0.5%).[43, 44] This risk can be minimized by using standard aseptic technique and, when indicated, 
by the use of antibiotic agents.  Additional contraindications : Additional contraindications for RF ablation include: 
hemodynamic instability, bacteremia, coagulopathy, prosthetic tricuspid valve, intra- atrial 
or venous thrombosis, and pregnancy.  Investigational device related risks  
 A review of the testing of the investigational devices verifies that risks associated with the designs are acceptable and no unacceptable (Intolerable) risks have been noted. Any testing 
deviations are discussed within the body of the respective testing reports and all deviations were reviewed and considered to be acceptable.  
 The designs of the investigational devices have been subjected to testing (bench top, thigh preparation, simulated clinical conditions via in vivo beating heart testing and 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 39 of 135 EMC/Electrical Safety testing). The results of the various testing performed have verified 
the safety of the investigational devices when used in accordance with the Instructions for Use.  
 Biocompatibility and Sterility Assessments for the applicable investigational devices have been performed and verify that the proposed design and packaging meet the existing requirements for both categories.    A review of the risk assessment d ocuments for the investigational devices has verified that 
there are no “Intolerable” ratings related to risks associated with the designs of the devices.  All ratings are “As Low As Practical” (ALAP).  
6.4.2 Minimization  of Risks  
Appropriate measures have been o utlined in the study protocol to minimize the risk to 
subjects, while still providing the possible benefits of the treatment options to be studied. Although there are potential risks posed during a cardiac RF ablation procedure, the criteria for subject selection, methods, personnel, facilities, and training that have been specified for this study are intended to minimize the risk to subjects undergoing this procedure.    Robust testing of the investigational devices at component and the system level, withi n 
simulated clinical conditions, was successful with no adverse events identified. During the QMODE+ design phase, systematic proactive risk analyses did not identify new hazards 
and harms . Additionally, the risk of potential a dverse events is mitigated by  the temp cutoff 
setting of the generator and the optimiza tion of the target temperature.   
 Subjects will be screened carefully prior to enrollment in the study to ensure compliance with the inclusion and exclusion criteria. The exclusion criteria have been developed to eliminate confounding co- morbidities that might interfere with study interpretation; to 
furnish a more homogenous study population that allows a focused characterization of the QDOT MICRO™  catheter for the treatment of PAF; exclude subjects with a medical 
history or condition that increases their risk of adverse events. Subjects will be evaluated for presence of left atrial thrombus prior to the procedure. Additionally, using esophageal monitoring techniques will be used while ablating the posterior wall, thus minimizing risk of injury.  Participating investigators will be experienced and highly skilled in performing electrophysiology studies, intracardiac mapping and ablation of AF with the use of RF ablation catheters.  Each site’s Principal  Investigator will have satisfied the established 
training criteria. Procedures will be performed in electrophysiology laboratories with the assistance of skilled nurses and technicians.  The laboratory will contain sufficient resuscitative equipment and f acilities to manage any potential complication.  Immediate 
access to cardiac surgical facilities, as well as a qualified cardiovascular surgeon, will be available during the ablation procedure in the event that surgical intervention becomes necessary.  
  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 40 of 135 6.4.3 Precautions  
Invasive electrophysiological evaluation  and catheter  ablation  may impart some degree  
of risk to the subject. The risk of serious complications  is generally  related  to the 
severity  of cardiac disease.  The degree of risk of the electrophysiological and catheter  
ablation  procedures versus the potential benefit  of the treatment  of a paroxysmal or 
recurrent  arrhythmia should be determined  by a qualified  physician. Cardiac 
catheterization  and electrophysiological procedures should be performed  by qualified  
and appropriately  trained  personnel in an electrophysiology laboratory. The laboratory  
should contain  sufficient  resuscitative  equipment and facilities  to manage most potential 
complication s. Failure  to observe the contrain dications, warnings, and precautions in 
these instructions and  the IFU may  result  in procedur al complication s. Immediate  risks 
from  ablation  treatment may include: cardiovascular  injury or perforation  with or 
without cardiac tamponade, pulmonary embolus, tricuspid  regurgitation, myocardial  
infarction, bleeding at the catheter  insertion  site,  sepsis,  and death.   
Contraindications for catheter  ablation  of arrhythmia  include: existing  hemodynamic 
instability,  bacteremia,  coagulopathy, prosthetic tricuspid  valve,  intra-atrial or venous 
thrombosis, and  pregnancy. 
 
6.5 Known Potential Benefits  
Current practice guidelines reflect extensive expert reviews of published risks and benefits 
among various treatment modalities and patient populations. All key published guidelines 
agree that the primary clinical benefit of catheter ablation for PAF is an improvement in quality of life, following abatement of arrhythmia- related symptoms.  
 The 
role of catheter ablation as first -line therapy, prior to a tr ial of a Class I or III 
antiarrhythmic agent, has been suggested as an appropriate indication for catheter ablation of AF in patients with symptomatic paroxysmal or persistent AF by the HRS/EHRA/ECAS 2017 Consensus Statement [4]. In this circumstance, the benefits of catheter ablation 
outweigh the risks (Class IIa); however, the strength of evidence/data supporting this therapeutic modality (Level  B) reflects a limited number of clinical studies. Not all expert 
bodies are in line with the aforementioned expert opinion.    The 2016 ESC -published guidelines and recommendations for the management of AF 
suggested that in patients who experience symptom atic recurrences of AF despite 
antiarrhythmic drug therapy, catheter ablation shows better sinus rhythm maintenance with catheter ablation than on antiarrhythmic drugs [53]. However, the guidelines also present 
that randomized trials showed only modestly improved rhythm outcome with catheter ablation compared to antiarrhythmic drug therapy[53].   Catheter ablation has been used for over two decades to treat AF patients to achieve PVI. 
Significant catheter design improvements (e.g., irrigated encircling catheters) focus upon improving physicians’ abilities to achieve finite entrance block following PVI, reducing damage to neighboring structures and improving procedural efficiency.   
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 41 of 135 The QDOT MICRO™  Catheter is a steerable multi -electrode luminal catheter with a 
deflectable tip with the force -sensing technology also incorporates six thermocouple 
temperature sensors and three micro electrodes embedded in the 3.5 mm tip electrode.  
  The measured temperature allows the operator to assess the efficiency of ablation in real time.  Thus providing a highly sensitive measure of cath eter location stability and/or 
movement during RF application and potentially  reducing the need for additional RF 
applications.    The micro electrodes provide high quality localized electrograms that allow finer 
endocardial electrical mapping and better assessment of possible conduction gaps in the ablation lesion sets used to isolate the pulmonary veins and determining bidirectional block of linear lesion sets.    The catheter tip has incorporated a new angled design of the irrigation ports. This new design allows for reduced incidence/risk of charring and coagulum on the catheter 
increasing safety during the ablation procedure. With improved contact force information and temperature feedback in any tip tissue orientation, the new QDOT Micro™  catheter is 
designed to create durable lesions, in shorter time thus reducing the procedural time, and improved irrigation flow with reduction in the amount of fluid load in the patient as compared to a typical irrigation ablation  catheter. The catheter also limits con ductive 
heating and collateral damage to neighboring structures including non -cardiac adjacent 
tissues, improving safety during the procedure[14, 19, 54] 
7.0 STUDY OBJECTIVE S AND PURPOSE  
7.1 Purpose  
The purpose of this study is to demonstrate the safety  and 12-Month effectiveness  of the 
QDOT MICRO™  catheter  when used with the nMARQ ™ RF generator in the treatment  
of drug refractory  symptomatic  paroxysmal atrial  fibrillation  (PAF)  during standard  
electrophysiology mapping and  RF ablation  procedures. 
7.2 Objectives  
The primary objective of this clinical investigation is to demonstrate the safety and 12-month effectiveness of the QDOT MICRO™  catheter when used with  the nMARQ ™ RF 
generator for pulmonary vein isolation (PVI) in the treatment of subjects with paroxysmal atrial fibrillation (PAF).  
• To demonstrate the safety based on the proportion of subjects with early-onset (within 7 days of ablation procedure) primary adverse events  
• To demonstrate the 12- month effectiveness based on the proportion of subject with 
freedom from documented atrial arrhythmia (atrial fibrillation (AF), atrial tachycardia (AT) or atrial flutter (AFL)) episodes during the effectiveness evaluation period (Day 91-365)  
The major secondary objectives of this study are:  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 42 of 135 • To evaluate the incidence of (serious) adverse events during and after procedure up 
to 3 months following procedure.  
• To evaluate Acute Procedural Success as defined by:  
o The % of subjects with electrical isolation of  PVs (entrance block) at the end of 
the procedure, and  
 The % of subjects with electrical isolation of PVs (entrance block) using 
QMODE+ as the only ablation strategy  
 The % of subjects with electrical isolation of PVs (entrance block) at all power settings combined 
o The % of subjects with electrical isolation of PVs (entrance block) after first pass isolation, after waiting period and adenosine challenge   
 
8.0 STUDY DESIGN AND ENDPOINTS  
8.1 Description of the Study Design 
The QDOT  study is a prospective, multicenter,  non- randomized  clinical  evaluation of the 
QDOT MICRO™  catheter  in treating  subjects  with symptomatic  PAF who have failed  at 
least one antiarrhythmic  drug.  
 
Main  Study  
Up to 185 subjects will be enrolled  at up to 30 sites.  A Cardiac CT/MRA image subset will 
be integrated within the Main  Study. 
Second (Variable flow) Study  
Up to 92 subjects will be enrolled at up to 26 sites.   
Both Studies  
Effectiveness and safety endpoints have been defined and will be compared to 
predetermined performance goals. Subjects who sign informed consent are considered enrolled in the study. Enrolled subjects who satisfy all eligibility criteria will then undergo the ablation procedure with the QDOT MICRO™ catheter.  
After  the study ablation  procedure, subjects will enter  a 3-Month blanking period (D ay 
0-90).   
After  the Blanking Period , subject s will enter  the Evaluation Period  (Days 91-365).  
Subjects  having AF recurrence and/or receiving  therapeutic interventions during the 
evaluation  period will be considered  effectiveness  failures  (refer to Section 8.2.2 for all 
effectiveness  failure  modes ).  
All subjects  will undergo follow up visits  at defined  intervals  (refer  to Table  13.8A 
Schedule of Treatments  and Evaluations). Subjects  complete  the IDE study after the 12-
month follow up visit.   
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 43 of 135 8.1.1 Cardiac CT/MRA Subset  
Main  Study  
At a subset of sites, subjects from the Main  Study will be enrolled in the cardiac 
CT/MRA subset and will undergo a 3 -month CT/MRA in addition to the baseline 
CT/MRA (all subjects will have a baseline CT/MRA) to assess incidence of post -
ablation severe PV stenosis. In order to be included in the cardiac CT/MRA population, 
the subject must have readable outcomes at baseline and 3 months. The first 40  subjects 
consecutively enrolled in the Main  Study ( included in the 185 total) at cardiac CT/MRA 
subset sites who have readable outcomes will be included in the CT/MRA subset (until sufficient CT/MRA subjects are accrued). The probability of observing at least one 
moderate/severe PV stenosis with 40 subjects is 87% assuming the event rate of 
moderate/severe PV stenosis is 5%.  
In addition to this subset, any subjects with signs or symptoms of PV stenosis will undergo a post ablation CT/MRA. These subjects will not be included in the CT/MRA subset analysis. If severe PV stenosis is present it will be reported as an adverse event.   
8.2 Study Endpoints  
8.2.1 Primary Safety Endpoint 
The primary safety endpoint is the incidence of any primary adverse event occurring within 7 days of the AF ablation procedure (including the initial and repeat procedures), using the QDOT MICRO™  catheter per protocol, except atrio -esophageal fistula and 
PV stenosis, which may also be considered as primary adverse events if occurring 
greater than seven (7) days and up to 90 days post the ablation procedure.[55, 56] 
Primary adverse events include the following conditions (refer to Table 14.2.1A: 
Primary Adverse Events  for detailed instructions for defining these adverse events): 
• Death  
• Atrio -esophageal fistula  
• Cardiac Tamponade*+/Perforation+ 
• Myocardial infarction (MI) 
• Stroke / Cerebrovascular accident 
(CVA) †, †† 
• Thromboembolism 
• Transient Ischemic Attack   • Phrenic Nerve Injury/ Diaphragmatic 
paralysis  
• Heart block  
• PV stenosis 
• Pulmonary edema (Respiratory 
Insuffi ciency)  
• Vagal Nerve Injury 
• Pericarditis  
• Major vascular access complication / 
bleeding  
 
* Hemodynamic compromise or instability is defined as Systolic BP < 80 mm Hg. 
+  Cardiac Tamponade/Perforation occurring within 30 days of the AF ablation process 
will be considered Primary AEs 
† Subjects with non-focal global encephalopathy will not be reported as a stroke without 
unequivocal evidence based upon neuroimaging studies. 
†† Modified Rankin score assessments should be made by certified individuals.   
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 44 of 135 Data from recent clinical trials for devices similar to  the device in the current study were 
reviewed as a first step to deriving the performance goal for the safety endpoint. A meta -
analysis approach was taken to estimate the average composite endpoint rate. Figure 8.2.1 
presents the results of the meta -analy sis for combining the safety rates. Based on the plot, 
the upper bound of the 95% confidence interval was estimated to be equal to 9%. The proposed performance goal of 14% would reflect an approximately 50% increase in risk from the upper bound of the 95% CI. Details of the meta -analysis can be found in Appendix 
C.   Figure 8.2.1 Meta-analysis results 
 
8.2.2 Primary Effectiveness Endpoint  
The primary effectiveness endpoint is defined as the freedom from documented atrial fibrillation, atrial flutter and atrial tachycardia (AF/AFL/AT) (hereinafter collectively referred to as “at rial tachyarrhythmias") recurrence (episodes ≥  30 secs on TTM or 
continuously recorded on the standard 12 -leads ECG) during the evaluation period (Day 
91-365) and freedom from the following failure modes:  
• Acute procedural failure, including: 
o Failure to co nfirm entrance block in all pulmonary veins post-procedure,  
o Use of a non-study catheter to treat left atrial ablation targets  and cavo -
tricuspid isthmus  
• Repeat ablation failure, including:  o > 2 repeat ablation procedures with the study catheter during the  3-Month 
Blanking Period (Day 0-90) after the index ablation procedure. 
o Use of a non-study catheter to treat study arrhythmia ablation targets during 
the blanking period  
o Any repeat ablation procedure during the Evaluation Period. 
• AAD failure: Taking a new  AAD  for AF or a previously failed AAD at a 
greater than the highest ineffective historical dose for AF during the evaluat ion 
period (refer to section 13.1 for details).  
This study is designed to compare the primary effectiveness of the QDOT MICRO™ 
Catheter to a pre -determined performance goal of 50%, which is indicated as the 

Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 45 of 135 minimum acceptable success rate at 12 months for a paroxysmal AF population in the 
2017 HRS/EHRA/ECAS/APHRS/SOLAECE consensus statement.   
8.2.3 Secondary  Endpoints(s)  
The secondary endpoints  will apply to both studies .   
8.2.3.1 Secondary Safety Endpoints  
• Incidence of Unanticipated Adverse Device Effects (UADEs)  
• Incidence of Serious Adverse Events (SAEs) within 7 days (early onset), >7 to 30 days (peri-procedural) and >30 days (late onset) of initial ablation  
• Incidence of bleeding complication (ISTH definitions): a) major, b) clinically relevant non-major and c) minor bleeding  
Refer to Section 14.3 for the definition of Serious Adverse Event.  Refer to Appendix A: 
Study Definitions for the ISTH bleeding complications definitions. 
8.2.3.2 Secondary Effectiveness Endpoints  
• Acute Procedural Success  
Acute procedural success is defined as confirmation of entrance block in all PVs. 
o % of subjects with electrical isolation of PVs (entrance block) at the end of 
the procedure  
 The % of subjects with electrical isolation of PVs (entrance block) using QMODE+ as only ablation strategy 
o % of subjects with electrical isolation of PVs (entrance block) after first 
encirclement (evaluated prior to the 20-minute waiting period and 
adenosine challenge  
o % of subjects with electrical isolation of all PVs (entrance block) after first encirclement  without acute reconnection, after waiting period and 
adenosine challenge  
o % of subjects and % of PVs with touch- up (i.e. touch- up is used to remove 
ablation of acute reconnection) among all targeted veins and touch- up 
location  
o Anatomical location of acute  PV reconnection after first encirclement  
• Repeat ablation procedures during 12-month period post-procedure 
o Incidence (%) of repeat ablation procedures  
o % PVs re -isolated among all the targeted PVs at repeat procedure  
o % repeat ablation procedures requiring  new linear lesions and/or 
identifying new foci outside of initially isolated area among the repeat 
ablation procedures 
• 12-Month Single Procedure Success 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 46 of 135 o The 12- month single procedure success is defined as freedom from 
documented AF/AFL/AT recurrence (epis odes > 30 secs) during the 
Evaluation Period after a single ablation procedure and off AADs. Any 
repeat ablation procedure or AAD therapy will be deemed effectiveness 
failure for this analysis.  
8.2.3.3 Additional Endpoints  
• Procedural Data:  
o Total procedure time, PV I time, RF application time, mapping time and RF 
application time per lesion  
o Total Fluoroscopy Time and Dose 
o Fluid delivered from the study catheter  
o Location of RF applications, number of RF applications 
o Repeat Ablation Rate  
o RF Ablation parameters per application  
o Device(s) utilized (per ablation)  
o VISITAG™ Settings 
o CF range 
o Power range  
o Tag Index Assessment per anatomical region 
NOTE:  Tag Index data (Force, Power, and Time) will be collected in the 
CARTO® 3 System during the ablation procedures. The data will be 
processed to generate the Tag Index. 
• Quality of Life:  
o Quality of Life (QOL) status will be evaluated by assessing A FEQT  
• Cardiac CT/MRA Subset  
o Incidence of severe PV stenosis at 3 months post ablation in the CT/MRA subse t assessment evaluation . The CT/MRA subset will be included in the 
main study only.  
8.2.3.4 Health Economic Data 
The cost and frequency of health care utilization during hospitalization for the study index ablation procedure, as well as any additional hospitalizations during the study period will be collected. Because this data does not support the safety and efficacy of the  QDOT 
MICRO ™ catheter , it will not be provided to the Food and Drug Administration (FDA) as 
part of the IDE reporting.    The hospitalization health care data to be collected may include but is not limited to: copies 
of the subject’s hospital bills (UB04) and/or itemized hospital bills.  Subject’s admission 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 47 of 135 date, discharge date, procedure date, ICD -10 and procedure code, Diagnosis Related Group 
(DRG) assignment and total cost for the hospitalization will be extracted from the forms.  
 
In addition, the sponsor will also collect health economic data associated with follow up care, including any repeat ablation procedure for treating arrhythmia, any inpatient or outpatient visit (including ER admissions) to address post -procedural complications or any 
procedure related condition and any inpatient or outpatient visit (including ER admissions) related to arrhythmia and cardiovascular conditions.    
9.0 STUDY POPULATION 
9.1 Subject  Selection   
9.1.1 Inclusion  Criteria  
Candidates  for this  study must meet  ALL  of the following  criteria:  
1. Symptomatic paroxysmal AF with one electrocardiographically documented AF episode 
within 6 months prior to enrollment and a physician’s note indicating recurrent self -
terminating AF  within 7 days. Documentation may include  electrocardiogram (ECG); 
Transtelephonic monitoring (TTM), Holter monitor or telemetry strip .  
2. Failed  at least one (1) antiarrhythmic drug (AAD)  (class I or III) as evidenced  by recurrent  
symptomatic  AF, contraindicated, or  intolerable  to the AAD.   
3. Age 18 years  or older. 
4. Signed Patient  Informed  Consent Form  (ICF).  
5. Able  and willing  to comply with  all pre-, post-, and  follow -up testing  and requirements.  
9.1.2 Exclusion Criteria  
Candidates  for this study will be EXCLUDED from  the study if ANY of the following 
conditions apply:  
1. Previous surgical  or catheter  ablation  for atrial  fibrillation .  
2. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non- cardiac cause.  
3. Patient on amiodarone at any time during the past 3 months prior to enrollment. 
4. Previously diagnosed with persistent or long- standing persistent AF and/or Continuous AF 
lasting > 7 days 
5. CABG surgery within  the past 6 months  (180  days) . 
6. Valvular cardiac surgical /percutaneous procedure ( i.e., ventriculotomy, atriotomy,  valve 
repair  or replacement  and presence of  a prosthetic  valve) . 
7. Any carotid  stent ing or endarterectomy  within the last 6 months.  
8. Documented LA  thrombus  on imaging  (within 48 hr prior to a study ablation procedure). 
9. Documented LA  size > 50 mm ( parasternal  long axis  view) . 
10. Documented LVEF < 40% . 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 48 of 135 11. Contraindication to  anticoagulation  (e.g. heparin) 
12. History  of blood clotting  or bleeding abnormalities  
13. MI/PCI within  the past 2 months (60 days)  
14. Documented  thromboembolic event  (including TIA) within  the past 12 months 
(365 days) 
15. Rheumatic  Heart  Disease  
16. Uncontrolled heart  failure  or NYHA function class  III or IV 
17. Severe mitral regurgitation (Regurgitant volume ≥ 60 mL/beat, Regurgitant fraction 
≥ 50%, and/or Effective regurgitant orifice area ≥ 0.40cm2) 
18. Awaiting  cardiac transplantation or other major cardiac surgery  within  the next 12 
months (365 days) 
19. Unstable angina 
20. Active  systemic  infection  or sepsis 
21. Diagnosed atrial  myxoma or presence of an interatrial baffle or patch . 
22. Presence of  implanted  ICD/CRT -D. 
23. Significant pulmonary disease,  (e.g., restrictive  pulmonary disease,  constrictive  or 
chronic obstructive pulmonary disease)  or any other  disease or malfunction  of the 
lungs or respiratory  system  that produces chronic symptoms. 
24. Severe Gastroesophageal Reflux Disease (GERD ; active requiring significant 
intervention not including OTC medication ) 
25. Significant congenital anomaly or medical  problem that in the opinion of the 
investigator would preclude enrollment in  this study. 
26. Women  who are pregnant (as evidenced  by pregnancy test if pre- menopausal) , 
lactating, or who are of child bearing age and plan on becoming pregnant during 
the course of the study. 
27. Enrollment in an investigational study evaluating  another device, biologic, or drug. 
28. Presence  of intramural thrombus, tumor or other  abnormality  that precludes 
vascular  access,  or manipulation of the catheter .  
29. Presence of an inferior vena cava filter.  
30. Presenting contra -indication for the devices (e.g. TTE, CT, etc.) used in the study, 
as indicated in the respective instructions for use. 
31. Life expectancy  less than  12 months 
 
9.2 Strategies for Recruitment and Retention  
Main  Study  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 49 of 135 The QDOT MICRO™  IDE study seeks to enroll up to 185 subjects in the study at up to 30 
clinical sites in the US.  Once enrolled, each subject will participate in the study for 12 
Months.  
Centers will be selected for participation in the study based on experience with RF focal 
catheter technology, ablation experience, their capacity to screen and enroll a reasonable 
number of eligible patients, and ability to perform the required procedures, according to this protocol.  
Historically, women and minorities have been underrepresented in or excluded from 
many clinical studies, leading to a lack of information for women and their physicians regarding the risk and benefits of many medical treatments and diagnostic procedures. It is the Sponsor’s intent to apply the principles from FDA’s guidance titled Evaluation of Sex -Specific Data in Medical Device Clinical Studies in this clinical trial to ensure 
adequate representation of women and minorities. The Sponsor will take reasonable 
steps to ensure adequate representation of women and racial or ethnic minorities in this clinical trial: 
In order to reflect the gender ratio of the intended population, Sponsor plans to enroll 
approximately 70% males and 30% females in the study. The gender ratio (male: female = 7:3) undergoing ablation procedures in the AF population is estimated based on previous studies.[57]
  
Sites will be instructed to screen all subjects wh o may be eligible for participation in the 
study without regard to sex or race. Statistical analysis of primary safety and effectiveness endpoints will be carried out to evaluate any interaction between treatment and gender. Subjects will be encouraged to remain in the study until they have completed the protocol required follow-up period.  
Sponsor will attempt to include a diversified group of research sites engaging a variety 
of academic and private institutions geographically located throughout the US and possibly other regions. To ensure generalizability of results and minimize the influence of any single site, no more than approximately 15% of the total enrollment will be allowed at a single site.  
Second (Variable Flow) Study  
Centers that have enrolled subjects in the main  arm of the study will be allowed to enroll 
subjects into the second (variable flow) study.  The 15% site enrollment cap also applies 
to the second (variable flow) study. 
9.3 Subject  Withdrawal/Early  Termination   
Subjects  may withdraw from  the clinical investigation  at any time . The  decision  for the 
subject  to withdraw informed  consent must be made  independently of influence by the 
investigator or site personnel . The subject’s decision  will be documented in the source 
and eCRF.  The investigator may also choose to withdraw a subject  from  the study if 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 50 of 135 there are safety  concerns. If a subject  withdraws  from  the study, the date and reason  for 
withdrawal  will be recorded  on the appropriate electronic case report form  (eCRF).    
All data will be collected  (as available)  until the subject  is withdrawn . If the subject  is 
withdrawn  due to an adverse event  (AE) or serious adverse  event  (SAE),  the investigator 
should follow the subject  until the AE/SAE  has resolved or is  considered  stable.  
9.4 Subjects  Lost to  Follow up  
Subjects  should be encouraged  to return  for protocol required, clinic  visits for evaluation  
during the study follow-up period. If a subject  is unable to return  for an office  or clinic  
visit or unable to be contacted  by telephone, 3 separate telephone calls should be made 
to obtain subject  related  safety  information. All attempts  should be documented in the 
source documents. If the subject  does not respond to the 3 telephone calls,  then the 
investigator must send a certified  letter  requesting the subject’s continuation in the study  
or confirming the subjection desire to terminate from the study. 
If the subject  does not respond to the phone telephone calls or letter,  then the subject  
will be considered  “lost  to follow-up.”  
9.5 Subject Disposition  
A 
subject is considered enrolled when they sign the informed consent. Because the 
treatment assignment is the same for both studies the subject disposition does not change 
for the second (variable flow) study. 
• Enrolled Subjects : subjects  who sign the informed consent. 
• Excluded Subjects : subjects that are enrolled but never undergo insertion of 
the study c atheter.  Excluded subjects will not be included in the safety 
evaluation of the study c atheter . 
• Discontinued Subjects : subjects that have the study catheter inserted but are 
not treated with the study catheter  (i.e., no RF energy applied). These 
discontinued subjects will be followed for 3 months and be part of the safety 
evaluation. 
• Evaluable Subjects : enrolled subjects who meet the eligibility criteria and 
undergo ablation with the study catheter. 
• Lost to Follow -up Subjects : subjects who are enrolled, but contact is lost after 
most recent follow -up visits (despite 3 documented attempts to contact the 
subject).  
• Withdrawn / Early Termination Subjects : subjects who withdraw consent 
for study participation or are withdrawn by the investigator or are term inated 
from the study prior to completion of all follow-up visits. 
• Completed Subjects : enrolled subjects who completed the 12- month follow -
up visit and have not been excluded, discontinued, withdrawn, early 
terminated, expired or lost- to-follow-up from the study prior to the final study 
visit.  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 51 of 135 10.0 RESPONSIBILITIES  
10.1 Study Timelines  
Study Duration: The study is expected to last approximately 20 months (8-9 months for 
enrollment for main study and 5 months for the second study; 12 months of follow -up 
for primary endpoint  for each study).  
10.2 Investigator Responsibilities  
The Principal Investigator is responsible for supervision of all study activities and is 
ultimately responsible for overall compliance with protocol, GCP, local and regional regulations, and IRB/REB requirements. Many study activities may be formally delegated to support staff, but the Principal Investigator retains responsibility for supervision of all study activities. 
Specific responsibilities include:  
• Obtaining IRB/REB approval and ren ewals  
• Providing Sponsor with: 
o Written IRB/REB approval letters and IRB/REB -approved consent forms, 
o Signed, dated Investigator Agreement, 
o Signed and dated Financial Disclosure form at study outset and any time 
financial changes occur, for up to one year following completion of the study 
o Curriculum vitae for each Investigator and key research staff member 
• Maintaining an accurate and current Study Personnel Log which identifies all individuals authorized to perform work for the study at each site 
• Completing appropriate training on the study device and the study protocol prior to enrolling and treating subjects 
• Maintaining accurate and current logs for the study as requested by the study 
team, including but not limited to: 
o Subject screening log 
o Device Accountability log 
• Obtaining informed consent (including privacy language) from patients 
• Performing the ablation procedure 
• Complying with the clinical protocol 
• Notifying the Sponsor and IRB/REB of adverse events, deaths, and deviations 
as defined in this protocol and per IRB/ REB  requirements.  
• Notifying Sponsor promptly of withdrawal of IRB/REB approval 
• Complying with IRB/REB (as applicable) and Sponsor annual report 
requirements  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 52 of 135 • Completing eCRFs accurately and as soon as possible after collection of data 
• Reviewing and signing designated eCRFs 
• Maintaining relevant source documentation to support future verification of 
data on the eCRFs.  
• Complete all subject follow -up visits, including efforts to maintain contact 
with subjects who fail to comply with the fol low-up schedule. Before a subject 
may be classified as ‘lost to follow -up’, the Investigator or authorized 
personnel should document attempts to contact the subject.  
• Retaining study records as described in section 2 2.1. The Sponsor will notify 
the Investi gator when records may be destroyed.  
• Preparing a final report and periodic IRB /REB  updates as required  
10.3 Sponsor Responsibilities  
The Sponsor (Biosense Webster) will be responsible for the following: 
• Preparing of study documents including but not limited to the protocol, eCRFs 
and template informed consent, if no local template is preferred 
• Completing pre-study site assessments and approvals 
• Obtaining approval from the FDA and regional Health Authorities ( HAs)/ 
Regulatory Authorities (RAs)  
• Providing protocol training to investigators and research personnel 
• Instructing operators and technicians in the proper use and monitoring of study 
devices  
• Monitoring the study throughout the duration of the investigation 
• Securing investigator/site compliance with the protocol and applicable regulations 
• Creation and maintenance of eCRF database  
• Conducting all communications with HAs/RAs 
• Submitting study supplements for regulatory approval (as necessary), e.g., 
request for study expansion 
• Preparing reports summarizing the status of the clinical study no less often than 
annually, which will be supplied to the FDA and to other HAs/RAs as requested. Annual reports may also be provided to each HA/RA, and possibly to the Principal Investigator as requested 
• Report the results of a n evaluation  of an unanticipated  adverse device effect to 
FDA within 10 working days after receiving notice of the adverse effect.  
• Access to clinical study data provides opportunities to conduct further research that may help advance medical science and improve patient care. This helps 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 53 of 135 ensure the data provided by research participants are used in the creation of 
knowledge and understanding. To this end, the study results on all pre -
specified outcomes, including negative outcomes, will be submitted to ClinicalTrials.gov no later than one year after completion of the primary endpoint (unless an extension has been approved via certification from the Secretary of Health and Human Services). Results submission could be delayed if an extension is granted to the results submission deadline; however, the release of all results on pre- specified outcomes will be hastened if the study 
is terminated early  
10.4 Training  
10.4.1 Research Team  
The training of appropriate clinical site personnel will be the responsibility of the Sponsor or the Sponsor’s representative. In some cases, training may be performed by 
an existing site staff member who has already been trained by the Sponsor (such as assigning a new CRC to the study). To insure uniform data collection and protocol compliance, t he Sponsor will present a formal educational session to study site 
personnel that will include review of the Clinical Study Protocol, techniques for the identification of eligible subjects, instructions on in- hospital data collection, follow -up 
schedules, and regulatory requirements. Remote as well as on -site contacts will be used 
to monitor study performance indicators such as enrollment compliance, data submission rate, data errors, protocol questions, and GCP compliance.  
10.4.2 Investigator Training  
QDOT MICRO™  Catheter Training:  
The training of applicable clinical site personnel will be the responsibility of the Sponsor. Prior to initiating subject enrollment at a site, appropriate study training will be provided. Investigators selected to participate in the study will be experienced in intracardiac mapping and AF ablation with focal ablation catheters. Investigators will undergo device training in accordance with the physician training charter.  To ensure uniform data collection and protocol compliance, the Sponsor will conduct a training session that will include reviewing the protocol, eCRF and data collection process, and the adverse event reporting process. The sponsor will reinforce the training or provide clarification throughout the study, as needed. 
 
11.0 STUDY DEVICE DESCRIPTION 
11.1 Device Acquisition  
After obtaining a fully executed clinical trial agreement and appropriate approvals, the Sponsor may initiate shipment(s) of investigational devices to the site. The Sponsor will keep records of  all investigational devices shipped to the site. Approved investigational 
devices will be shipped directly to the site and will be received by the site investigator or 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 54 of 135 designee. Site study personnel are responsible for appropriate logging of the devices 
received, verification of packing slip information (i.e., lot numbers and quantity shipped), 
recording the date of use and subject ID for each device used in the study, and recording device disposition information regarding disposal or return to the Sponsor.  
11.2 Device Storage and Stability  
Investigational Devices are to be stored in a secure/locked location. All devices are to be stored in accordance with the IFU. Do not use any devices after the “Use By” date.  
11.3 Instructions for Use (IFU)  
A copy of the IFU for  the QDOT
 MICRO ™ catheters and interface cable is included in 
each product package.  
11.4 Device Description  
11.4.1 QDOT MICRO ™ Catheter  
The Biosense Webster QDOT MICRO™ Catheter s are a steerable multi -electrode 
luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency (RF) current to the catheter tip electrode for ablation purposes. The catheter shaft measures 7.5 F with 8 F ring electrodes. For ablation, the catheter is used in conjunction with a compatible RF generator and a dispersive pad (indifferent electrode). The catheter has force-sensing technology that provides a real -time measurement of contact  force between the catheter 
tip and the heart wall.  
The catheter has a high -torque shaft with deflectable tip section containing an array of 
electrodes which includes a 3.5 mm tip dome with three microelectrodes. All of the electrodes may be used for recor ding and stimulation purposes. The tip electrode serves 
to deliver RF energy from the RF generator to the desired ablation site. The tip electrode and ring electrodes are made from noble metals.  
The catheter incorporates six thermocouple temperature sensor s that are embedded in 
the 3.5 mm tip electrode.   
At the proximal end of the catheter, a saline input port with a standard Luer fitting 
terminates from the open lumen. This saline port serves to permit the injection of normal saline to irrigate the tip electrode. During ablation, heparinized normal saline is passed through the internal lumen of the catheter and through the tip electrode, to irrigate and cool the ablation site as well as the electrode tip. An irrigation pump should be used to control the sa line irrigation.  
 
Figure 11.4.1A Overview of the QDOT MICRO™  Catheter with both Uni -directional 
and Bi-directional Tip Deflection  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 55 of 135  
 
 
Figure 11.4.1B QDOT MICRO™  tip Section  
 
    
SIDEARM  
LUER CONNECTOR  
HANDLE BARREL HOUSING  
34 PIN PCB 
CONNECTOR  
PISTON WITH 
THUMB KNOB  
PEBAX 
SHAFT  
QUAD LUMEN 
DEFLECTABLE TIP  
PALLADIUM/PLATINUM  TIP  
USABLE LENGTH 
115cm  

Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 56 of 135 Figure 11.4.1C QDOT MICRO ™ tip with Thermocouples (6), µElectrodes (3) and 
angled irrigation ports 
 
 
 An irrigation pump is used to control the saline irrigation. The catheter interfaces with 
standard recording equipment and a compatible RF generator via accessory extension cables with the appropriate connectors.  
This catheter features a location sensor embedded in the tip section that transmits location and contact force information to the CARTO® 3 v6 Navigation System (refer to Figure 11.4.1D ). An appropriate reference device is required for location ref erence 
position purposes. For information on using the catheter in mapping procedures and for information on appropriate reference devices, refer to the user manual for the CARTO® 3 v6 Navigation System. 
 Figure 11.4.1D Contact Force Sensor – External View    
 
 

Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 57 of 135 This catheter features a location sensor embedded in the tip section that transmits 
location and contact force information to the CARTO® 3 System. An appropriate 
reference device is required for location reference position purposes. The catheter connects to the CARTO
® 3 Navigation System through an interface box called the 
Patient Interface Unit (PIU). The catheter interfaces with standard recording equipment and a compatible RF generator via accessory extension cables with the appropriate connector s. For use in mapping procedures, for information on appropriate reference 
devices, and for further description of the operation of the CARTO
® 3 Navigation 
System, refer to the CARTO® 3 Navigation System User Manual.  
For further information on the irrigation pump (COOLFLOW® Irrigation Pump) RF Generator (nMARQ RF Generator), and required cables, refer to the respective Instructions for Use and/or User Manual. 
Refer to Section 11.5 (Required Study Equipment) for details on additional equipment 
required for this study.  
11.4.1.1 Bi-directional Catheter Description (D -1395- XX-SI) 
The catheter has a high -torque shaft with a bi -directional deflectable tip section 
containing an array of electrodes which includes a 3.5 mm tip dome. All of the 
electrodes may be used for recording and stimulation purposes. The tip electrode serves to deliver RF energy from the generator to the desired ablation site. The tip electrode and ring electrodes are made from noble metals. The catheter incorporates six thermocouple temperature sensors  and ECG electrodes that are embedded in the 3.5 mm 
tip electrode. A Rocker Lever is used to deflect the tip. The high- torque shaft also allows 
the plane of the curved tip to be rotated to facilitate accurate positioning of the catheter tip at the desired site. Additionally, a variety of curve types are available in symmetric 
or asymmetric combinations, providing two 180° opposed, single -planed curves. Five 
curve configurations designated “DD”, “FF”, “JJ”, “DF”, and “FJ” are available. 
11.4.1.2 Uni-directional Catheter Description (D -1394- XX-SI) 
The catheter has a high -torque shaft with a uni -directional deflectable tip section 
containing an array of electrodes which includes a 3.5 mm tip dome. All of the electrodes may be used for recording and stimulation purposes. The tip electrode serves to deliver RF energy current from the generator to the desired ablation site. The tip electrode and ring electrodes are made from noble metals. The catheter incorporates six thermocouple temperature sensors and ECG electrodes that are embedded in the 3.5 mm tip electrode. A Rocker Lever is used to deflect the tip. The high- torque shaft also allows 
the plane of the curved tip to be rotated to facilitate accurate positioning of the catheter tip at the desired site. Three curve types configurations designated “D,” “F,” and “J” are available.  
11.4.2 nMARQ® Multi -channe l RF Generator (D -1341-07- I) 
The nMARQ® Multi -channel RF generator software version 3.0.1 (main study) and 
version 3.0.6  (second [variable flow] study) are  intended for cardiac ablation applications. 
Its purpose is to generate RF energy for delivery to a site in the heart via compatible RF ablation catheters. The generator includes functions for controlling ablation parameters at 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 58 of 135 the ablation electrodes of the catheter. Ablation parameters, such as power, impedance, 
ablation duration, and temperature are recorded and can be exported at the end of the procedure to a USB device.  
 The generator consists of the following main components: 
• Console : The console contains the hardware that provides the delivery of RF 
energy. 
• Local Control Workstation (Local Monitor) : The local monitor contains a touch 
screen user interface. The monitor contains the software that controls the generator and tells the console what function to perform. It also provides communication with 
the CARTO® 3 workstation and the Remote Control Workstation. The local monitor attaches directly to the console. 
• Remote Control Workstation (Remote Monitor, optional) : The remote monitor 
is physically the same as the local monitor. The remote monitor connects to the local monitor via a connecting cable which allows the remote monitor to be used outside of the patient area. The only differences between the local and remote monitors are: o Log files can only be copied from the local monitor, not the remote monitor. 
o Technician settings are accessible only from the local monitor. 
o Only the local monitor communicates to the console. The remote monitor passes the user inputs to the local monitor that then passes the inputs to the console. Further, when the “Stop” button is pressed on the remote monitor, the signal is passed directly from the remote monitor to the console through the local monitor but without any intervention. 
• Foot Pedal : The foot pedal allows the user to start and stop ablation without 
pressing the Start and Stop buttons on the monitor. 
• Cart : The generator’s console and local monitor rest on the cart to facilitate 
movement of the equipment throughout the lab. 
• Connection Cables : Cables are used to provide  an interface between the various 
components of the generator and to provide connection to an external energy source to allow operation of the generator. 
11.4.3 TX eco EXT Interface Cable (D -1357-03- SI) 
The TX eco EXT Connection Cable (D -1357- 03-SI) is designed t o connect the QDOT 
MICRO™  Catheter that interfaces the Patient Interface Unit (PIU) of the CARTO® 3 EP 
Navigation System via the dongle. The TX eco EXT Connection Cable consists of a gray 
connector which connects to the dongle and a black connector that connects to the catheter receptacle.  
 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 59 of 135 Figure 11.4.3A: TX eco EXT  Connection Cable  
 
 
 
11.4.4 TX eco Cable Dongle (EM-5050-055F) 
The Biosense Webster TX eco Cable ( Dongle) (EM-5050- 055F) is an accessory device 
primarily intended to provide a means for the QDOT MICRO™  Catheter to interface with 
the CARTO®3 v6.0 EP Navigation System  and to the nMARQ® RF generator . The TX 
eco Cable ( Dongle) processes and transfers catheter loc ation signals to the CARTO® 3 
System. Additionally, the TX eco Cable ( Dongle) contains integrated firmware that reads 
the temperature from each thermocouple (six total) within the QDOT MICRO™  Catheter 
tip. The highest temperature will be sent to the compatible RF Generator and all six 
temperatures will be sent to the CARTO®3 System for real -time visual display.  
 

Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 60 of 135 Figure 11.4.4A: TX eco Cable ( Dongle) with Extension Cable  
 
 
Refer to Figure 11.4.4B below which depicts a functional block diagram of the TX eco 
Cable ( Dongle) signal processing and transfer activities. 
 Figure 11.4.4B Block Diagram of the TX eco Cable ( Dongle) Processing and Transfer 
Activities  
 
 
11.4.5 CARTO® 3 v6.0.60 QDOT MICRO™  Software Module 
The QDOT MICRO™  software module is an add- on software feature to the CARTO® 3 
System to display and record ECG, temperature, location and contact force information when the QDOT MICRO™ Catheter is connected and the QDOT MICRO™ software 
module is enabled. The temperatures recorded by the 6 thermocouples within the QDOT 
MICRO™  Catheter are transmitted to and displayed graphically on the CARTO® 3 
System. The purpose of sending all six (6) temperature readings to the CARTO® 3 System is to provide two graphical displays to the physician on the CARTO® 3 System.  

Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 61 of 135 Tip Temperature Display  
The CARTO® 3 System will display the temperature measured by the TX eco Cable in 
colored 2D and 3D imaging format. The image on the left is the temperature distribution around the tip electrode.  The image on the right is the “bulls eye” display.  Figure 11.4.5A: Information Displayed on the Carto 3 System 
 
 
 
Colored catheter 
temperature distribution 3D display  “Bulls eye” 2D display of 
values for each thermocouple 
reading  
  The “bulls eye” display provides temperature information to the physician.  An optional 
numerical value of the temperature from the RF Generator is displayed on the “bulls eye” determined by the physician’s preference to display or not to display).  The colored graphic 
of the bull’s eye provides relative tip to tissue interface temperature readings obtained from the 6 thermocouples. The colored tip graphic provides the physician with an indication as to which part of the catheter tip  has contact with the tissue. In addition, it can also provide 
the physician with an indication of the catheter’s tip to tissue stability; if the catheter tip slips, the temperatures obtained from the thermocouples will change which will be visually displayed on the “bulls eye” as well as on the graphic of the tip of the catheter. The colors in the displays change as the temperature of the thermocouples change. The colors range from dark blue (minimum temperature) to dark red (maximum temperature) and the circular presentation allows the physician to visualize the relative temperatures of distal 
and proximal thermocouples in the tip (viewed from the center outward). The outer halo provides the orientation of the catheter tip in 3- dimensional space.  
 The TX e co Cable is responsible for gathering the QDOT MICRO™  Catheter temperature 
and micro electrode signal information and transferring this data to the Carto 3 System for display. The temperature feedback display during ablation is described below.  
• Tip Temperature Distribution - monitor the maximum temperature measured and 
verify the proper response of the temperature distribution of the catheter tip during the RF session. In the figure below, the six small circles represent the 6 

Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 62 of 135 thermocouples: 3 distal and 3 proximal. The inner circle represents the tip electrode 
and the outer ring represents the tip sides. 
 Figure 11.4.5B: Temperature Distribution Display 
 
 
 
Any change in the desired Ablation catheter tip orientation – from a perpendicular 
orien tation to the tissue, would result in temperature rise of the corresponding part of the 
catheter tip electrode, as indicated by the red color the tip temperature distribution display as shown below.   Figure 11.4.5C: Temperature Display for Perpendicular Catheter Tip Orientation  
 
 
 
 
• Any change in the desired Ablation catheter tip orientation – from a parallel 
orientation to the tissue, would result in maximum temperature rise of the cylindrical part of the tip that is in contact with the tissue.   This is indicated by the 
red color at the tip temperature distribution display, as shown in Figure 11.4.5D. 
 
Figure 11.4.5D: Temperature display for Parallel Catheter Tip Orientation 
 

Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 63 of 135  
  
  
Figure 11.4.5E : CARTO ® 3 GUI with RF generator in Unipolar Mode, QDOT 
MIDRO ™ Catheter  
 
 
  
11.5 Required Study Devices  and Equipment  
The following devices are required for the AF ablation procedure during this study: 
Table 11.5A:  Required Study Equipment  
Equipment  Function or Specifics  

Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 64 of 135 Investigational Equipment 
QDOT MICRO™  Catheters  
• D-1394- XX-SI  
• D-1395 -XX-SI Delivers RF energy to the target tissue.  
TX eco EXT Connection Cable  
(D-1357 -03-SI) Provides a means to interface the QDOT 
MICRO ™ catheters with the Dongle   
TX eco Cable ( Dongle)  
(EM-5050-055F) Provides a means to interface the QDOT 
MICRO ™ catheters to the Multi-Channel 
RF Generator  
nMARQ Multi -Channel RF 
Generator (D -1341-07- I) 
• v3.0.1 – Main Study 
• v3.0.6  – Second (variable 
Flow) Study  Transmits RF energy to the Ablation 
Catheter  
CARTO 3 v6.0.60 QDOT 
MICRO™  Software Module  Provides a visual interface for the features of 
the QDOT MICRO ™ catheter  
Non-Investigational Equipment 
8.5 F compatible sheath Facilitate deployment of catheter into the 
atria.  
 Lasso® or PentaRay® (optional) Pre-ablation recording and mapping of the 
atria of the heart with the CARTO® system.  
CoolFlow® Irrigation Pump and 
Tubing Set  Delivers heparinized saline to the catheter 
for cooling during the RF energy application  
Esophageal temperature 
monitoring device  Esophageal temperature monitoring  
EP lab recording equipment Records multiple intracardiac electrograms 
and signals from the RF generator (power, 
temperature, impedance) and performs 
electrical stimulation.  
Adhesive electrical dispersive 
pads / indifferent electrode  Component of the RF current return path 
(Valley Lab recommended)  
Interface Cables  Connection of choice  
CARTO® System Junction Box Provide the interface to the catheter, 
generator, and the CARTO® System.  
Carto® 3 v 6.0 System  For mapping and visualization information. 
Version 6.0.60  or higher  
 
 
11.6 System  Components and Set -Up 
 A connectivity diagram for system set up is depicted in Figure 11.6A . 
 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 65 of 135 Figure 11.6A : System Set Up  
 
12.0 STUDY MEDICATIONS  
12.1 Antiarrhythmic Drugs  
12.1.1 Definitions  
• Antiarrhythmic drugs (AADs)  
The study protocol will classify and analyze the following: 
o Class I drugs (e.g., flecainide, propafenone, disopyramide, etc.) 
o Class III drugs (e.g., amiodarone, dronedarone, dofetilide, etc.) 
• Previously Failed AAD 
Any AAD that a subject has ever taken  for the treatment of his/her AF, prior to 
enrollment, is considered a “p reviously failed AAD” if it meets both of the following 
conditions: 
o prior to enrollment, the AAD was ineffective in controlling the subject’s AF 
or produced intolerable side effects leading to its discontinuation; 
o the AAD is administered for AF  
• New AAD  
ANY AAD that was never taken for the treatment of AF prior to enrollment is 
considered a “new AAD” if the drug is administered to treat an “atrial tachyarrhythmia” post- enrollment.  
 
Table 12.1A illustrates the corresponding status of primary effectiveness en dpoints based 
on AAD therapy administered in the blanking and post-blanking periods.  

Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 66 of 135   
Table 12.1A: AAD Usage and Impact on Primary Effectiveness Classification  
  Blanking period   
(≤ 90 days post procedure)   Post blanking period   
(> 90 days post procedure)   
Class I and/or 
Class III AAD 
 Can be initiated, continued from 
prior to study enrollment, or increased  in dose  as long as 
the AAD is  stopped on or before 
day 90 post procedure  and 
subject will not be classified as a primary effectiveness failu re.  
 If initiated for the treatment of  AF; 
subject will be classified as a primary effectiveness  failure . 
 
If initiated for the treatment of  AF during 
the blanking period and continued past Day 90; Subject  will be classified as a 
primary effectiveness  failure 
 
Can be initiated, continued from 
blanking period, or increased if drug is 
NOT for the treatment of atrial 
arrhythmia (e.g. hypertension)  other than 
CTI dependent AFL  and subject will 
not be classified as a primary 
effectiveness failure.   
Class II 
and/or Class IV AAD 
 Can be initiated, continued from 
prior to study enrollment, or increased in dose and subject will not be classified as a primary 
effectiveness failure.   Can be initiated, continued from prior to 
study enrollment, or increased in dose a nd 
subject will not be classified as a primary effectiveness failure.  
 
 
12.2 Study specific anticoagulation requirements  
• PRIOR to the procedure o Uninterrupted anticoagulation therapy should be in place at least 1 month prior to ablation procedure. 
 If receiving warfarin/coumadin therapy, subjects must have an 
international normalized ratio (INR) ≥ 2 for at least 3 weeks prior to treatment and the subject’s must be confirmed to be ≥ 2 within 48 hours pre-procedure. Any INR < 2 within 3 weeks prior to abl ation will lead 
to exclusion of the subject or postponement of the study procedure until the INR is ≥ 2 for at least 3 weeks prior to treatment. 
o Anticoagulation therapy should not be interrupted or stopped prior to the procedure (this means no doses should be missed or omitted) and daily regimen 
should be continued. 
• DURING the procedure  
o Administer a heparin bolus PRIOR to transseptal puncture. 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 67 of 135 o Target an ACT of ≥350 seconds prior to inserting the catheter and throughout 
the procedure.  
o ACT levels MUST be checked every 15 - 30 minutes during the procedure to 
ensure an ACT target of ≥350 seconds. All recordings (ACT level, timing of 
heparin administration and dose) must be documented in the medical records as 
source documentation. 
o Flush all tubing and sheath continuously with heparinized saline. 
• FOLLOWING the procedure o Anticoagulation therapy is strongly recommended for at least 2 months following ablation. 
13.0 STUDY SCHEDULE, PROCEDURES, AND 
ASSESSMENTS  
13.1 Screening and Informed Consent  
13.1.1 Patient S creening  
All patients considered for RF ablation procedure for drug refractory recurrent symptomatic PAF should be evaluated by the investigator or designated member of the research team for study eligibility per the protocol inclusion and exclusion criter ia.  
 Subjects are enrolled upon signing the informed consent form. No subject may undergo any protocol required tests or examinations falling outside the standard of care without first signing the Informed Consent form for this clinical investigation.   Screening for the second (variable flow) study can only begin after enrollment in the main  
study is complete.  
 
13.1.2 Informed Consent  
Signing of an approved Informed Consent form (ICF) or Patient Information/Informed Consent form (PI/ICF) by the study candidate documents the patient’s acceptance and enrollment in the study. Prior to signing, the investigator or authorized member of the research team should discuss the background, potential risks and benefits, and expectations 
of the study with the candidate. The candidate should have any questions answered to his or her satisfaction and should have access to an investigator for technical or medical 
questions as requested. Sufficient time must be given for this process. The subject or legal representative must sign the consent form prior to conducting any study- specific exams or 
tests that fall outside of the standard of care. The consent form used must have prior approval from a duly- constituted Institutional Review Board, Regional Ethics Board, or 
Ethics Committee. Failure to obtain informed consent renders the subject ineligible for participation in the study.  The informed consent will include an authorization for use and disclosure of the subject’s protected health information, in accordance with the Health Insurance Portability and Accountability Act (HIPAA) or as required per local regulations. Subject confidentiality 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 68 of 135 will be maintaine d throughout the clinical trial in a way that assures that individual subject 
data can be tracked back to the source data. For this purpose, a unique subject identification 
code will be used that allows identification of all data reported for each subject. Data 
relating to the trial may be made available to third parties, provided the data are treated as confidential and that the subject’s privacy is guaranteed.  The informed consent will also request authorization for release of billing information specifi c to the subject’s participation in the study. Specifically, the subject’s UB04 (an 
itemized bill for the study procedure), the explanation of benefits (EOB) and any other hospitalizations or ER visits that occur during the study will be requested for each procedure and/or hospitalization.  
13.2 Pre-Procedure/Baseline Assessments, Evaluations and Procedures  
Pre-procedure assessments must be performed within 30 days prior to the index AF 
ablation procedure unless otherwise noted. Some assessments (listed be low) have a 
shorter window prior to the AF ablation procedure.  
• Demographics  (age, gender, etc.)  
• Medical History : including but not limited to arrhythmia, heart disease, 
thromboembolic events, lung/respiratory problems.  
• AF History  (first evidence of AF, n umber of episodes, symptoms, etc. ).  
• NYHA Functional Class Scale  (for subjects with congestive heart failure).  
• CHA2DS2 VASc Score : Will be used to assess the risk of stroke 
• Medication History : Medication history (cardiac medication, AAD 
medication, anticoagulation regimen and any other clinically significant medication history) shall be gathered by interview or from medical records following enroll ment  but prior to the ablation procedure and should be 
recorded in the eCRF.  
• Anticoagulation Therapy: Uninterrupted anticoagulation management is mandatory for each study subject. For subjects on warfarin/coumadin therapy, subjects shall be maintained on Warfarin/Coumadin for at least 3 weeks prior to treatment with an INR ≥ 2 (to be confirmed maximum 48 hours pre-procedure). Any INR < 2 within 3 weeks prior to ablation will lead to exclusion of the subject or postponement of the study procedure. The results must be available prior to start o f procedure.  
• Physical Exam  including standardized neurological exam done by a physician 
(including cranial nerve, motor and sensory function, and gait  assessments), 
must be conducted at the pre-procedure visit   
• NIH Stroke Scale (NIHSS) administered by certified healthcare provider done 
pre-procedure 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 69 of 135 • Vital Signs : height, weight, heart rate, body temperature, blood pressure, pulse 
rate  
• Electrocardiogram : (12-Lead ECG)  Data from 12 -lead ECG recordings will 
be collected if available.  
• Transthoracic Echocardiogram (TTE) : Imaging to determine the atrial size 
prior to the AF procedure. If the subject has undergone an imaging procedure 
within the last 6 -months where the atrial size ( parasternal long axis view)  was 
assessed and documented, the pre -procedure imaging assessment is not 
required . 
• Cardiac Multi Slice Computed Tomography (CT) or Magnetic Resonance 
Angiogram (MRA) image : CT/MRA will be used to evaluate the number, size 
and anatomy of the pulmonary veins and the left atrial anatomy i n the CT/MRA 
subset . It is mandatory to conduct the CT/MRA assessment prior to the study 
ablation procedure. For each PV, a core lab will determine the following 
measurements:  
o Major axis (mm)  
o Minor axis (mm)  
o Average diameter (mm)  
• Imaging for detection of LA thrombus : performed within 48 h of the study 
procedure or day of ablation procedure. The following are allowable imaging 
modalities:  
o TEE 
o CT/MRI  
o Intracardiac Echocard iography (ICE) 
• Pregnancy Test : Pre -menopausal women only, performed within 24 hours 
prior to the procedure. 
• Baseline Quality of Life (QOL) Assessment : AFEQT must be collected prior 
to procedure  
• Adverse Events  must be collected from the time the subject sign s the informed 
consent onwards  
13.3 Study Ablation Procedure  
Subjects w ill arrive to the electrophysiology laboratory for their ablation procedure and 
will undergo preparation for the procedure per the hospital’s standard protocol (discretion of investigator).   The Study ablation procedure will utilize both QMODE and QMODE+ temperature control modes to treat subjects with PAF.  QMODE+ temperature control will be used primarily for PVI.  QMODE temperature control will be used primarily for AF application outside the PV ostia and for touch-up of the PVI, if necessary.    
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 70 of 135  
Table 13.3A: QMODE and QMODE+ RF and Flow Rate Settings during RF 
applications 
Power Target Temp*  Cut-off Temp  Nominal 
Irrigation Flow 
rate Range maximum 
allowed  Range Maximum 
allowed  
25-35 W 40-50ºC 50ºC 50-55ºC 55ºC 4mL** 
36-50W*** 40-50ºC 50ºC 50-55ºC 55ºC 15mL** 
90W† 40-60ºC 60ºC 60-70ºC 70ºC 8mL** 
Second study  (Variable Flow Rate)  
90W† 40-60ºC 60ºC 60-70ºC 70ºC 4-15 mL 
* Temperatures displayed on the RF generator do not represent tissue temperature or electrode tissue interface 
temperature.  
** A minimum flow rate of 2mL during mapping is recommended.  
*** RF applications at 36 -50W should not exceed 60 sec.  
† The study recommends using this power setting for PVI as a primary ablation Strategy.  RF applications at 
this power setting are limited to 4 sec . It is recommended to use lower target temp s etting for the posterior 
wall RF applications.  
. 
 Recommendation for CoolFlow® Irrigation Pump Setting and RF Power- delivery  
 The CoolFlow
® Irrigation Pump will deliver a continuous infusion of 2 ml/min of room 
temperature heparinized saline (1 u heparin/1 ml saline) when not delivering RF energy. Increase the irrigation to high flow rate starting minimal 2 seconds before the onset of RF energy delivery.  Main  Study  
 
• QMODE+  
For QMODE+ (90W), a flow rate of 8 ml/min will be used.  Do not use this catheter without irrigation flow and maintaining this higher flow rate.   
• QMODE  
For QMODE, a high flow rate starting up to minimal 2 seconds before the onset of RF energy delivery and maintaining this higher flow rate up to 4 seconds after termination of 
the energy application (refer to Table 13.3A and Section 13.3.5).  Second (Variab le Flow) Study  
 For the second study the flow rate for QMODE+ will incorporate a variable flow rate 
during RF applications.    
• QMODE+  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 71 of 135 For QMODE+ (90W), a flow rate will begin at 4 mL/min and change to 15 mL/min as 
temperature dictates .  Do not use this catheter without irrigation flow and maintaining the 
variable flow rate  during RF applications.  
  
• QMODE  
Flow rate remain the same as described above and in Section 13.3.5. 
 Recommended Contact Force (CF) Settings  
 When using the study catheter in QMODE and QMODE+, the recommended Contact Force working range should be between 5 and 30g.  Caution : For safety precautions, it’s recommended to not exceed CF values above 30g. 
Note : The QMODE and QMODE+ parameters, presented in Table 13.3A, are user -
adjustable, in case the investigator deems appropriate.  
 
13.3.1 QMODE+ Recommended Ablation Parameters  
In this study protocol, QMODE+ is to be used as the primary mode for pulmonary vein isolation. If  the investigator deems QMODE+ unable to achieve PVI, the study catheter in 
QMODE should be used to complete the procedure. (refer to Section 1 3.3.5 and Appendix 
B for QMODE  details ) 
 
The circumferential  anatomical approach will be used to isolate all PVs. To minimize the 
risk of PV stenosis, it is recommended that RF energy applications are at least 1 to 2 cm outside the PV ostium to isolate the left and right- sided PVs. Confirmation of entrance 
block in all targeted PVs is REQUIRED. 
 Main Study  
 Table 1 3.3.1A: QMODE+ RF and Flow Rate Settings during RF applications  
Power Target Temp*  Cut-off Temp  Nominal 
Irrigation Flow 
rate Range Maximum 
allowed  Range Maximum 
allowed  
90W† 40-60ºC 60ºC 60-70ºC 70ºC 8mL** 
* Temperatures displayed on the RF generator do not represent tissue temperature or electrode tissue interface 
temperature.  
** A minimum flow rate of 2mL  during mapping is recommended.  
† The study recommends using this power setting for PVI as a primary ablation Strategy.  RF applications at 
this power setting are limited to 4 sec.   It is recommended to use lower target temp erature se tting for the 
posterior wall RF applications.  
 
Note : The QMODE+  parameters , presented in Table 1 3.3.1A, are user -adjustable, in case 
the investigator deems appropriate.  
 Caution:  The parameters provided in this section are based on data obtained from animal 
studies. Use clinical judgment when using this catheter paying careful attention to catheter 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 72 of 135 movement, initial impedance, impedance drop, electrogram reduction, time of RF 
applicatio n, and with consideration of individual patient conditions. 
 
Second (Variable Flow) Study  
 For the second (variable flow)  study the flow rate for QMODE+ will incorporate a variable 
flow rate during QMODE+ RF application s.  At the onset of 90W RF application the flow 
rate will be at 4mL /min.  As the temperature approaches the target temperature the flow 
rate will change to 15 m L/min to maintain the tip temperature within the target range.  If 
the temperature reaches the set cut -off temperature the system will stop RF delivery.  
 The introduction of the variable flow is the only change to the system.  The catheter should be used in QM ODE+ as described in the remainder of this section.  
 Table 13.3.1A: QMODE+ RF and Flow Rate Settings during RF applications 
Power Target Temp*  Cut-off Temp  Nominal 
Irrigation Flow 
rate Range Maximum 
allowed  Range Maximum 
allowed  
90W† 40-60ºC 60ºC 60-70ºC 70ºC 4-15mL**  
*  Temperatures displayed on the RF generator do not represent tissue temperature or electrode tissue 
interface temperature.  
** A minimum flow rate of 2mL during mapping is recommended.  
† The study recommends using this power setting for PVI as a primary ablation Strategy.  RF applications 
at this power setting are limited to 4 sec.   It is recommended to use lower target temperature setting for 
the posterior wall RF applications.  
 
Note : The QMODE+ parameters, presented in Table 13.3.1A, are user -adjustable, in case 
the investigator deems appropriate.   Caution:  The parameters provided in this section are based on data obtained from animal 
studies. Use clinical judgment when using this c atheter paying careful attention to catheter 
movement, initial impedance, impedance drop, electrogram reduction, time of RF application, and with consideration of individual patient conditions.   
13.3.2 General AF Procedure Guidelines  for QMODE+  
The AF ablation  procedures  for this  study should follow the sequence below : 
• Diagnostic catheter  placement  
• Electrophysiology study (discretion  of investigator)  
• Cardioversion if  subject  is in AF (discretion  of investigator) 
• CARTO ® Respiratory Gating Mandatory (unless using Jet Ventilation) 
• Placement of esophageal temperature monitoring device  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 73 of 135 • Confirmation of ACT  in ≥ 350 sec. PRIOR to insertion of the QDOT 
MICRO™  Catheter into the left atrium and maintain ed throughout the 
procedure  
• Transseptal puncture 
• A left atrial  anatomical  map is required  prior to an ablation  procedure in the 
LA.  
o An anatomical  map is not required  of triggers  outside of the left atrium e.g. 
SVC/CS  etc.  
• Introduction of the QDOT MICRO ™ Catheter  
o Use the AUTOTAG feature in Carto to tag each QMODE+ ablation point 
after each application  
o At the new location ensure catheter stability before commencing RF application. 
o A pre -ablation flow rate delay of minimal 2 seconds will occur before RF 
application  
o Ablation: RF power application of up to 90W for up to 4 seconds (QMODE+)   
o Move the catheter to a new location (~4mm) if clinically effective ablation is achieved  
o QMODE+ should be used for full PV enci rclement . If the investigator deems 
QMODE+  unable to achieve PVI , the study catheter in QMODE should be 
used to complete the procedure (refer to Appendix B for details) . 
o Continue RF applications and catheter movement until the circumferential PVI is completed.  
o Precautions:  
 If the temperature increases above the temperature cutoff (default 65°C), RF application will stop immediately (automatically)  
 The decision to interrupt RF power delivery at any time during ablation should be guided by Clinical Investigator judgment and the monitoring of ablat ion effectiveness parameters commonly used 
such as catheter movement, EGM reduction and/or impedance 
changes.  
o For ablation  in the region  of the right superior PV, precautionary 
measures  such as pacing maneuvers  are recommended  to evaluate  
proximity  to the phrenic nerve.  
• Left Atrial ablation and real time PV isolation  
• Post ablation  a 20- min waiting period is REQUIRED before pacing 
procedure(s) and/or infusion of cardiac medications  to induce AF/reconnection 
(e.g., Adenosine, Isoproterenol 2-20 mcg/min)  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 74 of 135 • Confirmation of entrance block in all targeted PVs by Lasso® or PentaRay®  
• Conduct fluoroscopic (or equivalent) evaluation of the diaphragm  
13.3.3 Esophageal Monitoring 
REQUIRED: An appropriate strategy to minimize risk of esophageal injury MUST be 
used to ensure the physician has accurate information about the location of the esophagus 
relative to intended sites of ablation. The method used to localize the esophagus will be collected in the CRFs. 
At least one of the following methods MUST  be used for esophageal localization: 
• Use of an esophageal temperature probe, 
• Esophageal visualization with CARTOSOUND® and/or ICE, 
• Esophageal visualization using barium swallow. 
Safety Alert: when esophageal temperature rise observed, please allow necessary time 
for tissue to cool down, and do not apply additional lesion immediately at the same or nearby location until the temperature returns to baseline . 
In the event of Esophageal temp erature rise:
 
1. When esophageal temperature rise observed, please allow necessary time for tissue to cool down, and do not apply additional lesion immediately at the same or nearby location  
2. Move away from that spot and ablate the other areas first then return to that spot if isolation is not attained  
3. At the investigator’s discretion, Q MODE  may be used with the operator’s usual, 
chosen, posterior wall power and duration, still watching very carefully for temp erature rise and not starting until esophageal temperature returns to baseline. 
4. Ablate in an area nearby but slightly away from that area if the above 2 steps don’t accomplish the task. 
 Power reduction data and clinical practice associated with posterior wall RF applications will be collected in the CRFs and CART O
® data files for analysis.  
 NOTE 1 : The recommendations provided are based on data obtained from animal and 
clinical studies. Use clinical judgment when using this catheter paying careful attention to impedance drop, electrogram reduction, time of RF application, and with consideration of individual subject conditions when selecting settings.  NOTE 2: Reduce Power when high contact forces are observed during creation of RF 
lesions in the left atrium. For CF ≥ 20g power should be ≤ 35 watts.  
13.3.4 Ablation Outside the PV Ostia  
The ablation  procedure includes PVI, ablation  of non- PV triggers  and substrate 
modification.   For RF application outside the PV ostia QMODE+ and QMODE may be 
used at the d iscretion of the Investigator.   
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 75 of 135 Study  procedure requirements  are outlined  below : 
• PVI of all PVs  are required  (acute success)  
• Linear ablation lines are only required to treat documented macro- reentry atrial 
tachycardias  and limited to the following targets only: 
o LA roof line  
o MV isthmus  line 
o LA floor line  
o CTI  
• A right atrial  CTI linear  ablation  is REQUIRED in cases  with documented 
typical  atrial  flutter  either  prior to  or during the procedure. 
• Ablation  of spontaneous non- PV triggers  
• CFAE  ablation  (left  atrial,  right atrial  and CS) is not recommended 
• Ablation  of non- PV triggers  induced by adenosine or isoproterenol 
Prophylactic ablation  of empirical  sites  is not allowed . 
All linear  lesions require  confirmation  of bidirectional conduction block by pacing  
and/or mapping maneuvers. 
13.3.5 QMODE  Ablation Parameters and Workflow 
QMODE temperature control mode will be used for PVI once the investigator deems 
QMODE+ unable to complete PVI.  Additionally, QMODE temperature control mode will be used for all RF applications outside the PV ostia during the study ablation procedure (refe r to Section 13.3.4 and Appendix B for additional details).   
 
Table 13.3.5A : QMODE Ablation parameters  
Power Target Temp*  Cut-off Temp  Nominal 
Irrigation Flow 
rate Range Recommended  Range Recommended  
25-35 W 45-50ºC 50ºC 50-55ºC 55ºC 4mL** 
36-50W*** 45-50ºC 50ºC 50-55ºC 55ºC 15mL** 
* Temperatures displayed on the RF generator do not represent tissue temperature or electrode tissue interface 
temperature.  
** A minimum flow rate of 2mL during mapping is recommended.  
*** RF applications at 36 -50W should not exceed 30 sec.  
 
QMODE Contact Force (CF) Settings  
When using the study catheter in QMODE the recommended Contact Force working range should be between 5 and 30g.   
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 76 of 135 QMODE Ablation Workflow:  
• If the temperature increases rapidly, stop RF application immediately  
• RF power range of 15- 50 Watts (W) is recommended for atrial ablation  
• At anatomical locations, not on the LA posterior wall or CS: 
o Maximum allowed power should not exceed 50 W 
o Duration of ablation should not exceed 60 seconds of continuous ablation at a 
given location 
• Move/drag the catheter to a new loc ation when clinically effective ablation is 
achieved (EGM reduction and/or impedance drop). 
• Duration of ablation as well as the decision to interrupt RF power delivery at any time during ablation SHOULD be guided by: 
o Clinical Investigator judgment and the monitoring of ablation effectiveness 
parameters commonly used such as EGM reduction and/or impedance changes.  
Precautions while ablating on the Posterior wall and Coronary Sinus : 
• LA posterior wall and close to the esophagus:  
o Start ablation using standard workflow for posterior wall.  
o Move/drag the catheter to a new location if clinically effective ablation is 
achieved within 20 seconds (EGM reduction and/or impedance drop). 
o Maximum power used SHOULD NOT exceed 35 W, except when using QMODE+ . 
o Duration of ablation as well as the decision to interrupt RF power delivery at any time during ablation SHOULD be guided by: 
 Clinical Investigator judgment and monitoring of ablation effectiveness 
parameters commonly used such as EGM reduction and/or impedance changes  
 Esophageal temperature changes should be monitored by an endo- luminal 
esophageal probe or method used to move esophagus as needed (refer to Section 13.3.3) 
 Duration of ablation should not exceed 30 seconds on posterior wall. 
 
13.4 Post Ablation 
• Verification  of entrance block is  required  for all  PVs.  
o A 20- minute  waiting  period  is REQUIRED from  the last RF application 
at a PV before verification may be confirmed.  If reconduction is noted, 
additional RF applications  should be applied  and a second  20-minute  waiting  
period will be required  to recheck  for entrance block. If reconduction is  still 
noted, additional RF applications  may be applied  but a third  20-minute  
waiting  period is  not required  prior to  recheck  for entrance block. 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 77 of 135 • To verify  entrance block, analyze electrograms  in sinus and/or atrial  paced  
rhythm to  confirm  that no PV  potentials  are present. 
o Administr ation of  adenosine or isoproterenol after a 20-minute  waiting  
period is  REQUIRED to  rule out dormant conduction.  
• Demonstration  of entrance block MUST  be confirmed  and documented  by the 
LASSO® Circular  Mapping Catheter  or PENTARAY® NAV Ca theter .  
• Linear ablation lines  may only be performed to treat documented macro-
reentry atrial tachycardias  (LA roof line, MV isthmus line, LA floor line, CTI . 
o Bidirectional block must be confirmed  and documented 
• The ablation  procedure is considered  complete  when  confirmation of block is 
confirmed  and documented . 
• In addition to the data collected on the CRFs, a CARTO ® backup file 
identified with the subject’s study number must be made for each case and sent 
to the sponsor as part of the data collection. 
13.5 Data collection During the Study Procedure  
Procedural data collection will be done through anonymized (or de- identified) generator 
files, anonymized (or de- identified) CARTO® data  files, procedural worksheets and 
subject medical files. Documentation of procedur al data will be kept in the subject’s 
CRF, anonymized (or de- identified) back -up generator files and back-up CARTO® data 
files for study analysis. 
 The information collected during the procedure will include, but will not be limited to, the list below:  
• RF application -mode per lesion ( QMODE+ /QMODE /other) 
• Number of RF applications with QDOT MICRO™  catheter (total/  
QMODE+/QMODE ) and with non- study catheter  
• Duration of RF applications with QDOT MICRO™  catheter (total/  
QMODE+/QMODE ) and with non- study catheter  
• PVI ablation time (time between first RF application and last RF application on a PV before isolation confirmed and circumferential ablation achieved) 
• Subject PVI ablation time (time between first RF application and last RF application before all PVI compl ete) 
• Subject total ablation time (time between first RF application and last RF 
application in a subject) 
• Ablation parameters per RF application: location, temperature, impedance, power, 
contact force, RF duration, ablation index, lesion information on CARTO® 
• Ablation number on the generator for first RF application and last RF application per target (left PV targets, right PV targets and for targets outside the PV area)  
• Ablation parameters for touch-up applications (location, RF application-mode, amount of touch-up applications, duration and associated generator file number) 
• Total procedure time (from first femoral puncture to last catheter removal)  
• Atrial mapping time  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 78 of 135 • Fluoroscopy time and dose 
• LA catheter dwell time (from ablation catheter LA insertion to ablation catheter 
removal from the LA)  
• ECG data  
• Total fluid delivered via ablation catheter and via intravenous line; fluid output 
and net fluid input 
• Strategy used to minimize risk of esophageal injury 
• Abnormal esophageal temperature ri ses 
13.5.1 Collection of Ablation Procedure data for post-analysis 
At the completion of the study ablation procedure, two back-up copies of the CARTO® 
and generator log files will be made. One copy should be kept at the site within the investigator site or subject binders, and one fully anonymized copy will be sent to the Sponsor. 
13.6 Repeat Procedures  
Repeat procedures may be performed at the discretion of the investigator. Repeat procedures during follow up may be managed per investigator discretion using an approved ablation catheter. The follow-up schedule will remain based on the initial ablation procedure. 
13.7 Post Procedure Follow- up Assessments  
The subjects will be required to complete follow up visits through 12 months (365 days) post initial ablation procedure.  Follow-up schedules will be based on a 30-day month 
 Follow-up visits should be scheduled according to the following timeframes: 7 day (7D, day 7-10), 1 month ± 7 days (1M, day 23-37), 3 month ± 14 days (3M, day 76-104), 6 months ± 30 days (6M, day 150-210), and 12 month ± 30 days (12M, day 335-395). Follow-up visit schedule will not reset if subject undergoes a repeat AF ablation procedure. 
• Prior to  hospital discharge:  
o Physical Exam  including standardized neurological assessment  
(including cranial nerve, motor and sensory function, and gait assessment) conducted by a physician must be performed pre-discharge.  
 If neurological assessment demonstrates new abnormal findings as compared to the one performed at baseline, a formal neurological consult and examination with appropriate imaging (i.e., DW -MRI), needs to be done to confirm any suspected 
diagnosis of stroke. 
o NIH Stroke Scale (NI HSS) must be administered by certif ied healthcare 
provider done prior to discharge  
o Occurrence of arrhythmias, if  any 
o Electrocardiogram  (12-Lead  ECG)  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 79 of 135 o Transthoracic Echocardiogram (TTE) , for evaluation pericardium for 
possible  pericardial effusion and/or pericarditis.  In the event  significant 
pericardial  effusion  is identified,  subjects  should be followed until the 
condition resolves.  
o Cardiac- related concomitant medications  (such as  AADs, anticoagulation 
regimen,  etc.) All cardiac -related medications prescribed since the ablation 
procedure till the end of follow -up will be recorded, including the type and 
name of the medication, associated indications, starting and ending dates of 
the prescriptions, etc.  
o Adverse events,  if any 
o Collect Subject Hospitalization Billing infor mation ( including UB04  and 
EOB)  
• Data will be collected at the 7 day, 1M, 3M, 6M, and 12M follow -up, and at 
any unscheduled visits via in -clinic, telehealth or phone visit. 
o Physical Exam: Exam should be performed at all clinical visits. This 
includes vital signs reported by the patient via telehealth or phone visit.  
o Quality of Life questionnaire: AFEQT ™ is to be collected at the 3M, 
6M , and 12M visits via in-clinic, telehealth or phone visit. 
o Electrocardiogram (12-Lead ECG). Data from 12 -lead ECG recordings 
will be collected at the 3M and 12M follow-up visit (standard of care are acceptable).  ECG data will be collected at baseline, pre- discharge, and 
unscheduled visits if completed as standard of care and at 1M and 6M if a clinical visit occurs and ECG is completed as standard of care.  
o Transtelephonic Monitoring (TTM): Subjects will be asked to transmit 
any symptom -triggered episode that occurs from the time they receive the 
TTM device through the 12M follow -up visit.  See Section  13.10 for the 
TTM transmission schedule.  A core lab will be used to evaluate and 
assess the TTM tracings.  
o 24 Hour Holter: Holter monitor will be used at the 12M follow -up visit 
to monitor the subjects’ heart rhythm for 24 hours continuously. A core lab will be utilized to evaluate and assess the 24 -hour Holter recordings.  
o Cardiac Multi Slice CT/MRA Image: CT/MRA will be completed at 
the 3M follow -up visit for subjects in the Main study CT/MRA subset. In 
addition, any subjects who have symptoms suggestive of PV stenosis should undergo CT/MRA imaging.  
o Adverse Events: AEs must be collected from the time the subject signs 
the informed consent onwards.  
o AFL/AT/AF recurrence  
o Repeat Ablation: Any ablation procedure performed after the index 
procedure will be recorded at 3M, 6M, and 12M follow -up as well as at 
any unscheduled visits.  
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 80 of 135 o Health Economic Data for hospitalizations, ER visits and outpatient 
visits, if any  
 At each follow -up visit, health economic data to be collected 
may include, but is not limited to: hospitalization charge 
(UB04), repeat ablation procedure and/or procedures resulting from the ablation procedure, outpatient visits, and ER visits 
o End of Study Report  (12-Month) 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 81 of 135 13.8 Standard Tests  and Procedures  
The required  schedule for subject  treatments  and evaluations is summarized  in Table 
13.8A.   
Table 13.8A: Schedule  of Treatments  and Evaluations 
 Pre- Proced.    Phon
e Call  Follow -Up Visits   
(via in -clinic, telehealth or 
phone visit)   
 Screening /  
Baseline  Study  
Abl1 
Day 0  D/C 7 D 
D7-10 1 M 
D23-
37 3 M 
D76-
104 6M 
D150-
210 12M  
D335-
395 U
NS 
Visit no.  1 2 3 4 5 6 7 8 9 10 
Informed 
consent1 X          
Inc & Excl 
Criteria  X          
Demographics  X          
Vital Signs  X          
Physical Exam   X17  X17  X X X15 X X 
NIHSS   X  X       
Med History2  X    X2 X2 X2 X2 X2 X2 
Arrhythmias  
History  X          
ECG  X  X  X X X X X 
Adverse Events3,4  X X X X X X X X X 
CHA 2DS 2-Vasc 
Score  X          
NYHA  Scale   X         
QOL Assessment5  X     X X X  
Preg Test6  X         
LA thrombus 
Imaging7    X7        
TTE8,9  X8  X9       
Concomitant 
Medications10  X X X X X X X X X 
mRS16     X16 X16 X16 X16 X16 X16 
PV CT/ MRA 
Subset11 X      X11    
PV Stenosis 
CT/MRA11     X11 X11 X11 X11 X11 X11 
Ablation 
Assessments    X        
Repeat Ablation18      X X X X X 
Device Deficiency    X        
Health Economic 
Data Collection12    X12 X12 X12 X12 X12 X12 X12 
AF/AT/AFL 
recurrence     X X X X X X X 
TTM13       X X X X 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 82 of 135  Pre- Proced.    Phon
e Call  Follow -Up Visits   
(via in -clinic, telehealth or 
phone visit)   
 Screening /  
Baseline  Study  
Abl1 
Day 0  D/C 7 D 
D7-10 1 M 
D23-
37 3 M 
D76-
104 6M 
D150-
210 12M  
D335-
395 U
NS 
Visit no.  1 2 3 4 5 6 7 8 9 10 
24-hour Holter          X  
Subject 
Completion/ 
discontinuation 
form14         X14  
 
1 Initial ablation procedure should be done 
within 30 days of consent.  
2 Collected to confirm no changes in medical history since last visit  
3 AEs collected once consent has been signed Collected to confirm no changes in medical history since last visit.  
4 If AE results in hospitalization , health 
economic data collection is required.  
5 Quality of life tools (AFEQT).  
6 Pregnancy test must be done on pre -
menopausal women only, within 24 hours of the procedure.  
7 Subjects should undergo imaging for the presence of LA Thrombus.  
8 Imaging TTE to determine the atrial size (if the subject has undergone an imaging procedure within the last 6 -months where the 
atrial size was assessed, the pre- procedure 
imaging assessment is not required).   
9 Post procedure all Subjects will undergo a 
TTE procedure to assess the pericardium for 
pericardial effusion and/or pericarditis.  
10 Concomitant medications: only cardiac related (anti -arrhythmia drugs, 
anticoagulation regimen, etc.) .  
11 PV im aging (CT/MR A) for subjects who 
have symptoms suggestive of PV stenosis or are in the Main study CT/MRA PV Analysis 
Subset.  
  12 Health Economic Data for hospitalizations 
(UB04), ER visits and outpatient visits, if any.   
13 TTM: all symptomatic cardiac episodes 
should be recorded and transmitted at the 
time the event occurs.  Asymptomatic transmissions should be recorded and 
transmitted as described in Section 13.10.  
14 12-month visit or last completed visit  
15 Required only for clinical visit  
16 In the event of a stroke the Modified Rankin Score  will assess the degree of 
disability in the subject who suffered the stroke.  
17 A standardized neurological assessment  
(including cranial nerve, motor and sensory function, and gait assessment)  is to be 
done. If this neurological assessment demonstrates new abnormal findings, the patient should also have a formal neurological consult and examination with 
appropriate imaging (i.e., DW -MRI), used 
to confirm any suspected diagnosis of stroke.   
18 All subjects who under go a repeat ablation 
procedure during blanking period with the QDOT MICRO™  catheter will undergo 
follow -up for Day 7 and 1 month after the 
ablation procedure.  
 
 
Q-fficiency   Protocol# BWI_2017_07
   
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 83 of 135    
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 84 of 135 
 13.9 Unscheduled visit  
If a subject returns  for a potential study related cardiovascular or neurological visit 
outside of the protocol-defined visit schedule provided in Table 13.8A, the visit will be 
considered “unscheduled” (UNS). An Investigator may request an unscheduled visit in the presence o f a new or worsening cardiovascular condition or neurological deficit. If 
the unscheduled visit is for a repeat ablation procedure, the protocol follow-up schedule is based on the index ablation procedure. For all unscheduled visits, an unscheduled visit eCRF must be completed and the subject must also return for their next scheduled study visit.  
13.10 Heart  Rhythm  Monitoring  
ECG, Transtelephonic monitors (TTM)  and Holter Monitors  will be used to monitor the 
subjects’  heart  rhythm post- treatment .  
Transtelephonic Monitors ( TTM ): 
Transtelephonic monitors (TTM) will be provided to each subject no later than at the 3-
month follow -up visit for scheduled transmissions of heart rhythm status.  Subjects will 
be instructed to transmit all emergent symptomatic cardiac events and follow a detailed schedule if the subject remains asymptomatic post ablation during the Evaluation Period (Day 9 1-365 ).   
The TTM transmission schedule: 
• Subjects will complete a test transmission upon receipt of the TTM device to demonstrate a working understanding of the device.  
• Transmission will be  performed once every week  during the Evaluation Period, 
starting no later than the month 3 visit through t he end of month 5 of the follow -
up period. Starting  from month 6, subjects will record and transmit once every 
month until the end of the 12- month follow-up period.  
• All symptomatic cardiac episodes should be recorded and transmitted soon after the event occurs during the Evaluation Period (Day 91-365).   
13.11 Repeat  AF Ablation Procedures  
Repeat  AF ablations(s) may be performed  at the discretion  of the physician. The follow-
up schedule (Medication  Adjustment and Therapy  Consolidation periods and exam  
intervals)  will continue based  on the initial AF ablation  procedure performed , regardless  
of repeat  ablation s.   
The following assessments should be performed  before  each procedure: 
• Imaging for detection of LA thrombus – performed within 48 hours prior to 
the procedure (refer to Section 13.2 for details) .  
• Pregnancy  Test – Pre-menopausal women  only, performed  within  48 hours 
prior to  the procedure.  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 85 of 135 
 Note: All subjects who under go a repeat ablation procedure during blanking 
period with the QDOT MICRO™  catheter will undergo follow -up for Day 7 and 
1 month after the ablation procedure . 
13.12 Core Laboratory  
A core laboratory will be used to review  the ECGs, TTMs  and Holter Monitors  for the 
objective evaluation  of recurrence of atrial  tachyarrhythmias.  Evaluations will be reviewed  
by a physician. AF episodes  will be evaluated  per the definition  included in this protocol. 
A core lab will also be used to review the CT/MRA images.  
 
14.0 ASSESSMENT OF SAFETY   
14.1 Adverse Event  Recording   
An Adverse Event is any untoward medical  occurrence,  unintended disease  or injury, 
or untoward clinical signs (including abnormal laboratory findings) occurring during a 
clinical  study, whether  or not related  to the study device or ablation  procedure.  
For the purposes of this protocol, adverse events will be reported and recorded (via 
eCRF) if any of the following apply: 
o Event is vascular, cardiovascular, or neurologic in nature 
o The event is a serious adverse event  
o Causality is related to: 
o Investigational device 
o Ablation procedure 
o Unknown in nature 
The following clinical events will not be considered an adverse event for this clinical 
study: 
o Any medical condition that is present at the of screening. Such conditions should be added to the medical history, if not previously reported. However, if the study subject’s condition deteriorates at any time during the study, it should be recorded as an AE.  
o A trace / trivial pericardial effusion that is asymptomatic, requires no medical intervention, and does not extend hospitalization will not be considered an adverse event  
o Recurrence of pre -existing AF/AT/AFL  
o AF/AFL/AT recurrence requiring phar macological or direct current 
cardioversion at any time throughout the duration of the study. However, new onset of left atrial flutter occurring post-ablation is an AE. 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 86 of 135 
 o Re-ablation for AF or pre -existing AFL/AT itself is not an AE, however 
any complicatio n associated with the repeat ablation procedures is 
considered an AE and shall be reported within the applicable timelines. 
Subjects should be encouraged to report AEs spontaneously or in response to general, 
non-directed questioning (e.g., “How was your health been since last visit?”). Anytime 
during the study, the subject may volunteer information that resembles an AE. 
The investigator is responsible for ensuring that all reportable AEs, observed by the 
investigator/study staff or reported by the subject, that occur from the time that the 
subject has signed the informed consent through the end of the study are properly assessed, recorded, and reported as defined and described in the AEs, Adverse Device Effects and Device Deficiencies section of this protocol and whenever the physician becomes aware of an event. Investigators will determine, at each encounter, whether any adverse events (AE) have occurred, and judge their seriousness and relationship to  
the study device and procedure. Each investigator shall  provide source documentation 
as requested by the Sponsor to facilitate reporting and adjudication of these events.  
All adverse  events  meeting the above definitions , regardless  of classification,  
seriousness,  intensity,  outcome,  or causality,  must be recorded  in the electronic CRF(s)  
in a timely  manner  throughout the study. Onset  date of the event,  its treatment,  current  
status  (resolved, stabilized,  or ongoing), and assessment  of its seriousness and 
relationship  to the device should be provided when  available.  All AEs will be monitored 
until they  are resolved  or stabilized  (no further changes  anticipated).   
14.2 Classification  
Any of the following events,  and any death  or hospitalization  while  on study, is to be 
reported  to the sponsor immediately.  The Sponsor may request additional information 
after the initial notification.  
14.2.1 Primary  Adverse Event  
A Primary  AE is one of the following events  occurring within  seven  (7) days following 
an AF ablation  procedure with the QDOT MICRO™  catheter when used with the 
nMARQ™ RF generator , except atrio -esophageal fistula and PV stenosis, which may 
also be considered as primary adverse events if occurring greater than seven (7) days 
and up to 90 days post the ablation procedure:[55, 56] 
Table 14.2.1A: Primary  Adverse Events  
PRIMARY ADVERSE  
EVENT DESCRIPTION / CRITERIA 
Death  Patient  death  directly  related  to the device or  procedure  and 
occurs at  any time during or after  the procedure. 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 87 of 135 
 PRIMARY ADVERSE  
EVENT DESCRIPTION / CRITERIA 
Atrio -Esophageal Fistula  Is defined as  a connection between  the atrium  and the lumen  
of the  esophagus. Evidence  supporting this diagnosis includes 
documentation of  esophagus erosion  combined with  evidence 
of a fistulous  connection to the atrium such  as air emboli,  an 
embolic  event,  or direct  observation at  the time  of surgical  
repair.  A CT  or MRI  scan  is the most  common method of 
documentation of  an atrio -esophageal  fistula.  
Cardiac 
Tamponade*+/Perforation+ The development of  a significant pericardial  effusion during or 
within  30 days  of undergoing an  AF ablation  procedure.  A 
significant  pericardial  effusion is  one which  results  in 
hemodynamic compromise, requires elective  or urgent 
pericardiocentesis,  or results in  a 1 cm  or more  pericardial  
effusion  as documented  by echocardiography. Cardiac  
tamponade should also be classified  as "early”  or “late”  
depending on  whether it is diagnosed during or  following  
initial  discharge from  the hospital.  
Myocardial  Infarction The presence of  any one of  the following criteria: 
• Detection  of ECG  changes indicative  of new ischemia  
(new ST-T changes or  new LBBB)  which  persists  for 
more  than  1 h 
• Development of  a new  pathological Q waves  on an  
ECG,  and 
• Imaging evidence of  new loss of viable myocardium or  
new regional wall  motion  abnormality  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 88 of 135 
 PRIMARY ADVERSE  
EVENT DESCRIPTION / CRITERIA 
Stroke/  
Cerebrovascular Accident  Rapid onset of a focal or global neurological deficit with at 
least one of the following: change in level of consciousness, 
hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopia, 
amaurosis fugax, or other neurological signs or symptoms consistent with stroke. 
Duration of a focal or global neurological deficit ≥24 h; or <24 
h, if therapeutic intervention(s) were performed (e.g. thrombolytic therapy or intracranial angioplasty); OR 
available neuroim aging documents a new hemorrhage or 
infarct;  or the neurological deficit results in death.  
No other readily identifiable non- stroke cause for the clinical 
presentation (e.g., brain tumor, trauma, infection, 
hypoglycemia, peripheral lesion, pharmacological influences)†  
Confirmation of the diagnosis by at least one of the following: 
• Neurology or neurosurgical specialist   
• Neuroimaging procedure (MR or CT scan or cerebral angiography) 
• Lumbar puncture (i.e., spinal fluid analysis diagnostic of intracranial hemorrhage)  
Stroke: (diagnosis as above, preferably with positive neuroimaging study)   
• Minor —Modified Rankin score <2 at 30 and 90 days††  
• Major —Modified Rankin score ≥2 at 30 and 90 days  
Thromboembolism  Formation  of a clot (thrombus) insid e a blood vessel  causing 
obstruction to  blood flow.  The thrombus  can migrate  
(embolus) and obstruct distal  vascular  sites.  Diagnostic tests  to 
help detect  thromboembolisms  may include but are  not limited  
to angiography  (pulmonary or distal),  ventilation -perfusion 
(V/Q)  scans,  venography, Doppler ultrasonography, spiral  CT, 
and echocardiography. 
Transient  Ischemic  Attack  New focal neurological deficit with rapid symptom resolution 
(usually 1 to 2 h), always within 24h.  Neuroimaging without 
tissue injury.  
Phrenic Nerve Injury / 
Diaphragmatic Paralysis Absent phrenic nerve function as assessed  by a sniff test. A 
phrenic nerve  paralysis  is considered  to be permanent when  it 
is documented to be present  12 months or longer following 
ablation. 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 89 of 135 
 PRIMARY ADVERSE  
EVENT DESCRIPTION / CRITERIA 
Heart  Block  Impairment  of AV conduction requiring intervention  (e.g. 
temporary or permanent pacemaker) due  to iatrogenic  cause  
(e.g. inappropriate RF  application, traumatic  maneuvering of  
catheter  or other intracardiac  devices).  
Pulmonary  Vein  Stenosis  A reduction of the diameter  of a PV  or PV branch. PV  stenosis 
can be categorized  as mild  <50%, moderate 50-70%, and 
severe 70%  reduction in  the diameter  of the PV  or PV branch.  
PV stenosis (> 70% PV narrowing) regardless of the presence 
or absence of symptoms and PV stenosis with ≥ 50% PV 
narrowing when accompanied with relevant symptoms that 
cannot be explained by other etiologies  will be considered a 
primar y adverse event . 
Pulmonary  Edema  
(Respiratory  Insufficiency)  Respiratory  insufficiency  resulting in pulmonary 
complications  necessitating  intubation or other  significant 
intervention (including  diuretics administered  specifically  for 
treating  pulmonary edema or ICU  hospitalization requiring 
oxygen administration  but not intubation) Exclusion criteria  
include: 
• Pneumonia – infiltrate,  fever  and leukocytosis 
• Acute  Respiratory Distress Syndrome 
Vagal Nerve Injury  Injury to the vagal nerve that results in esophageal dysmotility or gastroparesis. Vagal nerve injury is considered to be a 
major complication if it prolongs hospitalization, requires 
hospitalization, or results in ongoing symptoms for more than 
30 days following an ablation procedure. 
Pericarditis  Should be considered a major complication following ablation 
if it results in effusion which leads to hemodynamic 
compromise or requires pericardiocentesis, prolongs hospitalization by more than 48 h, requires hospitalization, or 
persists for more than 30 days following the ablation procedure.  
Major Vascular Access 
Complication / Bleeding  Major Bleeding:  
A major complication of AF ablation if it requires and/or 
treated with transfusion or results in a 20% or greater fall in HCT.  
Major Vascular Access Complication:  
Defined as hematoma, an AV fistula, or a pseudoaneurysm 
which requires intervention such as surgical repair or 
transfusion, prolongs the hospital stay, or requires hospital admission.  
* Hemodynamic compromise  or instability  is defined as  Systolic  BP < 80 mm Hg.  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 90 of 135 
 + Cardiac Tamponade/Perforation occurring within 30 days of the AF ablation 
process will be considered Primary AEs 
† Subject s with  non- focal  global encephalopathy  will not be reported  as a stroke 
without unequivocal evidence based  upon neuroimaging studies. 
†† Modified Rankin score assessments should be made by certified  individuals.  
 
All reported  Primary  AEs  will be monitored until they are adequately  resolved  or explained. 
14.3 Serious  AEs   
A serious adverse event  (SAE) is any event  that meets  one or more  of the following 
criteria:  
• Lead to  a death  
• Lead to  a serious deterioration  in the health  of a subject  that: 
o Resulted  in a life -threatening illness  or injury 
o Resulted  in a permanent  impairment of a body structure  or a body 
function; 
o Required  in-patient  hospitalization  or prolongation of existing  
hospitaliz ation* 
o Resulted  in medical  or surgical  intervention to prevent permanent  
impairment to  body structure  or a body function 
• Lead to  fetal  distress,  fetal  death  or a congenital abnormality  or birth  defect.  
“Hospitalization”  means  the event  necessitated  an admission  to a health  care facility  
e.g., with at least an overnight stay. Emergency  room visits  that do not result  in 
admission  to the hos pital should be evaluated  for one of the other serious outcomes.  
*Planned hospitalization  for  a condition present  prior to the participant’s  enrollment in 
the study will not meet  the definition  of an SAE,  but should nevertheless  be included in 
routine study reporting.  
14.4 Non-Serious  AEs  
A non-serious AE is any event  that results  in minimal transient  impairment of a body 
function or damage to a body structure  and does not require  any intervention  listed  under 
the criteria  for “Serious  Adverse Event.” Non-serious adverse events  require  routine 
reporting via EDC.  
14.5 Anticipated  AEs  
An anticipated  AE is one that has been  reported  in previous studies of RF ablation  and 
can be anticipated  in this current  study as per the risk analysis . Table 14.5A provides a 
comprehensive list of anticipated  AEs.  
 
Table 14.5A: Anticipated  Adverse Events  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 91 of 135 
 Anticipated  Adverse  Events  
1. Acute  Respiratory  Distress  Syndrome  (ARDS)  
2. Air embolism  
3. Allergic  reaction   
4. Anaphylactic  shock  
5. Anemia  
6. Allergic  reaction  to Anesthesia  (e.g.,  hair loss)  
7. Apnea  - sedation  induced  
8. Arrhythmia:  bradycardia  
9. Arrhythmia:  tachycardia  
10. Arrhythmia:  pro-arrhythmias  
11. Arrhythmia:  ventricular  tachyarrhythmia  / pro-arrhythmia  
12. Aspiration  pneumonia  
13. Asthmatic  attack  
14. Atelectasis  
15. Atrial  fibrillation  
16. Exacerbation  of pre-existing  arrhythmia  
17. Atrio -Esophageal  fistula  
18. Typical atrial flutter  
19. Atypical  left atrial  flutter  
20. Atypical right atrial flutter  
21. AV fistula  
22. Bleeding  complications  
23. Bleeding  requiring  transfusion  
24. Cardiac  arrest  
25. Cardiac  perforation   
26. Tamponade  
27. Cardiac  thrombo -embolism  
28. Cerebro -vascular  accident  (CVA)  / stroke  
29. Chest  pain/discomfort  
30. Complete  heart  block,  temporary  or permanent  
31. Conduction  block:  ongoing  / resolved  
32. Congestive  Heart  Failure  
33. Coronary  artery  dissection  
34. Coronary  artery  occlusion  
35. Coronary  artery  spasm  
36. Coronary  artery  Thrombosis  
37. Death  
38. Deep  venous  thrombosis  
39. Dislodgement  of ICD (Implantable  Cardioverter  Defibrillator)   
40. Dislodgement  of permanent  pacing  leads  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 92 of 135 
 Anticipated  Adverse  Events  
41. Disseminated  Intravascular  Coagulation  
42. Dyspnoea  
43. Endocarditis  
44. Epistaxis  
45. Expressive  aphasia  
46. Fainting  
47. Fatigue  
48. Gastro -intestinal  NOS  
49. Gastric  reflux  
50. Nausea  
51. Gastrointestinal  diverticulosis  
52. Heart  Failure  
53. Hematoma  (local)  /ecchymosis  
54. Hemorrhage   
55. Hemothorax  
56. High  / increased  creatine  phosphokinase  (CPK)  
57. Hypotension  
58. Hypertension  
59. Hypoxia  
60. Infection,  localized   
61. Infection,  systemic  
62. Laceration  
63. Leakage  of air or blood  into the lungs  or other  organs  due to perforation  
64. Liver  toxicity  
65. Mobile  strands  in Inferior  Vena  Cava  
66. Myocardial  Infarction  
67. Neurological  disorders  (tremor)  
68. Neurological  disorders  (poor  coordination)  
69. Neurological  disorders  (headache)  
70. Obstruction  to the vascular  system  
71. Perforation  of the vascular  system  
72. Damage  to the vascular  system  
73. Pericardial  effusion  resulting  in tamponade  
74. Pericardial  effusion  without  tamponade  
75. Minor Pericarditis  
76. Major Pericarditis  
77. Peripheral  embolus  
78. Peripheral  nerve  injury  
79. Peripheral  thromboembolism  
80. Phlebitis  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 93 of 135 
 Anticipated  Adverse  Events  
81. Phrenic  nerve  damage   
82. Diaphragmatic  paralysis  
83. Pleural  effusion  
84. Acute  Respiratory  Distress  Syndrome  (ARDS)  
85. Pneumothorax  
86. Pseudoaneurysm  
87. Pulmonary  edema  
88. Heart  failure  
89. Pulmonary  embolism  
90. Pulmonary  hypertension  
91. Pulmonary  toxicity,  like acute  pulmonary  syndrome  
92. Pulmonary  vein dissection  
93. Pulmonary  vein Stenosis  
94. Pulmonary  vein thrombus  
95. Pump  failure  
96. Renal  failure  
97. Respiratory  depression  
98. Respiratory  failure  
99. Retroperitoneal  hematoma  
100. Rhabdomyolysis,  including  produced  by body  position  or propofol  
101. Sedation  induced  CO2  retention  with lethargy  and cholecystitis  
102. Seizure  
103. Sepsis  
104. Skin burns  (due to cardioversion,  tape,  etc.) 
105. Skin discoloration  
106. Skin injury  / muscle  or connective  tissue  injury  due to body  position,  electrical  
cardioversion  
107. Skin rash 
108. Thrombocytopenia  
109. Thromboembolism  
110. Thrombosis  
111. Thyroid  disorders  
112. Transient  extremity  numbness  
113. Extremity numbness  
114. Transient  ischemic  attack  (TIA)  
115. Unintended  complete  or incomplete  AV, Sinus  node,  or other  heart  block  or damage  
116. Urinary  retention  
117. Urinary  tract infection  
118. Urinary  tract injury  or infection  related  to the urinary  catheter  
119. Vagal Nerve injury  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 94 of 135 
 Anticipated  Adverse  Events  
120. Valvular  damage/insufficiency  
121. Vasovagal  reactions  
122. Vision  change  
123. Volume  overload  
124. Worsening  obstructive,  restrictive,  or other  form  of pulmonary  disease  
125. X-ray radiation  injury  of skin,  muscle  and/or  organ  
14.6 Unanticipated Serious  Adverse Device Effect  
A (serious)  adverse device effect  (SADE)  is any (serious) adverse effect  on subjects’  
health,  safety,  rights, welfare,  and life-threatening  problems including death,  which  is 
caused  by, or associated  with the study device.  Accordingly, relationship  to device or 
study is crucial  assessment  by investigators. An unanticipated  adverse device effect  
(UADE)  or unanticipated  serious adverse device effect  (USADE)  is any ADE  or SADE  
that has not been  previously identified  in nature,  severity,  or degree of incidence in the 
study plan or risk analysis  report.  An investigator shall submit to the reviewing IRB/EC 
a report of any unanticipated adverse device effect occurring during an investigation as 
soon as possible, but no later than 10 working days after the investigator first learns of the effect, where appl icable.  
14.7 Clinical Investigation Device Failure/Malfunction/Deficiency  
A device has failed  if it does not perform  according  to the instructions for use or fails to 
meet  the expectations  of the device and/or investigator ( i.e., related  to appearance of the 
device,  performance,  durability,  safety,  effectiveness,  quality, reliability,  labeling, etc.). 
If a device  failure  is detected  or suspected,  it should be documented on the appropriate 
CRF  and the device  must  be promptly returned  according  to the Sponsor’s 
instructions. If the device failure  is associated  with an AE, both  the device  failure  and 
AE must be reported  to the Sponsor immediately  upon a wareness  (refer to section  
14.8). 
14.8 R
eporting Requirements  
All serious AEs, UADE/SADE/USADE, and Study device failure/malfunction/deficiency, whether or not they are related to the device or 
procedure, must be reported by eCRF  to the Sponsor ( Biosense Webster Clinical 
Operations) .  
The sponsor is responsible for reviewing AEs (causality, classification, seriousness…) and for ongoing safety evaluations in accordance with the study  safety management 
plan. In case of disagreement between the sponsor and the principal investigator(s) that remain after query resolution, the sponsor shall communicate both opinions to the concerned parties.  
Biosense Webster will ensure that investigators  are instructed to return devices 
suspected of causing an AE or SAE (i.e., definitely device -related, probably device -
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 95 of 135 
 related, or possibly device -related) in accordance with relevant regulations and current 
company procedures. 
In the case of serious adverse device effects and device deficiencies that could have led 
to serious adverse device effects, the Sponsor will determine whether the risk analysis needs to be updated and whether corrective or preventive action is required. 
Timing for reporting the different types of AEs is described in Table 14.8A  
Table 14.8A Adverse Event Reporting Requirements  
Type of Adverse Event  Reporting Requirements  
Serious Adverse Events  Report to Sponsor as soon as possible but no later than 72 
hours upon awareness of the e vent  
UADE, USADE & SADE  Report to Sponsor as soon as possible but no later than 72 hours upon awareness of the event 
 
Study device deficiency associated with an AE 
 Report both study device deficiency and AE to Sponsor as 
soon as possible but no later than 72 hours upon awareness 
of the event  
All other Adverse Events  Routine reporting via eCRF as soon as possible but no later than 2 weeks upon awareness of the even t 
 
 
14.9 Intensity  or Severity  
Intensity  (or severity) of AEs is defined  as follows:  
Table 14.9A: Intensity  or Severity  Definitions  
Mild  Events that result  in minimal  transient  impairment  of a body  
function or damage to  a body structure,  and/or does  not require  
intervention  other  than monitoring.  
Moderate  Events that result  in moderate  transient  impairment  of a body  
function or damage to  a body structure,  or that  require 
intervention, such  as the administration  of medication,  to prevent 
permanent  impairment of a body function or damage to  a body 
structure.  
Severe  Events that are life threatening  and/or result  in permanent  
impairment of body functions or damage to  body structure s, or 
that require  significant intervention, such  as major  surgery, to  
prevent permanent impairment of a body function or damage to  a 
body  structure.  
Intermittent AEs  should be classified  according to  their  greatest  severity.  A continuous 
AE that changes  severity  should be reported  as a new  AE. 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 96 of 135 
 14.10 Outcome 
AE outcomes are assessed  according  to the following classifications: 
Table 14.10A: Adverse Event  Outcome Classifications  
Recovered/ Resolved  
without  Sequelae  Subject  fully  recovered  with no observable  residual  
effects.  
Recovering/ 
Resolving  Subject’s condition is improvin g but residual effects 
remain.  
Recovered/ Resolved  
with  Sequelae  Subject  recovered  with  observable residual  effects.  
Not rec overed/ 
resolved  AE is ongoing without improvement in overall 
condition  
Fatal Subject  died as a result  of the adverse  event,  whether  or 
not the AE  is related  to the device or  procedure. Note;  
deaths  from  any cause occurring  on this  study are to 
follow  expedited  reporting.  
Unknown  AE outcome is unknown (e.g., subject lost to follow -
up) 
14.11 Causality 
Cause of AEs  is defined  as follows: 
Table 14.11A: Adverse Event  Causality Classifications 
Caused By  Relation  Definition of Relation  
Device  Definitely 
(Causal 
Relationship)  The event is associated with the investigational device beyond 
reasonable doubt  
Probable The relationship with the use of the investigational device 
seems relevant and/or the event cannot reasonably be explained 
by another cause, but additional information may be obtained  
Possibly The relationship with the use of the investigational device is 
weak but cannot be ruled out completely  
Unlikely  The relationship with the use of the investigational device 
seems not relevant and/or the event can be reasonably explained 
by another cause, but additional information may be obtained  
Not related  Relationship to the investigational device can be excluded  
Study Procedure  Definitely 
(Causal 
Relationship)  The event is associated with the study procedure beyond reasonable doubt  
Probable The relationship with the study procedure seems relevant and/or 
the event cannot be reasonably explained by another cause, but 
additional information may be obtained  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 97 of 135 
 Possibly The relationship with the study procedure is weak but cannot be 
ruled out completely  
Unlikely  The relationship to the study procedure seems not relevant 
and/or the event can be reasonably explained by another cause, 
but additional information may be obtained  
Not related  Relationship to the procedure can be excluded  
 
14.12 Documentation 
All AEs must be documented on the appropriate eCRF.  All AEs must be monitored until 
they are adequately  resolved  or stabilized , with follow-up reports  submitted  to the 
Sponsor or designee as soon as new information  becomes  available.  Additional 
documentation may be requested  by the Sponsor or designee,  such as a written  event  
narrative detailing  the clinical  course, copies  of correspondence with the local  IRB/EC,  
hospital records,  death  certificate s, and autopsy report s, if applicable.  Follow-up 
information relative to the subject’s subsequent course must be submitted to the sponsor 
or designee until the event has resolved or, in case of permanent impairment, until the condition stabilizes. If the subject is withdrawn from the study because of the AE, the information must be included on the appropriate eCRFs. 
 
14.13 Safety Oversight 
Safety oversight will be conducted as described in the S afety Management Plan. 
Aggregate safety data will be reviewed regularly throughout the course of the study by 
the study safety lead or designee to promptly identify new issues or trends which may have an impact on the conduct of the study and/or subject safety. 
14.14 Clinical Events  Committee  (CEC) 
Primary  Adverse Events will be  submitted to the independent Clinical Events 
Committee (CEC) for review.  
 
15.0 DEVIATIONS FROM PROTOCOL AND GOOD CLINICAL PRACTICE  
The investigator is responsible for ensuring that the clinical investigation is conducted in accordance with the procedures described in this protocol except in medical emergencies. 
A protocol deviation is defined as an instance of failure to follow, intentionally or unintentionally, the requirements of the protocol (e.g., missed test or procedure, visit out of window, non -adherence to inclusion/exclusion criteria). Investigators are not allowed to 
deviate from the protocol. Protocol deviations will be monitored closely and may require reporting to the IRB/EC and/or regulatory authority per IRB/EC/regulatory authority requirements.  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 98 of 135 
 Under emergen cy circumstances, deviations from the protocol to protect the rights, 
safety and well -being of a subject may proceed. Such deviations shall be documented 
as protocol deviations in the eCRF and reported to the IRB/EC/regulatory authority as 
required.  
In eme rgencies, prior approval for a protocol deviation will not be required, but the 
Biosense Webster clinical operations personnel should be notified as soon as possible. The study monitors shall verify that the conduct of the study is in compliance with the currently approved protocol and applicable regulations and shall identify any issues of 
non-compliance with regulations or guidelines. Issues of non -compliance include but 
are not limited to repeated protocol deviations, failure to obtain proper informed consent, non- conformance to IRB/EC requirements, failure to report.
 IRB/REBs must 
also be notified promptly of significant protocol deviations as they are defined by the IRB/REBs.  
 
16.0 DEVICE ACCOUNTABILITY  
16.1 Device Accountability  
The Sponsor will keep records of  all investigational devices shipped to the site. 
Investigators are responsible for appropriate logging of the devices received, verification of packing slip information (i.e., lot numbers and quantity shipped), date and identity that each device was used in the study, and disposition information regarding return to the 
Sponsor. The Sponsor will label all devices as “Investigational device” (as applicable for the region) in a prominent location. All system installations will be performed by trained 
field se rvices personnel according to internal processes. 
 The site Device Accountability Log will include the following information: 
• Date of receipt  
• Individual acknowledging receipt 
• Quantity received  
• Packing Slip Verification  
• Catalog number for catheters 
• Serial/lot numbers  
• Expiry Date 
• Dates devices were used  
• Subject IDs for whom devices were used 
• Dates of return (as applicable)  
• Type of disposal (i.e., return to Sponsor for adverse event, complaint, expired, end 
of study, etc.)  
16.2 Device Returns  
All study devices will be labeled “Investigational Device ” and are only to be used for 
subjects enrolled in this clinical study.  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 99 of 135 
 The allowable equipment for use in the study are those listed in the Study Protocol Section 
11.5.  
 Devices suspected of deficiency or devic e associated with a (device related or possibly 
related) adverse event should be returned immediately to BWI and will undergo thorough analysis. Device replacement at the site, except for disposable or resterilizable devices 
which are replaced according to  the respective IFU’s, will be performed by trained field 
services personnel according to internal processes.  Returned devices must be 
decontaminated per hospital policy and labeled with the following: 
• Subject identification number, or if unused, site num ber 
• Date of use/event or if applicable, specify “unused” 
• Return type (device deficiency related, AE related, etc.)  
All tracking information must be retained. All study devices  must be returned to:  
Complaints Lab  
Biosense Webster, Inc.  
  
17.0 MONITORING THE STUDY 
Clinical site monitoring is conducted to ensure that the rights and well -being of human 
subjects are protected, that the reported trial data are accurate, complete, and verifiable, 
and that the conduct of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with applicable regulatory requirement(s). Each 
site will undergo periodic monitoring of the study, which involves a visit from a trained Sponsor representative. Monitoring visits may include, but will not be limited to, the following: 
• Adherence of the protocol  
• Verification of accuracy of study logs such as the Delegation of Responsibility, etc. 
• Verification that informed consent is obtained for all subjects participating in the 
study in accordance with requirements described in the study protocol 
• Verification of completeness of the Regulatory Binder.  
• Source data verification with the eCRFs.  
• Identification and action to resolve any issues or problems with the study. 
 Data are to be submitted as soon as possible afte r collection via e -CRF. Missing or unclear 
data will be corrected as necessary throughout the trial. Biosense Webster may request further documentation such as physician and/or cardiac EP lab procedure notes when complications or malfunctions are observed and reported.  Monitoring activities will be documented through such means as contact reports and follow- up summaries of status and action items. Further details on clinical monitoring are 
provided in the study specific monitoring plan.  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 100 of 135 
 17.1 Early Termination Monitoring Visit  
If early termination of the study is required, each site will undergo a monitoring visit as 
described in the monitoring plan to conclude any outstanding issues, collect all outstanding CRF information, verify device accountability, and discuss any other items relevant to the conclusion of the study. Subjects will be notified of the termination of the study. Any enrolled subjects will continue to be followed per the study protocol requirements until a study closeout plan is imple mented that outlines alternative follow -up procedures. 
 
18.0 STATISTICAL ANALYSIS METHODS  
18.1 Study Design  
Prospective, multicenter, non-randomized, clinical evaluation of the QDOT MICRO™  
catheter compared to a historical control performance goal.   There are two st udy arms for 
the treatment; Main  Study, QDOT MICRO™ catheter  with constant flow rate (8 mL/min) 
during QMODE+ RF application and second (variabl e flow) study, variable flow rate (4 -
15 ml/min)  during QMODE+  RF application .  QMODE RF applications will use the same 
flow rates for both studies .   
The tral  will enroll 𝟏𝟏𝟏𝟏𝟏𝟏 evaluable subjects  in the Main  study and 92 subjects in the 
second ( variable flow ) study for a total of 277 subjects . The analysis for the Main study 
is a standalone analysis and it is not dependent on data from the variable flow study. 
The results from the v ariable flow study will only be used for additional claims.   
18.2 Treatment Assignment  
The treatment assigned for both studies  is the QDOT MICRO™  catheter.   The 
difference in the 2 studies  is the irrigation f low rate during QMODE+ RF application; 
Main  study irrigation flow rate is 8 mL/min constant and the second study is variable  
flow of 4-15 mL/min (dependent on catheter tip temperature).   
Enrollment into the two studies  will be in a sequential fashion. The first 185 subjects 
will be enrolled in the Main  study.  Subjects  enrolling after the completion of enrollment 
in the Main  study will be enrolled into the second ( variable flow ) study.  
18.3 Interval Windows 
Refer to section 13.7 and Table 13.8A.   
18.4 Primary and Secondary Endpoint(s), and Associated Hypotheses  
 The primary goal of the trial is to demonstrate safety and effectiveness . For each study to 
be successful, both safety and effectiveness endpoints must be statistically significant 
relative to their respective performance goals.   
 Study Success  
The study will be considered successful if the primary endpoints are met for main  study.  
If the main study is not successful, the data for the second (variable flow) study will not 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 101 of 135 
 be submitted for labeling. The second (variable flow) study will be considered successful  
if both the primary safety and primary effectiveness performance goals are met.   
 
18.4.1 Primary Endpoint(s) and Associated Hypotheses  
Acute Safety : The primary safety endpoint is the proportion of subjects with any Primary 
Adverse Event occurring within 7 days of ablation procedure. The PAE rate will be 
compared against an PG of 14%.  The primary safety endpoint will be assessed by testing the hypotheses:   
𝐻𝐻
0:𝑝𝑝𝑆𝑆≥0.14  vs .  𝐻𝐻 𝐴𝐴:𝑝𝑝𝑆𝑆< 0. 14, 
 
where 𝑝𝑝𝑆𝑆 is the proportion of patients with PAE at early onset (within 7 days of ablation 
procedure). 
 The primary safety analysis will be performed at the time of the interim analysis  for the 
Main study. In the variable flow study, the primary endpoints will be evaluated after full 
12-month follow-up is completed on all subjects.    12-Month Chronic Effectiveness : The primary effectiveness  endpoint is the proportion 
of patients that are free from documented atrial arrhythmia (atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL)) episodes at Month 12 (that is, during the 9-month post-blanking period, i.e. Day 91-365).   The primary effectiveness endpoint will be assessed by testing the hypotheses:   
𝐻𝐻
0:𝑝𝑝𝐸𝐸≤0.50  vs .  𝐻𝐻 𝐴𝐴:𝑝𝑝𝐸𝐸> 0. 50, 
 
where 𝑝𝑝𝐸𝐸 is the proportion of patients that are free from AF, AT, and AFL episodes at 12-
month follow-up (includes a 3-month blanking period).  
 
 In case early success is achieved, the study will continue to follow up the subjects for the full follow -up duration. The primary effectiveness endpoints based on full 12-month 
follow- up data will be descriptively summarized in subjects in the PP population. The 
primary effectiveness endpoint in the variable flow study will be evaluated at the end of 
the study, i.e. completion of 12-month follow-up in all subjects. 
18.4.2 Secondary Endpoints and Associated Hypotheses  
No formal statistical hypothesis and inferential statistics will be formulated and performed for the secondary safety and effectiveness endpoints.  
Refer to Section 8.2.3.1 for secondary safety endpoint, and Section 8.2.3.2 for secondary 
effectiveness endpoints. 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 102 of 135 
 18.4.3 Other Endpoints  
No formal statistical hypothesis and inferential statistics will be formulated and 
performed for the additional safety and effectiveness endpoints.  
 Refer to Section 8.2.3.3 for additional endpoints. 
18.5 Levels of Significance 
The type I error for the interim and final analyses of the primary endpoints  for the main 
study is controlled at one -sided 2.5%. Two- sided 95% confidence intervals will be 
presented around the percentages unless otherwise specified . For the variable flow 
study,  both primary endpoints will be tested at the end of  the study at the 2.5% 
significance level,  and all confidence intervals will be presented at the 95% confidence 
level unless otherwise specified.  
    
18.6 Analysis Set   
The treatment for both studies  is the QDOT Micro Catheter , there for  the analyses  sets 
are defined identically for  both studies. 
Safety  Population (SP)  : The Safety population will include all enrolled subjects who 
have the investigational device inserted, regardless if RF energy is delivered. 
 
 Modified Intent -To-Treat (mITT) Population : the modified Intent-To -Treat (mITT) 
 population will consist of all enrolled subjects who have the investigational device inserted  AND 
 meet all eligibility criteria .. 
 
Per Protocol (PP)  Population:  The PP population will include subjects who satisfy  
the following criteria:  
o are enrolled and  meet all  eligibility  criteria  
o have undergone RF ablation  
o are treated  with the study  catheters,  and have been  treated  for the study-
related  arrhythmia   
CT/MRA (CTS)  Population :  The CT/MRA set will consist of the first 40 subjects 
who are consecutively enrolled in the main study with 3- month CT/MRA assessment. 
The subject must have readable outcomes at baseline and 3 months.  
18.7 Sample Size Justification  
The Main  study : 
 
The Final analyses for primary safety and effectiveness end points will apply Bayesian 
methods and use a beta -binomial model after all subjects complete the 12 months 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 103 of 135 
 follow- up (assuming early success is not achieved for the primary effectiveness 
endpoint). Non-informative Beta priors will be used for both safety and effectiveness 
endpoints. Trial simulations were performed to estimate the power for the success of 
the safety and effect iveness endpoints. Based on PG of 14% for the primary safety 
endpoint and PG of 50% for the primary effectiveness endpoint, the sample size of 185 
subjects will provide above 80% power to declare success for both endpoints controlling 
the overall type -I error rate at one -sided 2.5% assuming the true PAE rate is 7% and the 
true effectiveness failure- free rate is 65%. It is also a ssumed that there are 5% and 12% 
dropout rates for the safety and effectiveness endpoints, respectively.    Simulations were also performed to estimate the overall type I error for this study under 
various hypothetical scenarios. The highest type I erro r rates were reached in the 
following two scenarios, including 1) the true primary safety rate was on the decision boundary (i.e. equal to 14%) and the device was assumed to be effective: type I error rate was 0.023, and 2) the true primary effectiveness r ate was on the decision boundary 
(i.e. equal to 50%) and the devices was assumed to be safe: type I error rate was  0.011 . 
As the primary safety or effectiveness moves away from the decision boundary, the overall Type -I error decreases. Therefore, consideri ng all scenarios, the overall type I 
error for claiming success for both safety and effectiveness was controlled at 2.5%.  Based on the simulation results, the study is adequately powered to meet the primary safety and effectiveness endpoints and Type -I error for the overall trial success is 
controlled at 2.5%.   The Second ( variable flow) Study : 
 The analyses for primary safety and effectiveness endpoints in the variable flow study 
will apply Bayesian methods using a beta- binomial model with data borrowing from the 
Main study using a propensity score -integrated power prior approach.  Based on a PG of 
14% for the primary safety endpoint and a PG of 50% for the primary effectiveness 
endpoint, and allowing borrowing up to 91 subjects  from QDOT MICRO (IDE # 
G180176) Main study, the sample size of 92 subjects in the variable flow study provides  
close to 80% power at a one- sided signficance level of 2.5% to declare success for both 
the safety and effectiveness endpoints  assuming the true PAE rate is 7% and the true 
effectiveness failure- free rate is 65%.  Overall power for the variable flow study is 
maintained c lose to 80% when information from at least 80 subjects in the Main study 
is borrowed. It is also assumed that there are 5% and 12% attrition  rates for the safety 
and effectiveness endpoints in the variable flow  study, respectively.   
 
 
 
18.8 Data Monitoring Committee 
Data Monitoring Committee will be formed for this study  and will evaluate data from 
both studies . An independent statistician will be responsible for conducting the interim 
analyses and reviewing the results with the designated Data Monitoring Committee 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 104 of 135 
 (DMC). The DMC charter will document the role and responsibilities of the committee , 
Sponsor and the independent statistician .  
18.9 Analyses to be Conducted 
18.9.1   General Conventions  
In general, descriptive statistics will be provided  for all primary  and secondary safety and 
effectiveness endpoints  and other endpoints as appropriate.  For continuous variables, 
number of subjects/events, mean, standard deviation, median, 25% percentile, 75% 
percentile, minimum, and maximum will be provided.  For categorical variables, frequency and percentage will be presented for each category.  
 Confidence intervals for binary variables, including the primary outcome variables, will be computed using the exact binomial distribution.  Categorical variables will be compared using Chi -square or Fisher’s exact test .  Continuous variables will be compared using 
ANOVA or Kruskal -Wallis test.  
18.9.2   Disposition of Study Subjects  
 Disposition and accountability of the study subjects will be summarized and listed. 
18.9.3   Demographic and Baseline Characteristics  
Demographic and baseline characteristics will be summarized and listed . 
18.9.4   Analysis of Primary Endpoint Analyses 
The Main  study : 
The final analyses for primary safety and effectiveness endpoints  in the main  study will 
apply Bayesian methods and use a Beta-B inomial model.  A vague Beta(1,1) prior will be 
used for both safety and effectiveness endpoints.  
If the primary safety endpoint is met (at the time of the interim analysis) and early success 
is achieved for the primary effectiveness endpoint, then the tri al will be declared a success. 
If the safety endpoint is not met the study will be deemed unsuccessful. Under the success  
scenario, the study will continue to follow up the subjects for the full follow -up duration, 
and the primary effectiveness endpoint based on full 12- month follow -up data will then be 
descriptively summarized in subjects in the PP population. If early success is not achieved 
for the primary effectiveness endp oint, then the final effectiveness analysis  for the main  
study will be based on complete follow -up data for effectiveness endpoint and will use a 
beta-binomial model . 
Primary safety endpoint will be analyzed in the mITT population and primary effectiveness endpoint will be analyzed in the PP population.  
Assuming ea rly effectiveness success is not achieved, t he trial will be considered a 
success if BOTH  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 105 of 135 
                                                   Pr(𝑝𝑝𝑆𝑆< 0. 14|𝑦𝑦,𝑛𝑛) > 0. 975 
AND  
Pr(𝑝𝑝𝐸𝐸> .50| 𝑥𝑥,𝑛𝑛)> 0. 9775 . 
These thresholds control the overall Type I error  rate for the trial below one -sided 2.5% 
(see appendix C report for additional discussion of Type I error control). 
The Second ( variable flow) study : 
The analyses for primary safety and effectiveness endpoints in the variable flow  study will 
apply Bayesian methods and use a Beta -Binomial model. A propensity score -integrated 
power prior approach will be used to borrow data from the Main study for establishing 
safety and effectiveness  of the variable flow  study. The  borrowing approach follows the 
method described in Yue, L. et al[59] . The catheter design and the procedure workflow 
with the exception of the flow rate are identical between the Main study and the variable 
flow study. Preclinical and bench testing concluded comparable performance of the 
catheter for constant or variable flow rates.  Accordingly, data from  up to 91 subjects in the 
Main study will be borrowed for the variable flow  study based on similarity in baseline 
characteristics.  Details on the borrowing approach are defined in SAP for the variable flow  
study.  
 
The primary  safety endpoint will be considered met  if                           
Pr(𝑝𝑝𝑆𝑆< 0. 14|𝑦𝑦,𝑛𝑛) > 0. 975, 
and t he primary effectiveness endpoint will be considered met if                           
Pr(𝑝𝑝𝐸𝐸> .50| 𝑥𝑥,𝑛𝑛)> 0. 975 . 
  
18.9.5 Analyses of Secondary and Additional Endpoints  
Secondary and additional endpoints will be analyzed separately in each study. 
Descriptive statistics will be presented for the secondary safety endpoints in the Safety Population.. Descriptive statistics for the secondary effect iveness endpoints will be 
analyzed in the PP population. For the Main Study, descriptive  statistics for additional 
endpoints will be analyzed in the Safety Population, particularly, incidence of severe PV stenosis will be analyzed in the CMSP population. All of these analyses will be 
performed after the 12 months follow up is complete. No for mal statistical hypotheses 
and inferential statistics will be formulated and performed for the secondary and additional effectiveness and safety endpoints. Details of analyses methods for secondary and additional endpoints will be provided in SAP. 
 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 106 of 135 
 18.9.6   Plans  for Interim Analysis  
One (1) interim analys is per arm is planned for early success claim  in the Main study. 
The details on the timing of the interim analysis are provided in th e simulation report 
and the SAP . For the safety endpoint, the outcome for all patients will be known at the 
time of the interim analysis  in each arm , and therefore, the primary safety analys es will 
be performed at the time of the interim analys es. Early success will be declared at the 
interim analysis for the Main study if:  
1. The safety objective has already been met, and  
2. Posterior probability of the effectiveness proportion 𝑝𝑝𝐸𝐸 being greater than 50% is 
greater than 0.9975 
 
  
18.9.7   Handling of Missing Data 
            Missing data will be queried for reasons and handled on an individual basis.   
At the time of early success interim analysis  in the Main study (final safety analysis), if a 
subject’s safety follow -up data is missing but a PAE has occurred earlier, then the subject 
will be considered having an event.  If a subject’s follow -up data is missing for the 3-month 
follow- up and the subject has not had a PAE, then that subject will be excluded from the 
early success safety analysis. For each early success interim analysis of the effectiveness endpoint, the subjects with incomplete follow- up data will be censored at the time of their 
last follow -up visit, and only their observed partial follow -up time will contribute to 
estimating model parameters.
  
 For the variable flow study, i f a subject is missing 3 -month follow -up and the subject has 
not had a PAE, the subject will be excluded from the primary safety endpoint analysis. Information will not be borrowed from subjects in the Main Study without PAE but were missing 3 -month follow-up.   
 For final effectiveness analysis  in the Main Study, if a subject has an effectiveness failure 
at any time during the evaluation period, then the subject will be considered having an 
event. Subjects without an effectiveness failure who do not have full 12 months of follow -
up will be excluded from the final effectiveness analysis.  
 
For the primary effectiveness endpoint analysis  in the variable flow study, if a subject has 
an effectiveness failure at any time during the evaluation period, then the subject will be considered having an event. Subjects without an effectiveness failure who do not have full 12 months of follow -up will be excluded from the final effectiveness analysis.  No 
information will borrowed from subjects who are failure free in the Main study but do not have full 12-month follow-up.       
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 107 of 135 
 18.9.8   Sensitivity Analyses 
The Main study:   
The primary safety endpoint will be analyzed in the Safety Population as sensitivity 
analyses. The primary effectiveness endpoint will be analyzed in the Safety  Population 
for those subjects who have undergone RF delivery with the study catheter as sensitivity 
analyses. In addition, tipping point analysis [59] will be performed  for the primary 
effectiveness endpoint in the PP population and for the primary safety endpoint in the mITT  
population to assess  the impact  of missing  outcomes on study conclusions.  These 
sensitivity analyses will be done after the 12 months follow -up is complete. Additional 
details will be defined in the SAP    for the Main study.  
 
The Variable Flow study: 
Details are defined in the SAP for the variable flow study.   
 
18.9.9   Subgroup Analyses  
For the Main study, subgroup analyses for the primary endpoints and acute effectiveness 
endpoints will be performed after the 12 months follow -up is complete, including but not 
limited to: age, gender, ablation mode, individual site,  CF and ablation index etc.  PP 
population will be used for primary effectiveness endpoint and Safety  population will be 
used for primary safety endpoint  for the subgroup analyses . Details o f analyses methods 
will be defined in the SAP.  
Ablation mode subgroups:  
• Set 1- QMODE+ alone for PVI, QMODE+ & QMODE for PVI, QMODE alone for 
PVI;  
• Set 2 - QMODE+ alone for index procedure, QMODE+ & QMODE for index 
procedure, QMODE alone for index procedur e   
18.9.10   Assessment of Site Homogeneity  
For the Main study, t here will be up to 30 sites recruiting the approximate 185 subjects in 
US.  
 Each site should enroll no more than 15% of the total enrollment in each study to minimize 
the possibility that the study results could be highly influenced by a few sites. Sites with 
less than five subjects will be combined according to geographic regions. Using this pre - 
determined criterion, sites with less than five subjects within the same geog raphic region 
will be combined such that the combined center(s) would have five or more subjects and no more than 5 sites combined.  Chi-square test will be used to examine the homogeneity across sites for the primary 
effectiveness and safety endpoints  using data from the patients in the Main study. A p -
value less than 0.15 will be considered statistically significant for an assessment of 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 108 of 135 
 homogeneity across sites. A non- significant result will support pooling of sites for the 
primary analyses . 
 
If the sites are not poolable, logistic regression models treating site as a random effect will be fit to examine the impact of site heterogeneity on the primary endpoints. The claim of trial success will be based upon the totality of the data. 
19.0 ETHICS  AND PROTECTION OF HUMAN SUBJECTS  
19.1 Ethics Review  
Study materials including informed consent must be reviewed and approved by an appropriately- constituted IRB/IEC/REB before enrollment of subjects. Biosense 
Webster and the IRB must approve in writing any changes to the protocol. 
Proof of IRB/IEC/REB review and approval must be obtained prior to subject 
enrollment. Investigators are responsible for submitting and obtaining initial and continuing review (per local regulations) of the study by their IRB/IE C/REB.  
19.2 Patient Informed Consent  
Biosense Webster and the reviewing IRB/IEC/REB must approve any modifications to the ICF or PI/ICF.  The ICF may be translated as appropriate. Certification of accurate translation will be required.  
Informed consent is mandatory and must be obtained from all subjects prior to their 
participation in this study. Copies of all signed consents must be retained in the records of the study, and an unsigned sample copy of the approved ICF must also be in the study file. Subjects mu st each receive a copy of the ICF.  
19.3 Confidentiality  
All information and data sent to Biosense Webster concerning subjects or their participation in this study will be considered confidential. Only authorized Biosense Webster personnel or representatives, or  representatives of Health Authorities (HA) or 
Regulatory Authorities (RA) acting in their official capacities will have access to these confidential files. No data transmitted to Sponsor for evaluation and reporting will contain identifiable references to  individual subjects. 
19.4 Subject Confidentiality/Record  
All representatives of the Sponsor have undergone training for Privacy regulations and appropriate conduct for their compliance. For the duration of this study, all representatives of the Sponsor will comply with all privacy regulations regarding contact with subjects, their medical record information, copying of information, protection of the subject identities, and other aspects.  Authorization for limited access to Protected Health Information by Sponsor personnel will be obtained as part of subject informed consent. 
Site personnel should also be attentive to privacy considerations and should not transmit 
PHI outside of PI control (e.g., via .pdf or FAX) without redaction of patient identifiers.   
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 109 of 135 
 Priva cy considerations such as above will also be covered in protocol training for both 
Sponsor representatives and study site personnel.  
20.0 DATA MANAGEMENT  
The Sponsor will be responsible for all data management activities. These activities 
include development of a database, utilizing validated database software, into which all study data will be entered by the clinical sites. The Sponsor will be responsible for ensuring the overall integrity of the database. 
20.1 Electronic Case Report Forms (CRFs)  
Electronic CRFs wi ll be used to collect all subject data during the study.  
Electronic CRFs (eCRFs) have been developed to capture the information outlined in this Study Protocol. Data on these eCRFs will be monitored, corrected if necessary, and entered into a validated da tabase. All changes made to the data will be tracked in the 
electronic audit trail, recording the current value, previous value, reason for change, date timestamp of data entry/change, and the name of the person who changed the data. The investigator will electronically sign all subject eCRFs as verification that the data have been reviewed and correctly reflects source documentation. Data from these eCRFs will be used to provide analysis of this study.  
20.2 Data Reporting 
The investigator, or a designated individual, is responsible for recording data from the trial on the eCRFs supplied by Biosense Webster. The investigator or a delegated individual is required to electronically sign eCRFs on the appropriate pages to verify that he/she has reviewed and attests to the correctness of the recorded data. Completed 
eCRFs will be reviewed and monitored remotely and at the research site by Biosense Webster personnel or designees throughout the trial. To this end, the investigator and institution must permit inspection of trial files including original (source) records and 
subject eCRFs by sponsor representatives and responsible government agencies. 
Table 20.2A. Responsibilities for Preparing and Submitting Reports  
Type of Report  Prepared by 
Investigator For  Time of No tification  
Subject 
withdrawal  Biosense Webster  Should report within 5 working days  
Withdrawal of IRB/EC approval 
 Biosense Webster  Should report within 5 working days  
Final report  Biosense Webster, 
IRB/EC  Will prepare a final report  separately 
for the main study and the variable 
flow study for the clinical 
investigation as required per national regulations. 
 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 110 of 135 
 Informed consent 
not obtained from subject 
 Biosense Webster, 
IRB/EC (per IRB/EC requirements) 
 Should report within 5 working days  
 
20.3 Data Review 
Biosense Webster will track the amount of missing data and contact sites as appropriate 
to instruct them on steps to minimize missing data and remain compliant with protocol 
required assessments.  Missing or unclear data points will be queried as necessary 
throughout the trial. Biosense Webster may request further documentation such as physician and/or cardiac EP lab procedure notes when complications or device deficiencies are observed and reported. Biosense Webster will be responsible for auditing the database and confirming the overall integrity of the data. 
20.4 Procedural Data  
It is the responsibility of the investigator to provide timely completio n of CRFs to the 
sponsor. 
20.5 Source Documentation  
Data entered into the eCRFs may be taken from source documentation, such as hospital procedure reports, admission and discharge summaries, and other hospital or physician office/clinic documents. If no standard hospital or office document exists to capture some of the information that may be unique to this study, a worksheet may be developed to record this information. Data collection instruments should clearly identify the individual collecting the data and the date of collection. The instrument of original capture of all study data will serve as the source document for future verification of for those data parameters. Privacy regulations will be observed during the use of these source documents during monitoring. 
21.0 QUALITY ASSURANCE AND QUALITY CONTROL  
QC procedures will be implemented beginning with the data entry system and ongoing QC checks will be run on the database. Any missing data or data anomalies will be communicated to the site(s) for clarification/res olution. 
Following written SOPs, monitors will verify that the clinical trial is conducted and data are generated, documented, and reported in compliance with the protocol, GCP, and the applicable regulatory requirements. If noncompliance is identified, Sponsor is required by regulation to implement measures to secure compliance.  
The investigational site will provide direct access to all trial related sites, source data/documents, and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory authorities. 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 111 of 135 
 22.0 ADMINISTRATIVE  RESPONSIBILITIES  
22.1 Records  and Reports  
22.1.1 Records  
Records  to be maintained  by the investigator include: 
• Study protocol and  all amendments  with  signature pages  
• Signed clinical  study agreement  and Statement  of Investigator 
• IRB/IEC/REB approval letter,  including approved ICF  document 
• Evidence of IRB/IEC/REB compliance  
• Other  significant IRB/IEC/REB correspondence  
• Significant sponsor correspondence relating  to the study 
• CVs for all  investigator(s) 
• Financial  Disclosure for key study staff  
• Records  of protocol and  supporting training  
• Site personnel delegation  of authority/responsibility  
• Clinical Monitor/Site  Visit sign- in log 
• Device accountability  log 
• Reports (e.g. annual  reports,  final  reports  from  investigator and  Sponsor) 
The following records  must be maintained  for each  subject  enrolled  in the study: 
• Signed Patient  ICF 
• All completed  electronic CRFs  and supporting source documentation 
• Supporting documentation of any  AEs  and/or death   
The investigator must retain  copies  of procedure reports, procedure nursing notes and 
the results  of any interventional procedures that occur  while  the subject  is enrolled  in 
the study. Biosense Webster  reserves  the right to secure data clarification  and additional 
medical  documentation on  subjects  enrolled  in this study. 
22.1.2 Record  R etention  
Records  and reports of the study will remain  on file at sites for a minimum of two (2) 
years  after its completion/termination.  Records  for U.S. sites must be maintained  in 
accordance with 21 CFR  812.140 [d], and for OUS sites, according to local 
requirements.   
If the principal investigator plans to leave the study site, he/she is responsible for 
identification  of another individual at site who will assume  the obligation for file 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 112 of 135 
 maintenance and management  of any continuing subjects.  Biosense Webster  and 
pertinent HA/RA,  per its requirements,  should be notified  of this  change.   
Records  and reports may be discarded  upon notification  by Biosense Webster  to the 
study site. Site personnel should contact  Biosense Webster  prior to destruction  of any 
study- related  records  and reports  to ensure appropriate record  retention. 
22.1.3 Investigator’s Final  Report  
Upon completion  or termination  of the Biosense Webster  study, the principal  
investigator must submit a final written  report to the approving Investigational Review  
Board/Ethics Committee  (as required  by the IRB/IEC/REB) and provide a copy to 
Biosense Webster.  The report  should contain  the information  required  by the 
IRB/IEC/REB and be submitted  in the time  frame  required  by the IRB/IEC/REB. 
23.0 TERMINATION OF THE STUDY  
The study may be suspended or terminated early at the discretion of the Sponsor, for 
reasons such as incidence of unanticipated serious adverse device effects that may pose a risk to other subjects. In any early termination, already enrolled subjects will continue 
to be followed per the study protocol requirements.  
Sponsor may also terminate a site prior to completion if it believes the site is no longer 
capable of participating (e.g., cannot fulfill subject enrollment or protocol compliance goals, site suspension by IRB/REB).  
At termination of the investigation, each active site will undergo closeout monitoring to 
conclude any outstanding issues, resolve all data discrepancies and make sure any outstanding eCRFs are completed, discuss responsibilities wit h the Principal 
Investigator, and discuss any other items relevant to the conclusion of the study. The termination process will be documented by a written report. 
24.0 DATA AND PUBLICATION POLICY 
Publications and/or presentation of clinical investigation results will be coordinated between Biosense Webster, Inc. and the clinical investigation author(s). Authorship will be determined prior to development of any manuscript. All information concerning the study, investigational medical device, sponsor operations, patent application, manufacturing processes, and basic scientific data supplied by the sponsor to the investigator and not previously published, are considered confidential and remain the sole property of the sponsor. 
25.0 DOCUMENT FILING  
A copy of all approved versions of the Investigation Protocol will be kept, by the site, in the Investigator Site File and in the Sponsor Trial Master File.  
 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 113 of 135 
 26.0 REFERENCES:  
1. January, C.T., et al., 2014 AHA/ACC/HRS guideline for the management of patients with atrial 
fibrillation: a report of the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines and the Heart Rhythm Society.  J Am Coll Cardiol, 2014. 64 (21): p. 
e1-76. 
2. Cain, M.E., Atrial fibrillation --rhythm or rate control.  N Engl J Med, 2002. 347(23): p. 1822 -3. 
3. Fuster, V., et al., ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practi ce Guidelines and the European Society of Cardiology Committee for Practice 
Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Asso ciation 
and the Heart Rhythm Society.  Circulation, 2006. 114 (7): p. e257- 354.  
4. Calkins, H., et al., 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on 
catheter and surgical ablation of atrial fibrillation.  Heart Rhythm, 2017. 14(10): p. e275- e444.  
5. Jazayeri, M.R., et al., Selective transcatheter ablation of the fast and slow pathways using 
radiofrequency energy in patients with atrioventricular nodal reentrant tachycardia. Circulation, 
1992. 85(4): p. 1318- 28. 
6. Pappone, C., et al., A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study.  J Am Coll Cardiol, 
2006. 48(11): p. 2340 -7. 
7. Wilber, D.J., et al., Comparison of antiarrhythmic drug therapy and radiofrequency catheter 
ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.  JAMA, 
2010. 303(4): p. 333 -40. 
8. Natale, A., et al., Paroxysmal AF catheter ablation with a contact force sensing catheter: results 
of the pro spective, multicenter SMART -AF trial.  J Am Coll Cardiol, 2014. 64 (7): p. 647- 56. 
9. Ullah, W., et al., Randomized trial comparing pulmonary vein isolation using the SmartTouch 
catheter with or without real -time contact force data.  Heart Rhythm, 2016. 13(9): p. 1761 -7. 
10. Kautzner, J., et al., EFFICAS II: optimization of catheter contact force improves outcome of 
pulmonary vein isolation for paroxysmal atrial fibrillation.  Europace, 2015. 17 (8): p. 1229- 35. 
11. Andrade, J.G., et al., Pulmonary vein isolation using "contact force" ablation: the effect on 
dormant conduction and long- term freedom from recurrent atrial fibrillation --a prospective 
study.  Heart Rhythm, 2014. 11(11): p. 1919 -24. 
12. Anter, E., et al., Acute pulmonary vein reconnection is a predictor of atrial fibrillation recurrence following pulmonary vein isolation. J Interv Card Electrophysiol, 2014. 39(3): p. 225- 32. 
13. Haines, D.E., The biophysics of radiofrequency catheter ablation in the heart: the importance of temperature monitoring. Pacin g Clin Electrophysiol, 1993. 16 (3 Pt 2): p. 586- 91. 
14. Bhaskaran, A., et al., Five seconds of 50 -60 W radio frequency atrial ablations were transmural 
and safe: an in vitro mechanistic assessment and force -controlled in vivo validation. Europace, 
2017. 19(5): p. 874- 880.  
15. Kuck, K.H., et al., A novel radiofrequency ablation catheter using contact force sensing: Toccata 
study.  Heart Rhythm, 2012. 9(1): p. 18- 23. 
16. Ikeda, A.N., H; Sharma, T;  Govari, A; Datta, K; Joshi, H; Lifshitz, A; Wittkampf, F and Jackman, W, High Power - Short Radiofrequency Applications Rapidly Produce Shallow Lesions Of Equal 
Diameter Without Increasing Risk Of Thrombus Or Steam Pop, in Heart  Rhythm Society . 2018: 
Boston, MA.  
17. Rozen, G., et al., Safety and efficacy of delivering high- power short -duration radiofrequency 
ablation lesions utilizing a novel temperature sensing technology. Europace, 2018.  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 114 of 135 
 18. Barkagan, M., et al., High-power and short -duration ablation for pulmonary vein isolation: 
Safety, efficacy, and long- term durability.  J Cardiovasc Electrophysiol, 2018. 
19. leshem, E., Zilberman I, Tschabrunn C, et al, High- Power and Short -Duration Ablation for 
Pulmonary Vein Isolation Biophysical Characterization.  JACC: Clinical Electrophysiology, 2018. In 
Press. 
20. Sandhu, R.K., et al., The epidemiology of atrial fibrillation in adults depends on locale of 
diagnosis. Am Heart J, 2011. 161 (5): p. 986 -992 e1.  
21. Lee, G., et al., Low risk o f major complications associated with pulmonary vein antral isolation 
for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center.  J Cardiovasc Electrophysiol, 201 1. 
22(2): p. 163 -8. 
22. Voskoboinik, A., et al., Low Rates of Major Complications for Radiofrequency Ablation of Atrial 
Fibrillation Maintained Over 14 Years: A Single Centre Experience of 2750 Consecutive Cases.  
Heart Lung Circ, 2018.  
23. Cappato, R., et al., Updated worldwide survey on the methods, efficacy, and safety of catheter 
ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol, 2010. 3(1): p. 32 -8. 
24. Bohnen, M., et al., Incidence and predictors of major complications from contemporary catheter ablation to treat cardiac arrhythmias.  Heart Rhythm, 2011. 8 (11): p. 1661- 6. 
25. Michowitz, Y., et al., Effects of sex on the incidence of cardiac tamponade after catheter ablation of atrial fibrillation: results from a worldwide survey in 34 943 atrial fibrillation ablation procedures.  Circ Arrhythm Electrophysiol, 2014. 7 (2): p. 274 -80. 
26. Muthalaly, R.G., et al., Temporal trends in safety and complication rates of catheter ablation for 
atrial fibrillation.  J Cardiovasc Electrophysiol, 2018.  
27. Teunissen C, V.B., Hassink, R, et.al, Incidence of Pulmonary Vein Stenosis After Radiofrequency 
Catheter Ablation of Atrial Fibrillation.  JACC: Clinical Electrophysiology, 2017. 3(6): p. 589 -598.  
28. Ha, F.J., et al., Prevalence and prevention of oesophageal injury during atrial fibrillation ablation: 
a systematic review and meta- analysis. Europace, 2018.  
29. Knopp, H., et al., Incidental and ablation- induced findings during upper gastrointestinal 
endoscopy in patients after ablation of atrial fibrillation: a retrospective study of 425 patients.  
Heart Rhythm, 2014. 11(4): p. 574 -8. 
30. Kapur, S., et al., Esophageal Injury and Atrioesophageal Fistula Caused by Ablation for Atrial 
Fibrillation. Circulation, 2017. 136(13): p. 1247- 1255.  
31. Nair, K.K., et al., Atrioesophageal Fistula: A Review.  J Atr Fibrillation, 2015. 8 (3): p. 1331.  
32. Scanavacca, M.I., How to prevent, recognize and manage complications of AF ablation?  Rev Port 
Cardiol, 2017. 36 Suppl 1 : p. 43- 49. 
33. Yong Ji, S., et al., Phrenic nerve i njury: An underrecognized and potentially preventable 
complication of pulmonary vein isolation using a wide -area circumferential ablation approach. J 
Cardiovasc Electrophysiol, 2013. 24 (10): p. 1086 -91. 
34. Haegeli, L.M. and H. Calkins, Catheter ablation of atrial fibrillation: an update.  Eur Heart J, 2014. 
35(36): p. 2454- 9. 
35. Cappato, R., et al., Prevalence and causes of fatal outcome in catheter ablation of atrial 
fibrillation.  J Am Coll Cardiol, 2009. 53 (19): p. 1798 -803.  
36. Funayama, N., et al., Acute right coronary artery occlusion after radiofrequency catheter ablation of cavotricuspid isthmus: Vascular response assessed by optical frequency domain 
imaging. HeartRhythm Case Rep, 2017. 3 (10): p. 496 -498.  
37. Rillig, A., et al., Catheter ablation within the sinus of Valsalva--a safe and effective approach for 
treatment of atrial and ventricular tachycardias. Heart Rhythm, 2008. 5 (9): p. 1265 -72. 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 115 of 135 
 38. Fujii, S., J.R. Zhou, and A. Dhir, Anesthesia for Cardiac Ablation.  J Cardiothorac Vasc Anesth, 
2017.  
39. Liu, Y., et al., Incidence and outcomes of cerebrovascular events complicating catheter ablation 
for atrial fibrillation.  Europace, 2016. 18 (9): p. 1357- 65. 
40. Housley, B.C., et al., Acute Pulmonary Hemorrhage Following Radiofrequency Ablation of Atrial Fibrillation. J Cardiothorac Vasc Anesth, 2017. 31 (4): p. 1397- 1400.  
41. Bessiere, F. and P. Chevalier, Pulmonary vein hematoma after atrial fibrillation cryoablation: a new complication. Heart Rhythm, 2013. 10 (9): p. 1359.  
42. Desimone, C.V., et al., Catheter ablation related mitral valve injury: the importance of early recognition and rescue mitral valve repair.  J Cardiovasc Electrophysiol, 2014. 25 (9): p. 971 -975.  
43. Scheinman, M.M. and S. Huang, The 1998 NASPE prospective catheter ablation registry.  Pacing 
Clin Electrophysiol, 2000. 23(6): p. 1020- 8. 
44. Lin, A.C. and D. Wilber, Complications associated with radiofrequency catheter ablation, in Radiofrequency Catheter  Ablation of Cardiac Arrhythmias: Basic Concepts and Clinical 
Applications , S.K.S. Huang and D.J. Wilber, Editors. 2000, Futura Publishing Company, Inc.: 
Grouponk, NY. p. 737 -746.  
45. Kovoor, P., et al., Risk to patients from radiation associated with radiofrequency ablation for 
supraventricular tachycardia. Circulation, 1998. 98(15): p. 1534 -40. 
46. Nahass, G.T., Fluoroscopy and the skin: implications for radiofrequency catheter ablation.  Am J 
Cardiol, 1995. 76 (3): p. 174 -6. 
47. Calkins, H., et al., Radiat ion exposure during radiofrequency catheter ablation of accessory 
atrioventricular connections.  Circulation, 1991. 84(6): p. 2376- 82. 
48. Cox, B., M.E. Durieux, and M.A. Marcus, Toxicity of local anaesthetics.  Best Pract Res Clin 
Anaesthesiol, 2003. 17 (1): p. 111 -36. 
49. Mertes, P.M. and M.C. Laxenaire, Allergic reactions occurring during anaesthesia.  Eur J 
Anaesthesiol, 2002. 19 (4): p. 240- 62. 
50. Morcos, S.K., et al., Prevention of generalized reactions to contrast media: a consensus report 
and guidelines . Eur Radiol, 2001. 11 (9): p. 1720- 8. 
51. Gruchalla, R.S., 10. Drug allergy.  J Allergy Clin Immunol, 2003. 111 (2 Suppl): p. S548 -59. 
52. Bick, R.L. and E.P. Frenkel, Clinical aspects of heparin- induced thrombocytopenia and thrombosis 
and other side effects  of heparin therapy.  Clin Appl Thromb Hemost, 1999. 5 Suppl 1 : p. S7 -15. 
53. Kirchhof, P., et al., 2016 ESC Guidelines for the management of atrial fibrillation developed in 
collaboration with EACTS. Eur Heart J, 2016. 37 (38): p. 2893- 2962.  
54. Liu E, S.E. , Belden W, Thosani AJ, High power short duration radiofrequency catheter ablation for 
atrial fibrillation: Safety and acute procedural outcomes.  , in HRS , H.R. Society, Editor. 2017.  
55. Holmes, D.R., Jr., K.H. Monahan, and D. Packer, Pulmonary vein stenosis complicating ablation 
for atrial fibrillation: clinical spectrum and interventional considerations.  JACC Cardiovasc Interv, 
2009. 2(4): p. 267 -76. 
56. Oh Jk, S.J., Tajik AJ, The Echo Manual.  2006: Lippincott Williams & Wilkins.  
57. Milman, A., et al.,  Gender Differences in Patients with Brugada Syndrome and Arrhythmic Events: 
Data from a Survey on Arrhythmic Events in 678 Patients.  Heart Rhythm, 2018.  
58. Leon, M.B., et al., Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium.  J Am Coll 
Cardiol, 2011. 57 (3): p. 253 -69. 
59. Yan, X., S. Lee, and N. Li, Missing data handling methods in medical device clinical trials.  J 
Biopharm Stat, 2009. 19 (6): p. 10 85-98. 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 116 of 135 
 27.0 APPENDIX A:  STUDY  DEFINITIONS  
Term  Definition  
Adverse Event  (AE)  Any unfavorable and unintended sign, medical  occurrence,  disease or 
injury (including abnormal  laboratory findings) in subjects,  users  or 
other persons temporally  associated  with the use of a medicinal  
product or device whether  or not related  to the spons or’s product. 
This definition  includes events related  to the medical  device and/or the 
comparator,  and events  related  to the procedure in which  the device  
was used. 
Adverse Device 
Effects  (ADE’s)  Adverse  events  related  to the use of the medical  device.  This definition  
includes adverse events  resulting  from  insufficient or inadequate 
instructions for use deployment, implantation,  installation,  or 
operation, or any malfunction  of the medical  device.  This definition  
includes any event  resulting  from  use errors  or from  intentional misuse  
of the investigation  medical  device.  
AF/AT/AFL  Episode  An episode  of AF/AT/AFL  ≥ 30 seconds  in duration.   
AF Episode  An atrial  fibrillation  episode  is defined  as AF which  is documented  by 
ECG  monitoring and has a duration of at least 30 seconds, or if less 
than 30 seconds, is present  continuously throughout the ECG  
monitoring tracing.  The presence of subsequent episodes of AF 
requires  that sinus rhythm be documented by ECG  monitoring 
between  AF episodes  
Anticipated  AE An effect  which  by its nature,  incidence,  severity  or outcome  has been  
identified  as possible complications  associated  with the medical  
device  and/ or intervention  procedure.   
Atypical Flutter  Macro -reentrant  circuits  within  the atria where  activation  rotates  
around large obstacles  that does not meet  the criteria  for Typical 
Flutter.   
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 117 of 135 
 Term  Definition  
Bleeding 
Complications (ISTH definition): Major (ISTH definition):  
Fatal bleeding AND/OR symptomatic bleeding in a critical area or 
organ, such as intracranial, intraspinal, intraocular, retroperitoneal, 
intraarticular, pericardial, or intramuscular with compartment 
syndrome AND/OR b leeding causing a fall in hemoglobin level of 2 
g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of blood. 
Clinically relevant nonmajor bleed (ISTH definition):  
An acute or subacute clinically overt bleed that does not meet the 
criteria for a major bl eed but prompts a clinical response such that it 
leads to one of the following: hospital admission for bleeding; 
physician guided medical or surgical treatment for bleeding; change in antithrombotic therapy (including interruption or discontinuation). 
Minor bleeding (ISTH definition): 
All nonmajor bleeds. Minor bleeds are further divided into clinically 
relevant and not.  
Catheter  Insertion  Defined  as the QDOT MICRO™  catheter  breaching  the sheath  and 
entering  the bloodstream.    
Device Deficiency  Inadequacy  of a medical  device  related  to its identity,  quality,  
durability, reliability,  safety  or performance,  such as malfunction 
(failure  of a medical  device to perform  in accordance with its intended 
purpose when  used in accordance with the instructions for use or 
protocol),  misuse  or use error  and inadequate  labeling.   
Documented  
AF/AT/AFL  episode  An AF/AT/AFL  episode  documented  by an electrocardiographic  
monitoring tool. This may include ILR, ECG,  TTM,  Holter monitor, 
or telemetry  strip.   
Reporting of a symptomatic  episode by a patient  or in a referral  letter  
is not considered  a documented  AF episode.  
Minor Pericarditis  Pericarditis will be considered ‘minor if is treated using only 
analgesics and does not extend hospitalization by more than 48 
hours.  
Paroxysmal AF   Paroxysmal  AF is defined  as recurrent  AF (≥ 2 episodes)  that 
terminates  spontaneously within  7 days. Episodes of AF of ≤ 48 hours 
duration that are terminated  with electrical  or pharmacologic 
cardioversion  should  also be classified  as paroxysmal  AF episodes.  
Permanent  AF  Not appropriate  in the context  of patients  undergoing  catheter  ablation  
of AF; refers  to a group of patients  where a decision has been  made  
not to pursue restoration  of sinus rhythm by any means,  including 
catheter  or surgical  ablation.  
Persistent  AF (PsAF)  Persistent  AF is defined  as continuous  AF that is sustained  beyond  7 
days and less than 1 year.   
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 118 of 135 
 Term  Definition  
Serious  adverse event  
(SAE) 1. Any adverse  event  that: 
• Led to a death  
• Led to a serious deterioration in  health  that either:  
o Resulted  in a life -threatening illness  or injury, or 
o Resulted  in a permanent  impairment of a body structure  
or a body function, or 
o Required  in-patient  hospitalization  or prolongation of 
existing  hospitalization,  or 
o Resulted  in medical  or surgical  intervention  to prevent 
life threatening  illness  or injury or permanent 
impairment to  a body structure  or a body function 
• Led to fetal  distress,  fetal  death  or a congenital abnormality  or 
birth  defect  
2. Any Device Deficiency  that could have led  to an SAE   
A planned hospitalization  for pre-existing  condition, or a procedure 
required  by the protocol, without a serious deterioration  in health,  is 
not considered  to be a serious adverse event.  
Medical  and scientific  judgment should be exercised  in deciding 
whether  expedited  reporting is appropriate in other situations,  such 
as important medical  events  that may not be immediately  life-
threatening  or result  in death  or hospitalization  but may jeopardize  
the subject  or may require  intervention  to prevent one of the 
outcomes listed  in the definition  above. 
Serious  Adverse  
Device Effects  
(SADE’s)  Adverse device effects  that has resulted  in any of the consequences  
characteristic of a serious adverse event.  
Symptomatic  
AF/AT/AFL  Episode  Symptom(s)  which  is/are  exhibited  by the subject  which  made  them  
seek medical  attention  and are concurrent with a documented  episode 
of AF/AT/AFL  by either  ECG,  TTM,  Holter  monitor, or telemetry  
recording. Symptoms may  include but are not limited  to: palpitations,  
irregular  pulse (e.g., rapid, racing,  pounding, fluttering,  bradycardia), 
dizziness,  weakness,  chest  discomfort,  and breathlessness.  
Typical Flutter  Atrial  flutter  is caused  by a reentrant  rhythm  in either  the right  or left 
atrium.  Typically  initiated  by a premature  electrical  impulse  arising  in 
the atria,  atrial  flutter  is propagated due to differences  in refractory  
periods of atrial  tissue.  This creates  electrical  activity  that moves in a 
localized  self-perpetuating  loop. For each cycle around the loop, there  
results  an electric  impulse  that propagates  through  the atria.  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 119 of 135 
 Term  Definition  
Unanticipated 
Serious  Adverse 
Device Effect  
(USADE)  Serious  adverse  device  effect  which  by its nature,  incidence,  severity  
or outcome has not been  identified  in the current  version of the risk 
analysis  report.  
NOTE:  Anticipated  SADE:  an effect  which  by its nature,  incidence,  
severity  or outcome has been  previously identified  in the risk  analysis  
report  
Ventricular Tachycardia  (VT) Ventricular  tachycardia:  a tachycardia  (rate > 100/min)  with three  or 
more  consecutive beats  that originates from  the ventricles  independent 
of atrial  or AV nodal conduction. Continuous VT for > 30 s or that 
requires  an intervention  for termination  (such  as cardioversion).  
                               
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 120 of 135 
 28.0 APPENDIX B: QMODE  
 
Introduction QMODE Temperature Control Mode 
 The QDOT MICRO™  catheter with QMODE introduces temperature controlled  ablation 
to irrigated catheters.  Temperature controlled ablation allows RF power to be delivered safely without tip char or steam pops.  The QMODE temperature control mode  utilizes the 
temperature sensing capabilities of the QDOT MICRO™  catheter to optimize power 
delivery ensuring efficient ablation.  When using the QMODE temperature control mode  
the irrigation rate will vary based on temperature to both cool the catheter tip adequately and retain temperature sensitivity, ensuring the safety profile.  The QMODE temperature control  is designed to maximize RF lesion efficiency by using 
temperature feedback from the tip to adjust power and irrigation flow.  The QMODE temperature control mode  monitors the temperature rate of change in relationship to the set 
target temperature during RF application.  To maintain a desired power levels at a safe 
temperature, the algorithm applies an accurate correction to control the irrigation flow rate.  
 
• For maximum power settings, 35W or lower: The flow rate starts at low flo w (4ml, 
lowest setting) to increase temperature sensitivity.  If the set power is titrated down because the temperature exceeds the set target temperature (50°C), the generator changes the pump flow rate from low (4mL) to high flow (15 mL) to maintain the set maximum power.  Once the temperature decreases the pump irrigation flow rate is returned to low (4mL). 
 
• For maximum power settings, greater than 35W: The flow rate starts at high flow 
(15ml) for safety. If the temperature drops below the set maximum lo w flow 
temperature (45°C), the generator changes the pump from high (15 mL) to low (4mL) flow. The change to low flow allows the temperature to rise above the set maximum low flow temperature and closer to the target temperature.  
 
28.1 Use of the QDOT MICRO™  QM ODE algorithm 
In the event of spontaneous or induced AF and/or atrial flutter, the placement of additional RF lesions outside of the PV ostia in Qmode is at the discretion of the investigator and includes the following: 
• Linear lesions between both superior  PVs (roof line), the mitral annulus and the left 
inferior PV (mitral isthmus line) or between the LA roof and mitral annulus (anterior line)  
• Ablation for any non- PV foci in the LA and/or RA, including isolation of the 
superior vena cava (SVC)  
• Linear lesio ns in the cavo- tricuspid isthmus  
 If linear lesions are placed, it is recommended that complete conduction block across the ablation line be demonstrated by mapping and/or pacing maneuvers. 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 121 of 135 
  
28.2 Recommended ablation parameters  
QMODE temperature control mode  will be used for PVI once the investigator deems  
QMODE+  unable to complete PVI.   Additionally, QMODE temperature control mode will 
be used for all RF applications outside the PV ostia during the study ablation procedure  
(refer to Section s 13.3.4 and 13.3.5).   
 
The QDOT MICRO™  catheter with Q MODE  temperature control mode  is designed to 
maximize RF lesion efficiency by using temperature feedback from the tip to adjust power and irrigation flow.  For power levels  from 1 -50W , the generator changes the pump 
irrigation flow rate from low (4 mL/min) to high flow (15 mL/min) or from high to low 
flow to reach and maintain the set maximum power without exceeding the set target temperature ( 50°C). The QMODE temperature control mode minimizes the irrigation rate 
thus increasing temperature sensitivity at the catheter tip.  
 Table 28.2A: QMODE Ablation parameters  
Power Target Temp*  Cut-off Temp  Nominal 
Irrigation Flow 
rate Range Recommended  Range Recommended  
25-35 W 45-50ºC 50ºC 50-55ºC 55ºC 4mL** 
36-50W*** 45-50ºC 50ºC 50-55ºC 55ºC 15mL** 
* Temperatures displayed on the RF generator do not represent tissue temperature or electrode tissue interface 
temperature.  
** A minimum flow rate of 2mL during mapping is recommended.  
*** RF applications at 36 -50W should not exceed 30 sec.  
 
Note:  The default parameters for QMODE temperature control are user -adjustable, in case the 
investigator deems appropriate.  
 
Recommendation for CoolFlow® Irrigation Pump Setting and RF Power- delivery  
The CoolFlow® Irrigation Pump will deliver a continuous infusion of 2 ml/min of room temperature heparinized saline (1 u heparin/1 ml saline) when not delivering RF energy. Increase the irrigation to high flow rate starting up to minimal 2 seconds before the onset of RF energy delivery and maintaining this higher flow rate up to 5 seconds after 
termination of the energy application.  QMODE  Contact Force (CF) Settings  
When using the study catheter in QMODE the recommended Contact Force working range should be between 5 and 30g.   Visitag  Settings (recommendation)  
It is recommended that ACCURESP™ be enabled; Respiratory Gating Mandatory (unless using Jet Ventilation)  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 122 of 135 
 • Stability Settings:  
o Range: 3 mm 
o Time: 3 seconds 
• Filter (FOT) Settings: 
o If an FOT filter is desired, the percentage of time of the chosen gram force is 
recommended to be set on 50% 
 Recommended Temperature Range and RF Power Settings  
• QMODE  Temperature settings  
o Below or equal to 35 W 
 Temperature Cut -Off:  55°C  
 Target Temperature: 50°C 
o Above 35W 
 Temperature Cut -Off:  55°C  
 Target Temperature: 50°C (prevents overheating) 
 Note: The default parameters are user -adjustable, in case the investigator deems 
appropriate.   QMODE Ablation Workflow:  
• If the temperature increases rapidly, stop RF application immediately  
• RF power range o f 15-50 Watts (W) is recommended for atrial ablation  
• At anatomical locations, not on the LA posterior wall or CS: 
o Maximum allowed power should not exceed 50 W 
o Duration of ablation should not exceed 60 seconds of continuous ablation at a 
given location 
• Move /drag the catheter to a new location when clinically effective ablation is 
achieved (EGM reduction and/or impedance drop). 
• Duration of ablation as well as the decision to interrupt RF power delivery at any time during ablation SHOULD be guided by: 
o Clinical Investigator judgment and the monitoring of ablation effectiveness 
parameters commonly used such as EGM reduction and/or impedance changes.  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 123 of 135 
 Precautions while ablating  on the Posterior wall and Coronary Sinus : 
• LA posterior wall and close to the esophagus:  
o Start ablation  using standard workflow for posterior wall.  
o Move/drag the catheter to a new location if clinically effective ablation is 
achieved within 20 seconds (EGM reduction and/or impedance drop). 
o Maximum power used SHOULD NOT exceed 35 W. 
o Duration of ablation as well as the decision to interrupt RF power delivery at any time during ablation SHOULD be guided by: 
 Clinical Investigator judgment and monitoring of ablation effectiveness 
parameters commo nly used such as EGM reduction and/or impedance 
changes  
 Esophageal temperature changes should be monitored by an endo -luminal 
esophageal probe or method used to move esophagus as needed (refer to) 
 Duration of ablation should not exceed 30 seconds on poster ior wall.  
 
• Ablation within the Coronary Sinus (CS):  
o A maximum of 35 W will be used if ablation is required in the CS  
o Duration of ablation is limited to 20 seconds per ablation location in the CS 
 
  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 124 of 135 
 29.0 APPENDIX C:  JUSTIFICATION OF SAFETY PERFORMANCE GOAL  
In a recent BWI study (Heliostar), the FDA had recommended using a meta-analysis for 
combining safety rates from relevant studies for deriving a performance goal. For this recent study, the agency had agreed to setting the performance goal by allowing a 50% increase in risk from the upper bound of the 95% confidence interval for the combined safety rate.  
Data from recent clinical trials for devices similar to the device in the current study were reviewed as a first step to deriving the performance goal for the safety endpoint. The following trials were reviewed:  TOCCASTAR, ZERO -AF, and SMART- AF. A meta -
analysis approach was taken to estimate the average composite endpoint rate. Since the definition of the safety composite varies across the studies reviewed, individual complication rates were reviewed and utilized to derive composite rates from each trial that are more closely aligned with the proposed endpoint definition. Table 1 summarizes the event rates as observed in each of the trials.  
 Table 1: Observed event rates  
* Number of events observed if reported . 
  TactiCath™ 
CF 
(n=152)  TactiCath™ 
TC 
(n=143)  Zero AF 
Blazer 
Open-
Irrigated  
(n=157)  Zero AF 
Thermocool  
(n=164)  Smart AF 
(n=161)  
Design  RCT  RCT  Single  
Device /Procedure Death       
Atrial esophageal fistula       
Myocardial Infarction    1 (0.6%)  0 (0.0%)   
Cardiac tamponade/ Perforation  1 (0.66%)  1 (0.70%)  4 (2.5%)  3 (1.8%)  4 (2.5%)  
Thromboembolism    1 (0.6%)  0 (0.0%)   
Stroke/CVA       
TIA      
Phrenic nerve paralysis          
PV Stenosis  0 (0.0%)  1 (0.7%)  1 (0.6%)  2 (1.2%)   
Major Vascular Access/ Bleeding 
Complication    2 (1.3%)  2 (1.2%)  3 (1.86%)  
Pulmonary or bronchial complication    5 (3.2%)  4 (2.4%)   
Pericarditis  2 (1.3%)  0 (0.0%)  1 (0.6%)  0 (0.0%)  2 (1.24%)  
Hospitalization      6 (3.72%)  
Heart Block      1 (0.62%)  
Pericardial Effusion      1 (0.62%)  
AF or AFL requiring cardioversion 
(12M)          
Atrial arrhythmia    1 (0.6%)  1 (0.6%)   
All cause death    1 (0.6%)  1 (0.6%)   
Events*      17 
Subject level rate  3 (1.97%)  2 (1.4%)  16 (10.2%)  13 (7.9%)  16 (9.9%)  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 125 of 135 
  
  Table 2 summarizes the event rates consistent with the proposed safety composite definition.  Table 2: Observed event rates consistent with the proposed safety composite definition (Translated safety rates)  
 
*Number of  subjects with events if reported.  
 
 Figure 1 Meta -analysis results  TactiCath™ 
CF 
 (n=152)  TactiCath™ 
TC 
 (n=143)  Zero AF 
Blazer Open -
Irrigated  
(n=157)  Zero AF 
Thermocool  
(n=164)  Smart AF 
(n=161)  
Design  RCT  RCT  Single  
Device / Procedure Death       
Atrial esophageal fistula       
Myocardial Infarction    1 (0.6%)    
Cardiac tamponade/ 
Perforation  2 (1.3%)  2 (1.4%)  4 (2.5%)  3 (1.8%)  4 (2.5%)  
Thromboembolism    1 (0.6%)    
Stroke/CVA       
TIA      
Phrenic nerve paralysis       
PV Stenosis   1 (0.7%)  1 (0.6%)  2 (1.2%)   
Major Vascular 
Access/Bleeding 
Complication  3 (2.0%)  3 (2.1%)  2 (1.3%)  
1 Hematoma 
(Ablation 
procedure)  
1 Sanguineous 
drainage  2 (1.2%)  
1 AV fistula  
1 Rectus Sheath 
Hematoma  3 (1.86%)  
Pulmonary or bronchial 
complication  2 (1.3)  
P. edema  2 (1.4%)  
P. edema  5 (3.2%)  
2 Heart failure / 
pulmonary 
edema 
3 Pulmonary  4 (2.4%)  
Pulmonary  
Pericarditis  2 (1.3%)   1 (0.6%)   3 (1.86%)  
Heart Block      1 (0.62%)  
Event total  9 (5.9%)  8 (5.6%)  14 (8.9%)  11 (6.7%)  11 (6.8%)  
Rate * 7 (4.6%)  8 (5.6%)    11 (6.8%)  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 126 of 135 
     
 
Figure 1 shows the result of the meta-analysis for combining the safety rates. Based on the plot, the upper bound of the 95% confidence interval was estimated to be equal to 9%. The proposed performance goal of 14% would reflect an approximately 50% increase in risk from the upper bound of the 95% CI.  
  

Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 127 of 135 
 30.0 APPENDIX D ADAPTIVE DESIGN MAIN STUDY  
Simulation Report for Q-FFICIENCY  Study  Main Study  
30.1 Introduction 
This document describes the single-arm trial design for Biosense Webster's pre- market 
clinical evaluation of the QDOT MICRO ™ Catheter to demonstrate the acute safety and 
12-months effectiveness. The trial will enroll N=185 subjects. One interim analysis for 
early success will be performed at 6 months after the last patient is enrolled . 
30.1.1 Endpoints  
30.1.1.1 Primary Efficacy Endpoint 
The primary effectiveness endpoint is freedom from documented atrial arrhythmia (atrial 
fibrillation (AF), atrial tachycardia  (AT) or atrial flutter (AFL)) episodes at Month 12 
(that is, during the 9-month post-blanking period). The proportion of patients that are free from failure at Month 12 will be compared against a performance goal (PG) of 50%. 
30.1.1.2 Primary Safety Endpoint 
The p rimary safety endpoint is occurrence of primary adverse events(PAE) within 7 days 
of an ablation procedure. The PAE rate will be compared against a PG of 14%. PAE includes the following AEs and are defined in the protocol: 
• Death  
• Atrio -Esophageal Fistula 
• Cardiac Tamponade/Perforation  
• Myocardial Infarction  
• Stroke / Cerebrovascular Accident  
• Thromboembolism 
• Transient Ischemic Attack  
• Diaphragmatic Paralysis  
• Pulmonary Vein Stenosis 
• Pericarditis  
• Vagal Nerve Injury 
• Major Vascular Access Complication / Bleeding  
30.2 Adaptive Design 
30.2.1 Primary Analysis 
The primary goal of the trial is to demonstrate effectiveness and safety. For the trial to be successful, both primary safety and effectiveness endpoints must be statistically significant relative to their respective PGs.  
 The effectiveness endpoint will be assessed by testing the hypotheses (assuming early success for effectiveness is not achieved) :  
 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 128 of 135 
 𝐻𝐻0:𝑝𝑝𝐸𝐸≤0.50  vs .  𝐻𝐻 𝐴𝐴:𝑝𝑝𝐸𝐸> 0. 50, 
 
where 𝑝𝑝𝐸𝐸 is the proportion of patients free from effectiveness events. 
 
Let 𝑋𝑋 be the number of patients that are failure-free through 12 months. We model the 
number of patients free from an event as 
 
𝑋𝑋 ∼ Binomial (𝑛𝑛,𝑝𝑝𝐸𝐸), 
 
where 𝑛𝑛 is the number of p atients. We u se a vague Beta(1, 1) prior distribution for 𝑝𝑝𝐸𝐸. 
Then the posterior distribution is   
(𝑝𝑝
𝐸𝐸|𝑥𝑥,𝑛𝑛)∼Beta(1 + 𝑥𝑥, 1 +𝑛𝑛−𝑥𝑥 ). 
 
Similarly, the hypothesis test for the safety endpoint is:   
𝐻𝐻
0:𝑝𝑝𝑆𝑆≥0.14  vs .  𝐻𝐻 𝐴𝐴:𝑝𝑝𝑆𝑆< 0. 14, 
 
where 𝑝𝑝𝑆𝑆 is the 7 -day PAE. We mode l the number of patients with PAEs as  
 
𝑌𝑌 ∼ Binomial (𝑛𝑛,𝑝𝑝𝑆𝑆) 
 
with a vague Beta(1, 1) prior distribution on 𝑝𝑝 𝑆𝑆. 
 Assuming early success for effectiveness is not achieved, t he trial will be considered a 
success if BOTH  
1. Pr(𝑝𝑝
𝐸𝐸> 0.5|𝑥𝑥,𝑛𝑛) > 0. 9775  AND  
2. Pr(𝑝𝑝𝑆𝑆< 0. 14|𝑦𝑦,𝑛𝑛) > 0. 975 . 
 These thresholds control the overall Type I error rate for the trial below one-sided 2.5% (see Section 29.5.1 of this report for additional discussion of Type I error control). 
 
30.2.2 Interim Analyses for Early Success  
One interim analysis is planned for an early success claim. The interim will occur 6 months after enrollment is complete; that is, 6 months before the final analysis. For the safety endpoint, the outcome for all patients will be known at the time of the interim analysis and therefore the primary safety analysis will be performed at the time of the interim analysis. It should be noted that because these two tests are identical there will not be an increase in type- I error.  
 At the interim analysis, the trial will declare early success if:  
1. The safety objective is met.  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 129 of 135 
 2. Posterior probability of the effectiveness proportion 𝑝𝑝 𝐸𝐸 being greater than 50% is  
greater than 0.9975. 
3. . 
30.2.3 Longitudinal Modeling for Effectiveness 
 For effectiveness, the time- to-failure during the 9- month(39 weeks) post -blanking period 
is modeled by using a piecewise exponential model. The model has three distinct time 
intervals: (0, 2], (2, 8], and (8, 39] weeks. Failure times during each interval is exponentially distributed, with different hazard rates in each segment. The model is:  
 
  
𝑓𝑓(𝑡𝑡) = exp(−𝑡𝑡ℎ (𝑡𝑡)), 
  where  
ℎ(𝑡𝑡) =�ℎ
1 0 <𝑡𝑡 ≤ 2;
ℎ2 2 <𝑡𝑡 ≤ 8;
ℎ38 <𝑡𝑡 ≤ 39. 
 These intervals are based on a model used in the ThermoCool Pivotal trial. A vague Gamma(1, 1) prior distribution will be used for each ℎ in the model.  
 Given hazard rates ℎ
1,ℎ2 , and ℎ3, the failure -free rate at 12 months 𝑝𝑝𝐸𝐸 can  then be 
estimated by 
𝑝𝑝𝐸𝐸=exp(−[2ℎ1+(8−2)ℎ2+(39−8)ℎ3]). 
 At the interim, the total number of primary effectiveness events and the total 
subject exposure time will be used to update the vague Gamma prior and obtain the posterior Gamma distribution for each segment. Then 10,000 random hazard rates will be sampled from the posterior distribution for each segment and each triplet set of hazard 
rates will be used to calculate 𝑝𝑝
𝐸𝐸. The distribution of 𝑝𝑝 𝐸𝐸 is estimated based on the 10,000 
calculated 𝑝𝑝𝐸𝐸𝑠𝑠. If the probability of 𝑝𝑝𝐸𝐸 being greater than 50% is greater than 
0.9975(99.75%), the trial will declare early success.  
30.3 Simulation Scenarios  
The operating characteristics of this trial were determined through trial simulation. We hypothesized several scenarios for the underlying rates for the effectiveness and safety endpoints and simulated the entire trial multiple times under each scenario. In each virtual trial, the interim analysis was conducted according to the pre- specified rules, and 
results were tracked for each trial, including whether the trial was successful on each endpoint individually and on both endpoints, whether trial success was achieved early, etc. This section describes the parameters that were used to simulate subject -level data for 
the virtual trials.  
 
30.3.1 Effectiveness Profiles  
In order to s imulate the effectiveness outcome for a virtual subject, we need to simulate 
whether the subject has a failure and when that failure occurs. As previously discussed in section 29.2.3, a piecewise exponential time- to-failure model is assumed and calibrated to 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 130 of 135 
 have a particular failure rate ( 1−𝑝𝑝𝐸𝐸) at the end of follow-up. The profiles are 
constructed by taking advantage of the relationship: 
  
𝑝𝑝𝐸𝐸=exp(−[2ℎ1+ (8−2)ℎ2+ (39−8)ℎ3]), 
 
where 𝑝𝑝𝐸𝐸 is the failure -free rate at 12 -months. Previous study of catheter is assumed to 
estimate the hazard rates for the three pieces. From ThermoCool SSED, the reported 
hazard rates have the following pattern:  
 
ℎ1= (38.06)ℎ3; 
ℎ2= (1. 71)ℎ3; 
ℎ3= (1)ℎ3. 
 To simulate data, we use the above multiplicative factors from ThermoCool and then find 
a value for ℎ
3, such that when multiplied by each of the assumed rates for the three- time 
intervals, the failure -free rate at 12 months (39 weeks following 13weeks blanking 
period) matches the desired scenarios. Table 1 shows the derived hazard rates that were 
used to simulate data for a range of assumed failure- free rates.  
 
Table 1:  Parameters to generate failure times  
 Hazard Rate ( h) 
Failure -free Rate  ℎ1 ℎ2 ℎ3 
0.50 0.2248  0.0101  0.0059  
0.55 0.1938 0.0087 0.0051 
0.60 0.1656  0.0074  0.0044  
0.65 0.1397 0.0063 0.0037 
0.70 0.1157  0.0052  0.0030  
0.99 0.0032  0.0001  0.0001  
 
In order to compute the predictive probability of success for the effectiveness endpoint, 
2500 imputations were performed for each subj ect with missing outcome in the 
simulations  
30.3.2 Adverse Event Rate Profiles  
The 7 -day PAE outcome for each subject is simulated as a Bernoulli random variable, 
with scenarios defined by the rates shown in Table 2.  
Table 2:  Parameters to generate PAE outcomes  
True AE Rate  
0.01 
0.07 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 131 of 135 
 0.08 
0.10 
0.12 
0.14 
30.3.3 Enrollment Rates  
We simulate three scenarios for the enrollment rate. The "expected" scenario assumes 
that full enrollment of N=185 would take approximately 7 months on average. The “fast” and "slow" scenarios assume that full enrollment would take, on average, 6 and 8 months respectively. Table 3 shows the rates for each scenario.  
 Table 3:  Monthly enrollment rates 
 
30.3.4 Attrition Rate Profile  
For each subject, a time- to-withdrawal is simulated from an exponential distribution with 
a 5% dropout rate for the safety outcome and a 12% dropout rate for the effectiveness outcome. Both dropout rates are per year of follow- up. If a subject experiences a failure 
prior to their withdrawal time, then their outcome is recorded as a failure. A subject is censored at the time of withdrawal if the simulated withdrawal time is prior to the simulated failure time.  
 
30.4 Operating Characteristics  
For the scenarios des cribed above, we simulate multiple virtual trials and track the 
behavior of each trial, including the final outcome of the trial, whether success was declared early, etc. The results for Type I Error are based on 10,000 simulated virtual trials per scenari o. For all other scenarios, 5,000 virtual trials were simulated. 
30.4.1 Type I Error Control  
This section summarizes the probability of a successful trial under the null hypotheses for both safety and effectiveness.  Table 4 summarizes Type I error rates for the trial under various scenarios; that is, the probability of declaring success on both endpoints under two scenarios: (1) Assuming the true failure-free rate is 50% with various range of the true PAE rates; and (2) Assuming the true PAE rate is 14% with various range of the true failure -free rates.   Month  
Rate(patients/month)  1 2 3 4 5 6 7 8 
Expected  5 15 25 30 40 40 30  
Fast 5 20 35 45 45 35   
Slow  2 10 20 30 35 35 35 18 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 132 of 135 
  
The scenario that is expected to have the largest Type I error rate is either when the true PAE rate is 14% and the device is assumed to be effective (true failure- free rate is 99%) , 
or when the true failure- free rate is 50% and the device is assumed to be safe (true PAE 
rate is 1%). The table shows the largest Type I error rate for the trial in the simulations was 0.023, still below the 2.5% threshold.  In adaptive trials, the enrollment rate to the trial directly impacts the amount of information that is available at the time of the interim and may influence the probability of stopping at the interim.  In this simulation, however, there is little to no impact of different enrollment rates on Type I error, and notably, all values are below 2.5%.  
Table 4:  Type I error rate  
 
                        Pr(Declaring Success)  
 Failure -free 
Rate PAE Rate Expected     Fast    Slow     
0.50 0.01 0.011  0.007  0.010  
0.50 0.07 0.008  0.009  0.007  
0.50 0.08 0.007  0.007  0.006  
0.50 0.10 0.004  0.005  0.004  
0.50 0.12 0.001  0.001  0.001  
0.50 0.14 0.000  0.000  0.000  
0.55  
0.60 0.14  
0.14 0.003  
0.012  0.004  
0.013  0.003  
0.012  
0.65 0.14 0.019  0.021  0.019  
0.70 0.14 0.021  0.021  0.020  
0.99 0.14 0.023  0.021  0.023  
 
30.4.2 Probability of Success  
For the full range of effectiveness and safety scenarios, this section summarizes the probability of trial success for the expected enrollment rate. Table 5 summarizes the probability of success in the following ways:  
• Both : the proportion of virtual trials that were successful (on both endpoints) 
either at an interim or at the final analysis  
• Effectiveness : the proportion of trials that were successful on the effectiveness 
endpoint 
• Safety : the proportion of trials that were successful on the safety endpoint 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 133 of 135 
 • Early : the proportion of trials that met the criteria for success (on both endpoints) 
at the interim analysis  
• Final : the proportion of trials that met the criteria for success (on both endpoints) 
at the final analysis when the early  success is not declared.  
 
If the true PAE rate is 7% and the true failure -free rate is 65%, the trial has approximately 
81.7% power. Under this scenario, 64.8 % of the simulated trials claimed success at the 
interim and an additional 16.9% of trials achieved success at the final analysis.  
Table 5:  Pr(Declaring Success) (Expected Enrollment) 
 
Failure -free 
Rate  Pr(Declaring Success)   
PAE Rate  Both  Effectiveness  Safety  Early  Final  
0.50 0.07 0.008  0.010  0.856  0.002  0.007  
 0.08 0.007  0.010  0.696  0.001  0.006  
 0.1 0.004  0.009  0.342  0.001  0.003  
 0.12 0.001  0.010  0.105  0.000  0.001  
 0.14 0.000  0.009  0.021  0.000  0.000  
0.55 0.07 0.144  0.169  0.853  0.046  0.098  
 0.08 0.114  0.161  0.710  0.035  0.079  
 0.1 0.058  0.160  0.352  0.018  0.040  
 0.12 0.016  0.148  0.101  0.006  0.010  
 0.14 0.003  0.153  0.020  0.001  0.002  
0.60 0.07 0.530  0.625  0.847  0.270  0.261  
 0.08 0.439  0.613  0.705  0.225  0.214  
 0.1 0.209  0.613  0.340  0.104  0.105  
 0.12 0.063  0.625  0.104  0.030  0.033  
 0.14 0.012  0.617  0.021  0.006  0.006  
0.65 0.07 0.817  0.952  0.860  0.648  0.169  
 0.08 0.661  0.953  0.696  0.522  0.138  
 0.1 0.325  0.951  0.338  0.260  0.064  
 0.12 0.099  0.954  0.104  0.078  0.021  
 0.14 0.019  0.948  0.021  0.015  0.004  
0.70 0.07 0.852  0.999  0.853  0.824  0.028  
 0.08 0.699  0.999  0.700  0.680  0.019  
 0.1 0.347  0.998  0.347  0.336  0.011  
 0.12 0.107  0.999  0.107  0.104  0.003  
 0.14 0.021  0.999  0.021  0.020  0.001  
 
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 134 of 135 
 30.4.3 Sensitivity to Enrollment Rate  
In this section, we repeat the operating characteristics of the previous section under 
different trial enrollment rates. Table 6 and Table 7 show the probability of success for the 5 different categories under the fast and slow enrollment rates respectively.  
 In this simulation, there is little to no impact from different enrollment rates on  overall 
power, and notably, all values are about 81.7% when the true PAE rate is 7% and the true failure -free rate is 65%. However, it seems there is some impact on the early success rate 
for different enrollment rates since the amount of information avai lable at the time of the 
interim is changed according to the enrollment rate. If the enrollment is slower than expected, the trial has a little higher ability to reach a success decision before the final analysis. With the fast enrollment, the trial has a lower ability to reach early success.  
 Table 6:  Pr(Declaring Success) (Fast Enrollment) 
  
Failure -free 
Rate 
 Pr(Declaring Success)   
PAE Rate Both Effectiveness  Safety  Early  Final  
0.50 0.07 0.009  0.010  0.855  0.002  0.007  
 0.08 0.007  0.010  0.706  0.001  0.006  
 0.1 0.005  0.010  0.342  0.001  0.004  
 0.12 0.001  0.010  0.100  0.000  0.001  
 0.14 0.000  0.009  0.023  0.000  0.000  
0.55 0.07 0.132  0.155  0.861  0.040  0.092  
 0.08 0.107  0.151  0.705  0.030  0.077  
 0.1 0.054  0.154  0.345  0.016  0.039  
 0.12 0.015  0.144  0.102  0.005  0.009  
 0.14 0.004  0.153  0.021  0.001  0.003  
0.60 0.07 0.539  0.620  0.866  0.237  0.302  
 0.08 0.453  0.631  0.712  0.208  0.245  
 0.1 0.216  0.629  0.336  0.095  0.121  
 0.12 0.063  0.616  0.100  0.026  0.037  
 0.14 0.013  0.618  0.022  0.006  0.008  
0.65 0.07 0.818  0.951  0.859  0.621  0.196  
 0.08 0.669  0.957  0.700  0.503  0.166  
 0.1 0.316  0.952  0.330  0.239  0.076  
 0.12 0.097  0.953  0.101  0.073  0.024  
 0.14 0.021  0.954  0.022  0.016  0.006  
0.70 0.07 0.847  0.999  0.848  0.817  0.030  
Q-fficiency        Protocol# BWI_2017_07  
 Biosense Webster,  Inc  
Version 5.0 – Feb 3, 2021 CONFIDENTIAL  Page 135 of 135 
  0.08 0.683  0.999  0.684  0.658  0.025  
 0.1 0.347  0.999  0.348  0.334  0.014  
 0.12 0.102  0.999  0.102  0.099  0.003  
 0.14 0.021  0.999  0.021  0.021  0.000  
 
   
 Table 7: Pr(Declaring Success) (Slow Enrollment)  
 
Failure -free 
Rate  Pr(Declaring Success)   
PAE Rate  Both  Effectiveness  Safety  Early  Final  
0.50 0.07 0.007  0.009  0.862  0.002  0.006  
 0.08 0.006  0.008  0.708  0.002  0.004  
 0.1 0.004  0.010  0.334  0.002  0.002  
 0.12 0.001  0.008  0.101  0.000  0.001  
 0.14 0.000  0.008  0.022  0.000  0.000  
0.55 0.07 0.136  0.155  0.868  0.051  0.085  
 0.08 0.111  0.158  0.694  0.038  0.072  
 0.1 0.053  0.155  0.335  0.015  0.038  
 0.12 0.015  0.146  0.102  0.005  0.010  
 0.14 0.003  0.146  0.023  0.001  0.003  
0.60 0.07 0.546  0.632  0.857  0.299  0.247  
 0.08 0.434  0.623  0.691  0.238  0.195  
 0.1 0.206  0.612  0.337  0.113  0.093  
 0.12 0.064  0.610  0.099  0.035  0.029  
 0.14 0.012  0.609  0.020  0.007  0.006  
0.65 0.07 0.816  0.955  0.855  0.670  0.146  
 0.08 0.676  0.961  0.705  0.560  0.116  
 0.1 0.327  0.954  0.342  0.262  0.065  
 0.12 0.101  0.952  0.104  0.083  0.018  
 0.14 0.019  0.948  0.020  0.015  0.004  
0.70 0.07 0.850  1.000  0.850  0.834  0.016  
 0.08 0.700  0.999  0.700  0.685  0.015  
 0.1 0.324  0.999  0.324  0.318  0.007  
 0.12 0.097  0.999  0.097  0.095  0.002  
 0.14 0.020  0.999  0.020  0.020  0.000  
   
 